<?xml version="1.0" encoding="UTF-8"?><ml:doc-envelope xmlns:ml="http://marklogic.com/poolparty/worldbank"><ml:original-txt>Document of&#13;
The World Bank&#13;
Report No. 15399-MK&#13;
STAFF APPRAISAL REPORT&#13;
FORMER YUGOSLAV REPUBLIC OF MACEDONIA&#13;
HEALTH SECTOR TRANSITION PROJECT&#13;
May 24, 1996&#13;
Human Resources Sector Operations Division&#13;
Country Department I&#13;
Europe and Central Asia Region&#13;
&#13;
&#13;
&amp;#12;&#13;
CURRENCY EOUIVALENTS&#13;
Currency Unit = Macedonian Denar (MKD)&#13;
EXCHANGE RATES&#13;
June 1995        December 1995         February 1996&#13;
37. 1 MKD/US$        38.0 MKD/US$         38.0 MKD/US$&#13;
WEIGHTS AND MEASURES&#13;
Metric System&#13;
ABBREVIATIONS AND ACRONYMS&#13;
ALOS        Average Length of Stay&#13;
AMPPHC    Assistant Minister for Primary and Preventive Health Care&#13;
CAS         Country Assistance Strategy&#13;
CEE         Central and Eastern Europe&#13;
DALY        Disability-Adjusted Life Year&#13;
DHIF        District Health Insurance Fund&#13;
DoP         Department of Pharmaceuticals&#13;
EME         Established Market Economies&#13;
FESAC       Financial and Enterprise Sector Adjustment Credit&#13;
HSTP        Health Sector Transition Project&#13;
IDA         International Development Association&#13;
IPU         International Project Unit&#13;
LDP         Letter of Development Policy&#13;
MKD         Macedonian Denar&#13;
MOH         Ministry of Health&#13;
NHIF        National Health Insurance Fund&#13;
NIPH        National Institute for Public Health&#13;
PHC         Primary Health Care&#13;
PHRD        Policy and Human Resources Development Grant&#13;
PIP         Project Implementation Plan&#13;
PPF         Project Preparation Facility&#13;
SDR         Special Drawing Right&#13;
TC          Technical Committee&#13;
UNICEF    United Nations International Children's Emergency Fund&#13;
FORMER YUGOSLAV REPUBLIC OF MACEDONIA - FISCAL YEAR&#13;
January 1 - December 31&#13;
&#13;
&#13;
&amp;#12;&#13;
STAFF APPRAISAL REPORT&#13;
FORMER YUGOSLAV REPUBLIC OF MACEDONIA&#13;
Health Sector Transition Project&#13;
TABLE OF CONTENTS&#13;
Page&#13;
Credit and Project Summary  ............................................. i&#13;
I. HEALTH SECTOR BACKGROUND  ..................................... I&#13;
A.     Introduction            .................................................. I&#13;
B.     Issues for Health Sector Reform  ...................................... 3&#13;
C.     Government's Reform Strategy for Health  .............................. 11&#13;
11. PROJECT DESCRIPTION   .......................................... 14&#13;
A.     Project Objectives ..............................................  14&#13;
B.     Project Components  ............................................ 14&#13;
C.     Project Justification ............................................. 19&#13;
III. PROJECT COST, FINANCING, MANAGEMENT AND IMPLEMENTATION   ........ 27&#13;
A.     Project Cost                                                                     ..     . 27&#13;
B. Project Financing                    ..27&#13;
C.  Project Management and Implementation..                                                      28&#13;
D. Project Supervision                   ..28&#13;
E.  Procurement Arrangements                   ..28&#13;
F. Disbursements                      ..29&#13;
G.  Project Audits and Reporting                ..29&#13;
H. Status of Preparation                   ..30&#13;
IV. PROJECT BENEFITS AND RISKS ................................ 31&#13;
A.     Benefits .................................................... 31&#13;
B.   Risks .......................... 32&#13;
V.  AGREEMENTS REACHED AND RECOMMENDATIONS   .................... 33&#13;
This report is based on the findings of a preappraisal mission which visited Skopje in September/October 1995.&#13;
The mission was comprised of: Ms. E. Goldstein (Sr. Human Resources Economist/Task Manager); Dr. R.&#13;
Castadot (Sr. Population &amp; Health Specialist); Dr. Denis Broun (Pharmaceutical Specialist); Dr. Olusoji Adeyi&#13;
(Health Economist); Mr. Suwat Pananon (Information Technology Specialist); Ms. Sabrina Huffman (Operations&#13;
Analyst);  Mr.  R.  Anthony  (Consultant/Health  Finance  and  Management);  Dr.  E.  Lauridsen&#13;
(Consultant/Pharmaceutical Policy and Supply); Dr. C. Collard (Consultant/Basic Health Services); and Ms. A.&#13;
Kadihasanoglu (Consultant/Project Implementation). Details concerning project scope, content, costs, and financing&#13;
were finalized during the visit of a Government delegation to Washington in December 1995. Ms. Alvire Paul was&#13;
responsible for document processing. Peer Reviewers were: Messrs. M. Over, A.Preker, and G. Schieber. Mr.&#13;
Ralph W. Harbison is the Division Chief, and Mr. Kenneth Lay, Country Director.&#13;
&#13;
&#13;
&amp;#12;&#13;
Table of Contents (Continued)&#13;
TEXT TABLES&#13;
Table 1. 1: Comparative Demographic and Health Indicators ......................... 2&#13;
Table 1.2: FYR Macedonia: Fetal and Infant Death, 1991-1994 ...................... 4&#13;
Table 1.3: Age-Standardized Mortality Rates, Selected Causes and&#13;
Countries, 1991 .........................                                                5&#13;
Table 1.4: Health Revenues and Expenditures, 1991-1995 .......................... 6&#13;
Table 1.5: FYR Macedonia: Health Services, 1991-1994  .......................... 7&#13;
Table 1.6: Average Length of Stay in Hospitals, 1993  ............................ 8&#13;
ANNEXES&#13;
Annex 1: Letter of Development Policy&#13;
Annex 2: Project Implementation Plan - Policy Matrix: Progress Benchmarks&#13;
Annex 3: Selection Among Alternative Project Designs&#13;
Annex 4: Statistical Data&#13;
MAP IBRD 25501&#13;
&#13;
&#13;
&amp;#12;&#13;
FORMER YUGOSLAV REPUBLIC OF MACEDONIA&#13;
Health Sector Transition Project&#13;
STAFF APPRAISAL REPORT&#13;
Credit and Project Summary&#13;
Borrower:               Former Yugoslav Republic of Macedonia&#13;
Beneficiary:            Ministry of Health (MOH), National Health Insurance Fund (NHIF), National Institute&#13;
of Public Health (NIPH) and selected district health facilities.&#13;
Credit Amount:          SDR 11.8 million (US$16.9 million equivalent)&#13;
Tenns:                  Standard IDA; 35 years, including 10 years grace.&#13;
Project Obiectives:     The dual objective of the Health Sector Transition Project (HSTP) is to: (i) improve the&#13;
health of the population by enhancing the quality of basic health services; and (ii) support&#13;
an initial phase of policy reforms to increase cost-effectiveness, fiscal sustainability and&#13;
patient choice within the health system.&#13;
Project DescriDtion:    Project objectives will be achieved through activities under the following three&#13;
components, each designed around a core policy agenda:&#13;
(i) Health Finance and Management (base cost US$3.8 million): The objective is to build&#13;
capacity to analyze and apply information for policy-making and health system&#13;
management. Support will be provided fortechnical studies, strengthening of management&#13;
skills in the MOH, NHIF and health facilities, and the development of management&#13;
information systems.&#13;
(ii) Basic Health Services (base cost US$7.0 million): The objective is to strengthen&#13;
primary health care and health promotion, particularly in rural areas. Support will be&#13;
provided to equip rural primary health care centers, upgrade skills of primary care&#13;
personnel and supply essential materials to five high-priority disease prevention programs.&#13;
(iii) Pharmaceutical Policy and Supply (base cost US$5.7 million): The objective is to&#13;
reduce the cost of essential drugs through reforms which create a more competitive&#13;
pharmaceutical market. Essential drugs for primary care will be provided, along with&#13;
technical advice, training and equipment to improve public procurement, reimbursement&#13;
and quality control.&#13;
Total project cost is estimated at US$ 19.4 million equivalent (including contingencies).&#13;
This includes US$ 0.9 million to support establishment of an International Project Unit&#13;
(IPU) within the Ministry of Health (MOH) responsible for coordinating the&#13;
implementation of project activities. The Project will be implemented over three years&#13;
by the Ministry of Health and associated health institutions.&#13;
Project Benefits:       The economic benefits of the Project include better quality basic health services and a&#13;
more cost-effective use of public resources for health--both of which will counteract the&#13;
negative impact of recent economic and fiscal contraction on the health of the population.&#13;
Health Finance and Management: This component provides economic and fiscal benefits&#13;
through its impact on the allocation of public resources for health. It will result in a&#13;
reallocation of public resources toward more cost-effective health interventions, as well&#13;
as limitation of health expenditures to fiscally sustainable levels. The component&#13;
&#13;
&#13;
&amp;#12;&#13;
ii&#13;
implements a basic benefits package for health insurance based on cost-effective treatment&#13;
of national health priorities, and tailored to available resources. It also creates incentives&#13;
for efficiency and quality of care, through the establishment of new provider payment&#13;
mechanisms; and improves resource management through strengthening of managerial&#13;
skills and provision of management tools.&#13;
Basic Health Services:  Cost-effective reduction in the burden of disease, through&#13;
improved preventive and curative primary care, is the major economic benefit of this&#13;
component. With continued high levels of infant mortality due to infectious diseases and&#13;
maternal mortality due to high-risk pregnancies, as well as rapidly rising premature&#13;
mortality due to chronic diseases associated with unhealthy lifestyles, it is clear that&#13;
preventive and curative primary care is the most cost-effective way to reduce multiple&#13;
elements of the burden of disease. The component will result in adequately staffed and&#13;
equipped rural primary health care centers, and more effective reduction of the leading&#13;
causes of infant, child, maternal and other premature mortality through support for&#13;
national prevention programs.&#13;
Pharmaceutical Policy and Supply: The benefits of this component lie in its economy-&#13;
wide impact on the price of essential drugs, as well as the direct provision of essential&#13;
drugs for more effective primary care. Provision of drugs will be linked to reforms aimed&#13;
at increasing the affordability and availability of essential drugs. Legislative and&#13;
regulatory reform will ease market entry and create incentives to market lower-cost&#13;
drugs. Reform of public sector procurement and reimbursement procedures will lower&#13;
unit costs for drugs, and channel public resources toward more cost-effective drugs. The&#13;
economic and fiscal gains of the component far outweigh its economic costs, with fiscal&#13;
savings in the three-year period conservatively estimated at ten times the investment cost.&#13;
These large economic and fiscal benefits will continue beyond the life of the Project.&#13;
Prolect Risks:          The Project faces two key risks--one political, the other institutional. The political risk&#13;
is that the country cannot muster the political will necessary to implement fundamental&#13;
health sector reform, particularly with respect to limiting insurance benefits, squeezing&#13;
economic rents out of the pharmaceutical market and consolidating the public sector&#13;
facilities network. Government has only the health care consumer on its side, facing&#13;
powerful medical and pharmaceutical interest groups. To reduce this risk, the following&#13;
strategy has been pursued. First, technical working groups with broad stakeholder&#13;
participation were formed at an early stage for strategy formulation and project&#13;
preparation. Second, the project preparation team engaged in early interaction with the&#13;
media. Third, early efforts were made to market the emerging reform strategy to key&#13;
economic policymakers. Finally, and most importantly, resources have been included in&#13;
the Project to support a vigorous communications strategy, in order to inform and&#13;
persuade major stakeholders.&#13;
A secondary risk lies in the weak institutional capacity of the MOH, and its limited&#13;
experience in implementation of internationally funded projects. The MOH has a direct&#13;
staff of only 25, with mostly medical--as opposed to managerial--training. To alleviate&#13;
this risk, the Project will invest heavily in building managerial capacity within the MOH&#13;
and NHIF, as well as supplementing implementation capacity by providing local&#13;
management consultants to support the IPU. Although the reform agenda supported by&#13;
the Project is substantive, project investments are simple, and organized into a small&#13;
number of procurement packages. Medical equipment and drugs accounting for more&#13;
than 40 percent of the IDA credit will be procured by a local agent with sophisticated&#13;
infrastructure and a strong track record of international purchasing and local distribution.&#13;
&#13;
&#13;
&amp;#12;&#13;
iii&#13;
Estimated Proiect Costs "&#13;
Local         Foreien        Total&#13;
-----------------US$ million---------------&#13;
Health Finance &amp; Management                          1.2             2.6           3.8&#13;
Basic Health Services                                1.7             5.3           7.0&#13;
Primary Health Care                           0.6             2.4          3.0&#13;
Prevention Programs                           1.1             2.9          4.0&#13;
Pharmaceutical Policy and Supply                      1.0            4.7           5.7&#13;
Project Management                                   0.7             0.2           0.9&#13;
Total Base Costs                       4.6           12.9          17.5&#13;
Physical Contingencies                        0.2             1.2          1.4&#13;
Price Contingencies                           0.1             0.4          0.6&#13;
Total Project Costs                    4.9           14.5          19.4&#13;
Financine Plan&#13;
Government of FYR Macedonia                   2.5             0.0          2.5&#13;
IDA                                           2.4            14.5         16.9&#13;
Total Financing Requirements           4.9           14.5          19.4&#13;
IDA Fiscal Year Estimated Disbursements&#13;
(US$ million equivalent) 2/&#13;
FY97          FY98           FY99&#13;
Annual                       6.2           8.2            2.5&#13;
Cumulative                   6.2            14.4          16.9&#13;
Cumulative as % of total     37.0          85.0           100.0&#13;
1/     Figures may not total due to rounding.&#13;
2/     Assumes project effectiveness by September 1996.&#13;
&#13;
&#13;
&amp;#12;&#13;
&#13;
&#13;
&amp;#12;&#13;
I. HEALTH SECTOR BACKGROUND&#13;
A. Introduction&#13;
Economic and Political Context&#13;
1.1            Former Yugoslav Republic of Macedonia (FYR Macedonia), the poorest republic in the&#13;
former federated state, has spent the five years since independence struggling to avoid internal conflict&#13;
and gain full political and economic recognition from the international community. The country has been&#13;
forced to address structural problems in the economy which it inherited from Yugoslavia, while external&#13;
forces--notably regional conflict, trade embargo and transport blockade-- severely constrained economic&#13;
performance. As a result, real income dropped by nearly 40 percent between 1990 and 1994, to an&#13;
estimated per capita GNP of only US$790 in 1994. The deterioration in living standards has been&#13;
exacerbated by an inevitable fiscal crisis, which has undermined the social safety net and provision of&#13;
social services. Now, with tentative resolution of the regional conflict, and lifting of the trade embargo&#13;
and transport blockade, FYR Macedonia can begin to move beyond the crisis stage, deepening the&#13;
structural reforms necessary for resumption of growth. Key to the success of economic reform and to&#13;
long run economic growth will be provision of a fiscally sustainable social safety net and the effective&#13;
development of human capital.&#13;
Health Status, Services and Financinrg'&#13;
1.2            By Central and Eastern European (CEE) standards, FYR Macedonia has a young&#13;
population and relatively high fertility rate, resulting in positive population growth. During the 1960-90&#13;
period, the population enjoyed steadily improving health status, with rapidly declining infant and maternal&#13;
mortality. The infant mortality rate dropped from 112 per 1,000 live births in 1961 to just 28 in 1991,&#13;
with life expectancy rising from 61 to 72 years. Since the advent of the transition, improvement in health&#13;
status has stagnated--a key issue for health sector reform, as discussed below. Although life expectancy&#13;
in FYR Macedonia falls below that in established market economies (EME) countries, it equals or exceeds&#13;
that in other CEE countries and far surpasses that in developing countries at similar income levels. While&#13;
life expectancy is on par with higher income CEE countries, the determinants differ considerably. Infant&#13;
mortality in FYR Macedonia is twice the CEE average, while premature adult death due to chronic&#13;
disease and injury is far lower. In short, the country is not as far along in the demographic and&#13;
epidemiologic transition as other CEE countries--with both positive and negative implications for health.&#13;
11 See Annex 4: Statistical Appendix. For a more detailed discussion of health status, services and financing, see the sector note&#13;
"Former Yugoslav Republic of Macedonia: Health Services in Transition", September 1993.&#13;
&#13;
&#13;
&amp;#12;&#13;
- 2 -&#13;
Table 1.1: Comparative Demographic and Health Indicators, 1991&#13;
FYRM      EME            CtEE              Developing Countries&#13;
Weighted   Weighted       Columbia    Morocco   Congo&#13;
Average    Average&#13;
Per capita income (US$)             1150      21,183        1,390       1,260       1,030    1,120&#13;
Crude birth rate                      17          13           I l        24          32       49&#13;
Crude death rate                       7           9            9          6           8        16&#13;
Crude rate of natural increase        10           4            2          18         24       33&#13;
Pop. growth 1980-91 (% p.a)          1.1         0.6         -0.2         2.0        2.6       3.4&#13;
Population age 0-14 (%)             24.0        19.4         20.0        35.0       41.0      45.5&#13;
Life expectancy (male)                70          73           67         66          61       49&#13;
Life expectancv (female)              74          80           75         72          65       54&#13;
Total fertility rate                 2.3         1.7          2.1         2.7         4.3      6.6&#13;
Infant mortality rate                 28           8           17         23          57    115.0&#13;
Maternal mortality ratio              11           7           29          -- Estimated at 100-200 --&#13;
"Excluding Albania and the former republics of Yugoslavia.&#13;
Source: Statistical Office, WHO World Health Statistics and World Bank, World Development Report 1993.&#13;
1.3             Real income growth was not the sole determinant of improving health status in past&#13;
decades. The health system also made a positive contribution, offering universal coverage, broad risk-&#13;
pooling, wide access to facilities, abundant and relatively well-trained personnel and effective public&#13;
health activities, such as immunization  and vector control.   FYR  Macedonia inherited a highly-&#13;
decentralized and locally-funded health system (based on the former "Self-managed Communities of&#13;
Interest") which tended toward fragmentation, duplication and interregional inequities in the quality of&#13;
care. The country was divided into 33 districts (five in the capital, Skopje), each of which had its own&#13;
network of facilities which were "socially owned" by health workers and communities. In 1994, these&#13;
socially-owned facilities were converted into a single network of public sector health facilities under the&#13;
supervision of the MOH. The 33 districts remain, with 17 medical centers (each a complex of secondary&#13;
hospital and outpatient polyclinic) and associated primary health care (PHC) centers. The country also&#13;
has 14 disease-specific or chronic care treatment hospitals, as well as a university complex of tertiary care&#13;
facilities in Skopje. The public sector network consists, on average, of a PHC center per 6.,000&#13;
inhabitants and a general secondary hospital per 110,000 inhabitants. Private health services were&#13;
authorized in 1991, and have grown most rapidly in pharmaceuticals (wholesale and retail) and dentistry,&#13;
where private expenditures tend to be concentrated.&#13;
1.4             To overcome regional inequities in the quality of care, and maximize risk-pooling for a&#13;
population of only 2.1 million, the district health insurance funds were unified into a centralized National&#13;
Health Insurance Fund (NHIF) in 1991. Reimbursement of private health services by NHIF, as well as&#13;
the development of private health insurance, were also authorized at that time. Despite decentralized&#13;
&#13;
&#13;
&amp;#12;&#13;
financing in the past, the insurance system had uniformly offered universal coverage and a comprehensive&#13;
benefits package (preventive, curative, rehabilitative and chronic care), with no out-of-pocket costs. The&#13;
insurance system was, and is, financed predominantly through payroll contributions equaling 8.6 percent&#13;
of gross wages (payroll contributions as a whole--not including personal income tax--equal 31 percent of&#13;
gross wages).  Health insurance contributions from  the active labor force (wage earners and self-&#13;
employed) have provided around 60 percent of public revenues for health in recent years, with an&#13;
additional 23 percent from the Pension and Unemployment Funds to cover pensioners and registered&#13;
unemployed. Approximately 15 percent of revenues derive from user fees and other sources, and another&#13;
2 percent from the central budget, to cover MOH administrative costs and support national disease&#13;
prevention programs.  Public expenditures for health (not including cash transfers for sick pay) have&#13;
fluctuated at around 7-8 percent of GDP in the past four years, contracting roughly in proportion to the&#13;
economy. This contraction in spending--35 percent in real terms since 1990--has undermined the quality&#13;
and availability of basic health services, and given great urgency to the need for structural reform in the&#13;
financing and provision of health services.&#13;
B. Issues for Health Sector Reform&#13;
Preventable Burden of Disease&#13;
1.5            FYR Macedonia has succeeded in long-run improvement of health status, but continues&#13;
to suffer from a burden of disease which is largely preventable through cost-effective interventions at the&#13;
primary level. Two areas merit particular attention. Infant mortality (at 28 per 1,000 live births in 1991)&#13;
remains twice as high as the average for CEE countries, and three times the average for EME countries.&#13;
The long-term downward trend in infant mortality stagnated during the early transition, reflecting general&#13;
socioeconomic decline and the breakdown of basic health services-'. Approximately 40 percent of infant&#13;
deaths occur after the first month of life, largely as a result of infectious diseases. More than one quarter&#13;
of infant mortality is attributable to diarrheal disease and acute respiratory infection--both preventable or&#13;
treatable through cost-effective primary care.  High-risk populations (generally poor, rural and/or&#13;
members of ethnic minorities) in FYR Macedonia have infant mortality rates of 40 or more, and a larger&#13;
share of infant deaths due to infectious disease and malnutrition. These high rates reflect differences in&#13;
maternal education, as well as more high-risk pregnancies and lower rates of prenatal care, attended births&#13;
and immunization coverage among these populations. More effective health promotion, prenatal care,&#13;
nutrition education and clinical services for maternal and child health are needed at the primary level to&#13;
further reduce infant mortality.&#13;
if Recent declines in the infant mortality rate result from a sudden and implausible 30 percent decline among certain high-risk&#13;
populations, which is likely to be attributable to declining participation in vital registration, rather than a significant improvement in&#13;
health status.&#13;
&#13;
&#13;
&amp;#12;&#13;
- 4 -&#13;
Table 1.2: FYR Macedonia: Fetal and Infant Death, 1991-1994&#13;
(per 1,000 live births)&#13;
1991   1992   1993   1994&#13;
Stillborn rate                              8       9      9      10&#13;
Perinatal mortality rate                    19     22     20      20&#13;
Infant mortality rate                       28     31     24      23&#13;
Neonatal mortality rate (0-28 days)         16     16     14      14&#13;
% of which due to premature delivery and                       (39)&#13;
low birthweight&#13;
% of which due to respiratory conditions                      (16)&#13;
Post-neonatal mortality rate (28-364 days)  13     14     10       9&#13;
% of which due to diarrheal diseases                      (25)&#13;
% of which due to acute respiratory                      (17)&#13;
infection&#13;
Source: Statistical Office.&#13;
1.6           The second area of concern is the long-term buildup in premature death due to chronic&#13;
diseases associated with unhealthy lifestyles. FYR Macedonia is beginning to see chronic disease death&#13;
rates usually seen in far wealthier, post-industrial societies. This is particularly true for cardio- and&#13;
cerebrovascular diseases, which are by far the leading causes of premature death in both men and women,&#13;
and are associated with risk factors such as high-fat diet, lack of exercise, smoking and alcohol&#13;
consumption. Stress and social dislocation associated with the economic transition have undoubtedly&#13;
exacerbated this situation. Age-standardized death rates for cardio- and cerebrovascular diseases are 20-&#13;
40 percent higher than in much wealthier neighboring countries such as Greece and Italy, and are rising&#13;
toward the extreme levels seen in countries such as Hungary and Poland. Age-standardized rates for&#13;
other leading causes of death for men (lung cancer, liver disease) and women (breast cancer, stomach&#13;
cancer) are still below most EME countries, but rising steadily. Improvement in health status in FYR&#13;
Macedonia has ground to a halt during the transition as a result of trends in infant mortality and death&#13;
due to chronic diseases. If the country does not use health resources more cost-effectively for primary&#13;
and secondary prevention, it may soon face the worst of both worlds: infant mortality rates reminiscent&#13;
of developing countries and death due to chronic disease on par with wealthy post-industrial countries.&#13;
&#13;
&#13;
&amp;#12;&#13;
- 5 -&#13;
Table 1.3: Age-Standardized Mortality Rates. Selected Causes and Countries. 1991&#13;
(deaths per 100,000 inhabitants)&#13;
Aocue          Trachea         Breat     Stonach    Diabetes    Chronic Liver/    Pulmonary&#13;
Myocdial       Brhu/_ _          =      C     r     Melfita     Cirrhosis      Tuberculoses&#13;
Aurit                   131.7           64.7       n.a        23.9       16 9            41.5           2.4&#13;
Greece                  94.0            71.2       n.a        14.3        5.9            12.1            1.9&#13;
Italy                   S1.6            82.5       n.s       26.4        21.4            341             1.3&#13;
BulPria                 101.2           52.6       n.s       27.1        16.9            22.1           3.5&#13;
FYRM                    110.2           36.5       n.1       27.3        14.8             9.9           6.2&#13;
Hwnary                  174.0          109.6       n.a       34.6        14.0            79.8            7.5&#13;
Female&#13;
Auetris                 90.6            18.0      37.4        18.8       25.6            15.7            0.4&#13;
Greece                  58.3            13.6      24.0        10.3       12 1             5.5            0.8&#13;
laly                    49.6            13.9      35.2        19.2       39.1            18.1           0.5&#13;
Bulari                  48.5            12.0      24.1        19.8       25.0             7.9           0.9&#13;
FYRM                    71.2             7.5      22.8       18.1        26.7             3.1           3.1&#13;
Huigay                  110.9           27.7      39.7       21.5        22.2            32.6            26&#13;
boumce: blatist  I a Elce of FYR Maedonia. WHO World Heald Siustics. Based on siaix  rdized European population.&#13;
IneMfcent Rsoure fU&#13;
1.7               Adiustment to declining resources. Between 1991 and 1995, public revenues for health&#13;
declined by 40 percent in real terms, and have shown no sign of recovery. This decline is the result of&#13;
roughly proportional econornic contraction and a shrinking payroll tax base, as socially-owned enterprises&#13;
reduced wage payments and employment, emerging private enterprises evaded fiscal obligations and&#13;
statutory budget transfers were unfulfilled. The magnitude of the resource decline would have dramatic&#13;
consequences in any health system. In FYR Macedonia, ad hoc adjustment in spending resulted in the&#13;
virtual elimination of all capital expenditures and slashing of recurrent expenditures for personnel, drugs,&#13;
medical supplies and maintenance. This ad hoc adjustment was far from optimal, exacerbating long-&#13;
standing misallocation of resources. Personnel expenditures fell by 45 percent in real terms and drugs by&#13;
40 percent or more (partially compensated in some years through humanitarian aid), with similar spending&#13;
cuts across-the-board. Despite the cuts, arrears in the health sector have mounted to MKD 1.4 billion by&#13;
end-1995.&#13;
&#13;
&#13;
&amp;#12;&#13;
- 6 -&#13;
Table 1.4: Health Revenues and ExpDeditures, 1991-1995&#13;
(000 MKD)&#13;
1991        1992        193          1994         195&#13;
Health Revenues                     81,315      845,222    4,436,759    9,710,745   10,415,654&#13;
as % of GDP          9.0         7.2          7.4         7.9          7.6&#13;
in real terms (1991 =100)     100          70          62           63           59&#13;
Health Expenditures                 103,397     986,526    4,835,428   10,420,690   11,391,071&#13;
Health Expenditures without cash                917,988    4,651,227    8,758,567   10.413,813&#13;
transfers&#13;
Personnel     48,496      422,345    2,164,327    5,006,289    5,680,552&#13;
Drugs       10,805      88,340     328,016    1,190,686    1,497,982&#13;
Capital Investment      1,180      10,112      40,622      130,856      197,582&#13;
AS A PERCENTAGE OF GDP:&#13;
Health Expenditures                    11.4         8.4         8.0          8.4          8.4&#13;
Health Expenditures without cash       11.4         7.9         7.7          7.1          7.6&#13;
transfers&#13;
Personnel        5.4          3.6         3.6          4.1         4.2&#13;
Drugs          1.2         0.8         0.5          1.0          1.1&#13;
Capital Investment       0.1          0.1         0.1          0.1         0.1&#13;
IN REAL TERMS (1991 = 100)&#13;
Health Expenditures                    100           64          53          53           50&#13;
Health Expenditures                    100          60           51          45           46&#13;
without cash transfers&#13;
Personnel        100           59          51          55           54&#13;
Drugs         100          55           35          58           63&#13;
Capital Investment       100           58          39           59          77&#13;
source: National Health Insurance Fu          of   5839c77&#13;
1.8             While critical operating and investment expenditures have been cut, no fundamental&#13;
restructuring of the public sector health network has occurred. As with other socially-owned enterprises,&#13;
health facilities have protected employment at the expense of real wages and working capital. To an even&#13;
greater extent than in other socially-owned enterprises, public health facilities have not been restructured&#13;
or liquidated, but rather have limped along in a largely inoperable state for lack of working capital. The&#13;
combination of poorly paid personnel and shortages of critical drugs and medical supplies has undermined&#13;
productivity and the quality of care--particularly at the periphery. Even core public health functions, such&#13;
&#13;
&#13;
&amp;#12;&#13;
- 7 -&#13;
as childhood immunization, are at risk. In 1992, measles immunization coverage fell from over 90&#13;
percent to only around 60 percent--with measles epidemics following in 1993-94. Although humanitarian&#13;
assistance has temporarily shored up the immunization program in recent years, it is clear that the health&#13;
system needs to adjust to reduced public resources--but in ways which do not jeopardize the health of the&#13;
population.&#13;
1.9           Poor capacity utilization. With 2.4 physicians, 5.5 nursing staff and 5.4 beds per 1,000&#13;
population, staffing ratios and inpatient capacity in FYR Macedonia are on par with EME countries. This&#13;
is in contrast to many former socialist countries (e.g., Bulgaria, Russia) which have egregious excess&#13;
capacity. Nonetheless, FYR Macedonia cannot afford EME standards, and existing capacity in the system&#13;
is poorly organized and recent events have reduced demand for health services and shifted basic care up&#13;
the network to less cost-effective levels. Decentralization of health financing and management in the past&#13;
led to separate district networks of health facilities, with considerable fragmentation and duplication of&#13;
services. District secondary hospitals generally have catchment areas which are too small, and have&#13;
dramatically different ratios of physicians and nursing staff to occupied beds--implying widely varying&#13;
standards of care for similar acute care needs. Many specialized hospitals were established for treatment&#13;
of chronic diseases which today can be handled more efficiently in a general acute care or outpatient&#13;
setting.&#13;
Table 1.5: FYR Macedonia: Health Services. 1991-1994&#13;
1991   1992    1993   1994&#13;
Physicians per 1000 pop.           2.2    2.2      2.2    2.2&#13;
Qualified nurses per 1000 pop.     2.7    2.7      2.7    2.7&#13;
Hospital beds per 1000 pop.        5.45   5.35    5.25   5.2&#13;
Hospital admission rate (%)        9.4    9.7      9.2    9.3&#13;
Average length of stay (days)      14.4   16.1    17.6   14.1&#13;
Hospital occupancy rate (%)        68.2   80       84.2   68.5&#13;
of which: general hospitals  59.2   63.5    62.4   62.5&#13;
of which: specialized hospitals  75.4   102.9   119    73.2&#13;
% children immunized&#13;
DPT                             94     87      89      91&#13;
Measles                         90     60      94      91&#13;
Polio                           94     93      85      95&#13;
Tuberculosis                    98     87      n.a.   n.a.&#13;
Source: Natio-nal Institute of Public Health and Satstical Office. &#13;
&#13;
&#13;
&amp;#12;&#13;
- 8 -&#13;
1.10         The breakup of the Yugoslav Federation and the economic impact of transition rneant a&#13;
loss of non-Macedonian patients in the system, as well as reduced national demand resulting fror, redu, ed&#13;
income, increased out-of-pocket costs and dissatisfaction with the lack of drugs, supplies and eqL6prn!_nt.&#13;
In 1991, the hospital referral system was abolished, allowing patients to seek care at any level of the&#13;
system. In search of higher quality care, patients have since moved up the hierarchy, flooding high-cost&#13;
hospital services with basic primary care needs. As a result, the average number of consultations per day&#13;
for a general medicine physician dropped from 20 in 1990 to 10 in 1993. Hospital occupancy rates are&#13;
low, with rates in secondary hospitals which serve populations of over 100,000, averaging only 59&#13;
percent in 1993. At the same time, at the Department of Medical Faculty in Skopje--the top of the health&#13;
network pyramid--patient admissions from outside Skopje increased by 40 percent between 1991 and&#13;
1993, and occupancy rates remain around 100 percent.&#13;
1.11         Occupancy and utilization rates are low for all but tertiary care facilities, despite average&#13;
lengths of stay (ALOS) which are high and rising. In contrast to a sharply declining international trend,&#13;
in FYR Macedonia ALOS has remained between 14 and 18 days for the past decade. For most of the&#13;
major diagnostic categories, ALOS in FYR Macedonia are two to four times longer than in the United&#13;
Kingdom (see examples below). Thus, the system has both excess capacity and poor utilization of&#13;
capacity--inefficiencies which existing health financing mechanisms fail to squeeze out.&#13;
Table 1.6: Average Length Of Stay in Hospitals (days): 1993 data&#13;
Reason for Admission             FYR Macedonia                 United Kingdom&#13;
Infectious &amp; Parasitic Diseases           22.0                          7.3&#13;
Neoplasms                                 18.0                          9.5&#13;
Complications of Pregnancy &amp;              16.0                          3.5&#13;
Childbirth&#13;
1.12         Lack of fiscal sustainability. Like most socialist health systems, that of FYR Macedonia&#13;
had offered universal coverage for a comprehensive benefits package with no out-of-pocket costs. Since&#13;
1991, modest progress has been made in limiting public sector liability to finance health services. The&#13;
Health Protection Law adopted in 1991, and amended in 1993 and 1995, has begun to trim the benefits&#13;
package provided under compulsory national health insurance, and introduce copayments and user fees&#13;
for insured services. Services such as cosmetic surgery, thermal baths and certain prosthetic devices are&#13;
no longer reimbursed through the NHIF. The law also establishes the right to purchase supplemental&#13;
insurance for broader coverage, and the obligation to pay out-of-pocket for services not covered by&#13;
insurance. The 1993 amendment introduced copayments on insured services, ranging from 10 percent&#13;
for hospitalization to 50 percent for certain drugs and supplies. However, copayments are subject to&#13;
broad exemptions (children, the elderly, pregnant women, chronic disease patients) which undermine both&#13;
their revenue and incentive purposes. While some progress has been made to limit public sector liability,&#13;
it has obviously been insufficient to ensure fiscal sustainability, and has not involved a reallocation of&#13;
&#13;
&#13;
&amp;#12;&#13;
- 9 -&#13;
public resources toward the most cost-effective health interventions. A process is needed to identify&#13;
health priorities, based on the national burden of disease, and evaluate cost-effective strategies for&#13;
addressing these priorities. Coverage and reimbursement rates under the basic benefits package would&#13;
then need to be further limited, within the envelope of expected resources.&#13;
1.13          Lack of incentives for efficiency and quality of care. The financing mechanisms currently&#13;
in place offer no incentives to control costs, increase efficiency and improve quality. The NHIF relies&#13;
on input-based budgeting (staff, beds) to allocate funds to public sector facilities, without regard for&#13;
service volume, efficiency or quality. This budgeting system is a fallback method, following the&#13;
breakdown of an earlier "German-style" points system. A lack of cost accounting in public sector&#13;
facilities prevented the accurate valuation of points, rendering the system increasingly irrelevant. While&#13;
technically still in operation, the points system currently serves no allocative purpose. The existing&#13;
budgeting mechanism transfers no financial risk to providers, and, therefore, provides no incentives for&#13;
efficient behavior.  The lack of appropriate payment mechanisms also prevents the NHIF from&#13;
reimbursing private providers, despite its legal mandate to do so.  Thus, not only does the&#13;
underdevelopment of provider payment mechanisms fail to provide explicit incentives to public sector&#13;
facilities, but it also hinders privatization and private sector development which would offer competition&#13;
to the public sector.&#13;
1 .14         Inadequacy of managerial skills and tools. Despite past decentralization of the system,&#13;
many decisions (e.g., staffing ratios, wage levels) were centralized or made by the community council.&#13;
The managerial function--with managers taking risks and reaping the rewards of autonomous decision-&#13;
making--was nonexistent. Today, the MOH is committed to increasing managerial autonomy within an&#13;
appropriate regulatory framework, but facility directors tend to be physicians with no management&#13;
training. They also have little relevant information on which to base decisions, and few staff with the&#13;
necessary capacity to analyze information for decision-making. Health facilities lack a modem cost&#13;
accounting system, and there is little integration of medical and financial information needed to evaluate&#13;
efficiency and effectiveness. A systematic assessment of data needs has not been undertaken, nor a&#13;
strategy developed for the collection and use of data to improve health system management.&#13;
Poor Oualitv Services&#13;
1.15          Breakdown of primary health care. The quality and availability of PHC services have&#13;
deteriorated severely in recent years, particularly in rural areas. More than 40 percent of the population&#13;
resides in rural areas, and tends to be older and poorer than the general population. In the most isolated&#13;
border districts, the elderly constitute 10-19 percent of the population. The PHC budget is integrated in&#13;
the allocation to the district medical center--with rural PHC centers at the bottom of a budgetary hierarchy&#13;
which includes both the general hospital and outpatient polyclinics. Thus, the contraction in resources&#13;
has pinched hardest at the periphery. Separation of budgetary allocations and financial accounting for&#13;
hospital care, primary care and pharmacies is a badly-needed first step in clarifying financial priorities.&#13;
In a survey of 247 rural PHC centers, one quarter of those in need of a full-time physician were without&#13;
one. Virtually every center surveyed lacked some basic equipment for routine examination, minor surgical&#13;
intervention, sterilization and waste disposal. For example, around 30 percent lacked blood pressure&#13;
gauges and stethoscopes; 70 percent lacked infant scales and refrigerators; 90 percent lacked an otoscope&#13;
or a padded examination table. All were without health promotion materials. PHC staff are also too&#13;
narrowly trained, with doctors and nurses lacking a broad preventive and curative approach to family&#13;
medicine. Particularly damaging has been the lack of essential drugs at the primary level--a result of poor&#13;
&#13;
&#13;
&amp;#12;&#13;
- 10 -&#13;
procurement, distribution and reimbursement policies in the public sector.&#13;
1.16           Obstacles to affordable drugs. At an estimated three percent, the share of national income&#13;
spent on drugs in FYR Macedonia is extremely high by global standards. Approximately half of this&#13;
is financed by the public sector. For a small set of tracer drugs (all of which were common, essential&#13;
primary care drugs), it was found that market prices in public and private pharmacies in FYR Macedonia&#13;
were five to twenty times world market prices--a differential unjustified by distribution or other costs.&#13;
Such a situation is not surprising in the lucrative and imperfect pharmaceutical market, and calls for&#13;
effective government policy and regulation. Among the current problems: (i) a lengthy registration&#13;
process which requires cumbersome testing even for generic equivalents of registered drugs; (ii) a&#13;
prohibition on generic substitution by pharmacists; and (iii) pricing policies which   encourage&#13;
exaggeration of production and import costs and favor the marketing of higher-priced specialty drugs.&#13;
The public sector's purchasing and reimbursement practices are equally flawed. The public sector does&#13;
not limit its own purchasing or reimbursing to a list of essential drugs for primary and hospital care (the&#13;
existing "positive list" includes most drugs registered in the country). The public sector would also&#13;
benefit from bulk procurement of drugs and from a competitive bidding process, both of which would&#13;
lower unit costs. Finally, the NHIF places no ceiling on the amount of reimbursement for a particular&#13;
product (minus the copayment). Thus, the current policy framework provides no incentive to market&#13;
lower-cost drugs at competitive prices, and the existing financing mechanism permits this inefficiency to&#13;
flourish.&#13;
1.17           Inadeguate health promotion. Rising death rates from lifestyle-related chronic diseases&#13;
and persistent high rates of post-neonatal infant mortality speak to the need for more effective health&#13;
promotion. However, the modern concept of multi-sectoral and multi-media health promotion is largely&#13;
undeveloped. FYR Macedonia has some history of health education through a network of Public Health&#13;
Institutes whose dominant function is currently the collection of health statistics. Past health education&#13;
efforts were viewed with suspicion by the population, which saw them as a coercive, propagandistic arm&#13;
of the socialist state. Most health education efforts have not benefited from modern techniques of market&#13;
research and social marketing in order to select appropriate messages and media.  Finally, health&#13;
education and other disease prevention activities have functioned with minimal resources, with spending&#13;
amounting to less than two percent of total health expenditures in recent years.&#13;
1.18           Since the start of the transition, laudable efforts have been made to reorganize health&#13;
promotion activities according to health priorities, identify alternative funding and collaborate with&#13;
nongovernmental organizations (e.g., Red Cross) working at the community level. In 1993, government&#13;
activities were reorganized into eight national disease prevention programs, with funding for non-salary&#13;
expenditures from the central budget, in order to relieve pressure on the NHIF. However, budgetary&#13;
funding has fallen short of expectations, and NHIF resources have too often been channeled to short-term&#13;
curative needs by a medical community whose training is overwhelmingly oriented toward curative care.&#13;
Even the most basic disease prevention programs, such as maternal and child health care, are faltering,&#13;
and a medium term process of institutional development and resource reallocation is needed before health&#13;
promotion can fully play its role in reducing the burden of disease.&#13;
&#13;
&#13;
&amp;#12;&#13;
- 11 -&#13;
C. Government's Reform Strategy for Health&#13;
1.19           Reform of the health system since independence has included: (i) establishing a centralized&#13;
NHIF; (ii) introducing copayments, user fees and penalties for non-contribution; (iii) trimming the&#13;
guaranteed benefits package; (iv) increasing patient choice (although without retaining an appropriate&#13;
referral system); and (v) authorizing private health and insurance services, as well as NHIF&#13;
reimbursement of private services. The MOH and NHIF also enforced a radical--albeit insufficient--&#13;
downward adjustment in expenditures in response to fiscal crisis. Government quickly recognized,&#13;
however, the need for more fundamental reform and restructuring of the health system, in order to&#13;
reallocate resources toward cost-effective care and ensure fiscal sustainability of public spending. The&#13;
MOH took the decision to engage in a process of strategic planning--not only to define the health sector&#13;
reform program, but to identify the sequence of reforms most likely to ensure success. In mid-1994,&#13;
as part of the preparation process for the Health Sector Transition Project five technical working groups&#13;
were established consisting of MOH/NHIF personnel and representatives from other ministries, academia&#13;
and the medical community3'. Working together with World Bank and World Health Organization&#13;
support, these groups began to elaborate a strategy for medium-term health sector reform, including&#13;
appropriate sequencing of reform  measures.  They then identified the core policy agenda to be&#13;
implemented during the first phase of reform (1996-99), with support from an IDA project.&#13;
1.20           The overriding objective of Government's strategy for health system  reform  is to&#13;
overcome the current stagnation in health status by addressing high-priority health problems contributing&#13;
to infant, maternal and premature adult mortality. To achieve this, reforms will be aimed at: (i)&#13;
providing universal access to high-quality, basic preventive and curative health services and essential&#13;
drugs; (ii) promoting diversity and patient choice in the provision of services; (iii) establishing more&#13;
appropriate roles for the public and private sectors; (iv) ensuring the fiscal sustainability of public&#13;
spending for health; and, most importantly; (v) increasing the efficiency of resource allocation and use.&#13;
In the next three years, the core policy agenda will be implemented in the following areas: (i) Health&#13;
Finance and Management; (ii) Basic Health Services; and (iii) Pharmaceutical Policy and Supply.4'&#13;
Health Finance and Management&#13;
1.21           The objective for health financing reform in the next three years is to ensure universal&#13;
access to basic health services while introducing appropriate financial incentives, ensuring fiscal&#13;
sustainability and increasing the efficiency of resource use. Central to this goal will be the introduction&#13;
of a process to identify health priorities and cost-effective interventions, leading to the redesign of the&#13;
basic benefits package in order to address key health needs within a sustainable resource envelope.&#13;
Technical studies have been launched during the project preparation phase to examine the national burden&#13;
of disease and the cost-effectiveness of treatment. In redesigning the basic benefits package, supplemental&#13;
packages and premia will also be identified for those desiring broader coverage. Establishing an analytic&#13;
1/ The five working groups consisted of: (i) Health Finance; (ii) Hospital Care; (iii) Primary Health Care; (iv) Health Promotion; and&#13;
(v) Pharmaceutical Supply.&#13;
F For a more detailed discussion of the nature anid titning of specific policy measures, see the Government's Letter of Development Policy&#13;
for Health, included as Annex 1.&#13;
&#13;
&#13;
&amp;#12;&#13;
- 12 -&#13;
process within MOH for allocating resources will permit periodic adjustment of benefits packages and&#13;
premia in line with changing health priorities and resource availabilities. In conjunction with reform of&#13;
benefits, copayment, user fee and penalty policies will be reformed with an eye to eliminating excessive&#13;
exemptions, simplifying administration and minimizing barriers to essential health services.&#13;
1.22          Health financing reform  will also focus on introducing appropriate incentives for&#13;
efficiency and quality care. The current budgeting system will be superseded by provider payment&#13;
mechanisms which: (i) transfer some financial risk to health care providers; (ii) reward providers for their&#13;
level of effort and efficiency; (iii) remunerate public and private sector providers equally for equal&#13;
services; (iv) allow patient choice of physicians; and (v) establish predictable financial outflows from the&#13;
NHIF. Efforts will focus initially on the design, testing and nationwide implementation of a capitation&#13;
payment mechanism for primary health care. At the same time, pilot cost accounting data will be&#13;
generated which will permit the introduction of a case-mix based payment mechanism for hospital care.&#13;
Key to the success of the hospital payment mechanism, as well as to improved facilities management, will&#13;
be the design, testing and phased implementation of an integrated medical and financial information&#13;
system for public sector facilities, with appropriate linkage to the NHIF. This will involve a process of&#13;
identifying data needs, designing data collection mechanisms, developing an appropriate automation plan&#13;
and building analytic skills among future users of the information system. In addition, management&#13;
capacity will be enhanced througli training of MOH, NHIF and health facilities personnel. Intensive&#13;
training of trainers will ensure a core group for dissemination of management techniques and appropriate&#13;
feedback to line managers.&#13;
Basic Health Services&#13;
1.23          The objective of planned reforms in this area is to establish cost-effective, preventive and&#13;
curative primary health care as the backbone of the health system. Recently, Government took an&#13;
important step in this direction by reestablishing a mandatory referral system, in which individuals are&#13;
required to select a primary physician to serve as the first point of contact for routine care, and the&#13;
necessary referral for specialist outpatient and hospital care. In the next three years, Government intends&#13;
to redeploy public sector plysicianis to ensure adequate staffing of rural PHC centers, and invest in basic&#13;
equipment and in-service traininig for PHC staff to provide a broader, family medicine approach.&#13;
Streamlined PHC teams will be organized  in urban areas, and disease prevention programs will be&#13;
strengthened and modernized.&#13;
1.24          The complex task of restructuring and consolidating the public sector facilities network&#13;
will begin. Measures will be taken to reduce the number of public sector physicians, and limit the future&#13;
supply of doctors, dentists and pharmacists. The essential prerequisites to consolidation of the facilities&#13;
network--an appropriate referral system, adequate cost accounting and financial mechanisms in which&#13;
funds follow patients--will be put in place, followed by development and implementation of a&#13;
consolidation plan (to extend into the next phase of reform). An appropriate regulatory framework and&#13;
payment mechanisms will be established to promote voluntary and efficient development of private sector&#13;
health services.&#13;
Phannaceutical Policv and Supply&#13;
1.25          The goal of pharmaceutical reform in the 1996-99 period is to increase the availability&#13;
and affordability of essential drugs by creating a more competitive pharmaceutical market, establishing&#13;
&#13;
&#13;
&amp;#12;&#13;
- 13 -&#13;
efficient public sector procedures and promoting rational prescribing practices. A draft Drug Bill has&#13;
been reviewed by IDA, and will be considered by Parliament in the near future in order to support the&#13;
reform agenda. It establishes a streamlined registration procedure for generic equivalents, authorizes&#13;
generic substitution by licensed pharmacists and eliminates restrictive pricing policies which favored high-&#13;
priced drugs. Supporting regulations are being developed, as well as essential drug lists which will serve&#13;
as the basis for public sector procurement and reimbursement. The public sector will also develop&#13;
competitive bidding procedures for bulk procurement of essential drugs for public sector facilities, in&#13;
order to lower unit costs. The NHIF will place a ceiling on reimbursement of essential drugs based on&#13;
a low-cost reference price, as is comnmonly done in many western countries.  A National Drug&#13;
Information Center will be established to serve as a clearinghouse for global information on&#13;
pharmaceuticals, as well as to promote rational prescribing practices among physicians and develop media&#13;
campaigns to educate the public about low cost alternatives to branded specialty drugs currently on the&#13;
market.&#13;
&#13;
&#13;
&amp;#12;&#13;
- 14 -&#13;
II. PROJECT DESCRIPTION&#13;
A. Proiect Obiectives&#13;
2.1           The dual objectives of the Health Sector Transition Project (HSTP) are to: (i) improve&#13;
the health of the population by enhancing the quality of basic health services; and (ii) support an initial&#13;
phase of policy reforms to increase cost-effectiveness, fiscal sustainability and patient choice within the&#13;
health system. These broad objectives will be achieved through activities and reforms under three project&#13;
components. The specific objectives of these three components are as follows:&#13;
(a)    build capacity to analyze and apply information for policy-making and health system&#13;
management;&#13;
(b)    strengthen primary health care and support high-priority disease prevention and health&#13;
promotion programs; and&#13;
(c)    reduce the cost of essential drugs by creating a more competitive pharmaceutical market.&#13;
2.2           Project outcome indicators, as agreed with the Government, to measure the success in&#13;
achieving these objectives are defined in the Project Implementation Plan (Annex 2, para. 42).&#13;
B. Proiect Commonents&#13;
2.3           Each component of the HSTP (estimated total cost of US$19.4 million) is defined around&#13;
a core policy agenda. Project activities are designed to support implementation of this policy agenda,&#13;
while reversing recent declines in the quality of basic health care. Therefore, the description of each&#13;
component begins with a summary of the core policy agenda, which is outlined in detail in the&#13;
Government's Letter of Development Policy (LDP) for the health sector in Annex 1. Progress in&#13;
fulfilling the agenda set out in the LDP will be subject to joint annual review by the MOH and the IDA.&#13;
2.4           During negotiations, Government gave assurances that it will implement the policy&#13;
reform agenda detailed in the Letter of Development Policy, and will review jointly with IDA progress&#13;
in carrying out the agenda on an annual basis.&#13;
Component I: Health Finance and Manayement (estimated base cost US$3.8 million)&#13;
2.5           Core policy agenda. The MOH and the Health Insurance Fund (NHIF) have diversified&#13;
revenues and reduced public spending for health care in line with reductions in national income and fiscal&#13;
resources. This has been achieved through dramatic reductions in real wages, drugs, medical supplies,&#13;
maintenance and investment--but has not been sufficient to avoid the accumulation of arrears in the sector.&#13;
This ad hoc fiscal adjustment must now give way to a planned adjustment focusing on reallocation of&#13;
resources toward more cost-effective health care, appropriate limitations on public sector reimbursement&#13;
and introduction of financial incentives for efficient and effective care in both the public and private&#13;
sectors.&#13;
&#13;
&#13;
&amp;#12;&#13;
- 15 -&#13;
2.6           The MOH will carry out a comprehensive review of sources and uses of funds in the&#13;
health sector, including existing and potential revenue sources and expenditures for primary care,&#13;
ambulatory specialists, diagnostic and laboratory services and hospital care. This will provide a broad&#13;
basis for carrying out reform of health financing mechanisms. In this first phase of reform, the core&#13;
policy agenda supported under this component will be:&#13;
(a)    definition of a fiscally-sustainable benefits package (on the basis of burden of disease&#13;
priorities and cost-effectiveness of treatment) to be covered by mandatory national health&#13;
insurance, as well as supplemental premiums and packages;&#13;
(b)    revision of copayment/user fee policies and penalties for non-contribution to health&#13;
insurance;&#13;
(c)    adoption of a capitation payment mechanism for public and private sector primary health&#13;
care; and&#13;
(d)    adoption of an integrated medical and financial information system for the public sector&#13;
health network, as a prerequisite to defining a new payment mechanism for hospital care.&#13;
The nature and timing of these reforms is described in detail in the LDP (Annex 1, paras. 5-9).&#13;
2.7           Activities. The Project will provide technical support for preparation and implementation&#13;
of the health financing reforms summarized above, as a continuation of technical work begun during&#13;
project preparation. Technical support would include a resident Health Financing Advisor responsible&#13;
for coordinating short-term teams of local and foreign consultants to carry out policy studies related to&#13;
each reform. The Project will also provide support for public information/advocacy campaigns using&#13;
social marketing techniques, to enhance understanding and acceptance of health sector reforms among&#13;
policy-makers, interest groups and the general public.&#13;
2.8           The capability of NHIF personnel to analyze and implement policy options would be&#13;
strengthened through fellowships and in-country training workshops in health economics, principles of&#13;
insurance, health system planning and public advocacy techniques, as well as a study tour of comparative&#13;
health financing systems. Capacity building for the NHIF office would include technical and financial&#13;
support to develop trainers and training seminars for staff of district HIF offices. The Project will also&#13;
support a study tour, initial training seminars and development of a continuing education program in&#13;
facilities management for hospital administrators and medical directors.&#13;
2.9           To provide the tools for effective management, and allow for the future introduction of&#13;
a case-mix based hospital reimbursement system, the Project will support development and testing of an&#13;
integrated medical and financial management information system for public sector health facilities. The&#13;
Project will implement the first phase of a medium-term automation plan for this integrated information&#13;
system. The management information system will be tested in two pilot districts, each of which will&#13;
receive an automation package--tailored to the size of the population served and existing hardware--for&#13;
the participating Medical Centers (general hospital and polyclinic), two primary health care centers,&#13;
district Institutes of Public Health (responsible for national health statistics), and district HIF offices.&#13;
Information technology will also be provided to the NHIF and NIPH offices. The necessary electronic&#13;
linkage for data transfer and processing within the NHIF network will be established.&#13;
&#13;
&#13;
&amp;#12;&#13;
- 16 -&#13;
2.10           Prior to negotiations, Government selected two pilot districts according to agreed upon&#13;
criteria for testing of: (i) the medical and financial management information system; (ii) the health&#13;
statistics information system; and (iii) the capitation payment mechanism for primary care.&#13;
Component 11: Basic Health Services (estimated base cost US$7.0 million)&#13;
2.11           Core Policy Agenda. Government's decision in 1991 to centralize district insurance funds&#13;
into a unified health insurance fund has helped to maintain universal access to care, while allowing&#13;
maximum  risk-sharing and alleviation of regional inequities in the quality of basic care.  In 1992,&#13;
national disease prevention programs were reorganized, and funding for materials and supplies was shifted&#13;
from the NHIF to the central budget, as an attempt--with mixed success--to ensure adequate support for&#13;
high-priority prevention and health promotion activities. Greater success was achieved in securing&#13;
humanitarian assistance to supply vaccines and essential drugs for health services during the transition.&#13;
However, this source has dwindled as donors await reform aimed at reorienting public sector resources&#13;
toward primary care. Under the Project, this reform will focus on providing cost-effective primary care&#13;
as the backbone of the health system, through:&#13;
(a)    reinstatement of a hospital referral system through mandatory annual enrollment with a&#13;
primary care physician;&#13;
(b)    assignment of full-time physicians to selected rural primary health centers;&#13;
(c)    adoption of a simplified staffing structure for primary health care teams in urban areas,&#13;
and of a guaranteed package of primary health services which provides cost-effective care&#13;
(based on successful models from other countries);&#13;
(d)    net reduction of at least 200 public sector physicians through attrition (retirement,&#13;
voluntary privatization) over the three year period;&#13;
(e)    reduction of enrollments in medical faculties for physicians, dentists and pharmacists; and&#13;
(f)    provision of adequate central budget funding for selected disease prevention activities.&#13;
The nature and timing of these reforms are described in detail in the LDP (Annex 1, paras. 10-16).&#13;
2.12           Activities.  The MOH  working group on basic health services undertook a needs&#13;
assessment and established a standard equipment list for rural PHC centers. Under the Project, basic&#13;
equipment kits corresponding to these needs will be distributed to all rural PHC centers in the country&#13;
(the list of basic equipment proposed is found in the PIP). In the first year of the Project, kits will be&#13;
distributed to 150 centers with one or more full-time physicians. The following year, kits will be&#13;
distributed to 50 additional PHC centers to which a full-time physician will be assigned. A more limited&#13;
equipment kit, appropriate for 50 centers without full-time physicians, will also be distributed in the&#13;
second year of the Project. In addition to equipping rural PHC centers, the Project will provide technical&#13;
and financial support for workshops and study tours to help MOH and professional associations develop&#13;
their own permanent programs for: (i) continuing education of primary care personnel; (ii) broadening&#13;
the skills of primary care physicians; and (iii) identifying and enforcing quality assurance standards for&#13;
primary care. Short-term fellowships will also be provided to develop capacity within the MOH for&#13;
&#13;
&#13;
&amp;#12;&#13;
- 17 -&#13;
planning and implementation of primary care strategies.&#13;
2.13          The Project will provide material support for five national disease prevention and health&#13;
promotion programs for: (i) immunization, (ii) maternal and child health; (iii) tuberculosis prevention;&#13;
(iv) AIDS prevention; and (v) blood donation and supply. These programs were selected on the basis&#13;
of their potential impact in reducing the national burden of disease and on the cost-effectiveness of the&#13;
proposed interventions. With respect to the immunization program, the Project will contribute to&#13;
maintaining coverage rates at 95 percent or more. While UNICEF will provide parallel financing for&#13;
most vaccines needed to combat childhood diseases and control epidemics, the Project will supply&#13;
necessary hepatitis B vaccines. In the area of maternal and child health, the Project will provide material&#13;
support for reproductive health services, as well as drugs and equipment for prevention and treatment of&#13;
disease in neonates and infants. Support will also be given for restructuring and expanding the existing&#13;
cervical cancer screening program. For prevention of tuberculosis, the Project will improve screening&#13;
capacity through provision of spare parts for x-ray equipment, photographic film and replacement of two&#13;
decrepit mobile clinics with one new mobile van. Under the AIDS prevention program, test kits will be&#13;
provided for HIV screening. To increase blood supply, the Project will build on the early success of&#13;
public campaigns aiming to restore donation levels to 60,000 units per annum, by providing support for&#13;
promotional materials in several local languages. Finally, the Project will provide equipment and&#13;
materials to strengthen laboratory diagnostics for the prevention and treatment of infectious diseases.&#13;
2.14          Prior to negotiations, Government gained parliamentary approval for amendments to the&#13;
Health Protection Law reinstating the hospital referral system through annual enrollment with primary&#13;
care physicians.&#13;
Component III: Phannaceutical Policy and Supply (estimated base cost US$5.7 million)&#13;
2.15          Core Policy Agenda. The share of national income spent on drugs in FYR Macedonia is&#13;
among the highest in the world. Prescribing practices favor overconsumption, while procurement, pricing&#13;
and reimbursement policies favor high-priced specialty drugs and limit competition. Private sector activity&#13;
has grown rapidly within a largely unregulated environment. An estimated half of national consumption&#13;
is financed by the public sector through the NHIF (US$28 million in 1994). Past public spending patterns&#13;
for drugs have been difficult to maintain as NHIF revenues have declined by 40 percent in real terms&#13;
since 1991. Public spending was supplemented with humanitarian assistance in the 1992-94 period, but&#13;
this source has dwindled rapidly. The time has come for Government to work within its real resource&#13;
constraints, and focus on more efficient procurement, pricing, reimbursement and prescribing in order&#13;
to ensure an affordable supply of essential drugs. With technical support from the World Health&#13;
Organization, the MOH has begun revision of drug legislation, as well as organizing seminars on rational&#13;
drug use and national drug policy.  The Project will build on these past efforts, emphasizing&#13;
implementation of key reforms in the following areas:&#13;
(a)    streamlining of registration procedures for equivalent products and authorization of&#13;
generic substitution;&#13;
(b)    adoption of pricing policies which favor lower-cost drugs;&#13;
(c)    adoption of appropriate essential drug lists for primary care and hospital care;&#13;
&#13;
&#13;
&amp;#12;&#13;
- 18 -&#13;
(d)    introduction of competitive bidding for public sector drug procurement;&#13;
(e)    establishment of a reference price reimbursement system for essential drugs; and&#13;
(f)    promotion of rational prescribing practices.&#13;
The nature and timing of these reforms are described in detail in the LDP (Annex II, paras. 17-24).&#13;
2.16           Activities. The Project will provide technical support for further revision of the Drug&#13;
Bill and accompanying regulations with respect to registration, pricing and generic substitution, as well&#13;
as establishment of essential drug lists for primary and hospital care. It will build local capacity for&#13;
competitive procurement and for implementation of a reference price reimbursement system for NHIF&#13;
which would place ceilings on allowable payments according to drug type. Capacity-building would&#13;
occur through external internships in international procurement offices, coupled with follow-up technical&#13;
support and studies to establish reference prices and carry out initial international tenders for drugs.&#13;
Essential drugs and supplies from the agreed lists would be procured in the second year of the Project,&#13;
to ease NHIF resource constraints and provide practical experience in international competitive bidding&#13;
for pharmaceutical products.&#13;
2.17          Under the Project, equipment, short-term fellowships, in-country training and technical&#13;
support will be provided to upgrade the present drug quality assurance system. Supply of advanced drug&#13;
testing equipment for quality control labs will enable government to match the increasing technical&#13;
sophistication of the domestic industry and foreign suppliers. It will facilitate bioequivalence testing to&#13;
permit rapid introduction of generic equivalents. The Project will also support the establishment of a&#13;
drug information center, as well as a srnall center for adverse drug reaction monitoring. Parallel funding&#13;
from EU/PHARE and WHO will contribute to improvements in the drug inspection system, as well as&#13;
provide institutional support and training for the drug information and adverse drug reaction centers.&#13;
Through the drug information center, the Project will support information campaigns directed at&#13;
prescribers, dispensers and the public to promote more rational use of drugs.&#13;
2.18           Prior to negotiations, Government submitted to IDA a satisfactory draft Drug Bill,&#13;
reflecting the Government's drug policy reform strategy.&#13;
2.19           As a condition of effectiveness of the proposed credit Government will sign a contract&#13;
with a procurement agency to ensure procurement and distribution of pharmaceutical products, medical&#13;
equipment and supplies under the Project in accordance with IDA's Guidelines for Procurement&#13;
(January 1995). As a condition of disbursement of the pharmaceutical component a Drug Law,&#13;
satisfactory to IDA, regulating the registration, trade and distribution of drugs in the territory of the&#13;
Borrower, will be enacted, and all provisions for implementation of this legislation completed.&#13;
International Proiect Unit (estimated base cost US$0.9 million)&#13;
2.20           The Project will support establishment of an IPU in the Ministry of Health. The IPU will&#13;
be responsible for coordination, management and monitoring of the Health Sector Transition Project, as&#13;
well as coordination of other donor-funded activities in the health sector. The IPU will be headed by a&#13;
Director, with support from a core staff funded under the Project. This core staff will consist of a&#13;
Procurement Officer, Disbursernent Officer/Accountant, and Office Administrator/Interpreter employed&#13;
&#13;
&#13;
&amp;#12;&#13;
- 19 -&#13;
full-time for the Health Sector Transition Project.&#13;
2.21          IPU responsibilities will include: (i) project administration and coordination (including&#13;
liaison with the World Bank and agencies/institutions involved in implementation of the Project);&#13;
(ii) follow-up and reporting; and (iii) maintaining project records and accounts. It is also expected that&#13;
the IPU will provide a focal point for coordination of health sector reform activities, and assist in&#13;
dissemination of information about the reform program to policy-makers, interest groups and the general&#13;
public. To facilitate the work of the IPU, the Project will make available funding for short-term foreign&#13;
and local consultancy services, in project-related areas such as procurement and project management, as&#13;
well as policy-related areas such as health economics and private sector development  With additional&#13;
staff, the IPU could also serve to coordinate implementation of other donor-funded activities (e.g.,&#13;
EU/PHARE, UNICEF) to ensure that all externally-funded activities support the MOH's medium-term&#13;
strategy for health sector reform.&#13;
2.22           Prior to negotiations, Government established the International Project Unit within MOH&#13;
and appointed a full-time director and procurement officer with authorization to carry out the project&#13;
activities.&#13;
2.23           During negotiations, Government gave assurances that the MOH  will maintain&#13;
continuous staffing of the IPU to include a Director and staff devoted full-time to the Health Sector&#13;
Transition Project consisting of a procurement officer, disbursement officer/accountant and office&#13;
administrator/interpreter. It was further agreed that decisions would be taken jointly during project&#13;
implementation for recruitment of additional IPU staff, if necessary to entsure effective implementation&#13;
of the proposed Project.&#13;
C. Project Justification&#13;
Proiect Alternatives&#13;
2.24           As noted above, the dual objectives of World Bank intervention in the health sector in&#13;
FYR Macedonia are to: (i) improve the health of the population by enhancing the quality of basic health&#13;
services; and (ii) promote reforms to increase cost-effectiveness, fiscal sustainability and patient choice&#13;
in the health system. To achieve these objectives, alternative project designs were considered, and&#13;
ultimately rejected for the following reasons-'.&#13;
2.25           Improving health status. The known determinants of health status are--in descending&#13;
order of importance--(i) economic status; (ii) lifestyles/behaviors; (iii) quality of the health system; and&#13;
(iv) environmental risks. Socioeconomic conditions in FYR Macedonia have declined dramatically in the&#13;
past five years, exerting a negative impact on health status. Despite strong efforts by Government and&#13;
the World Bank to encourage stabilization, structural adjustment and capital investment, economic&#13;
recovery is expected to be slow--even if ideal policy and investment decisions are taken. Therefore,&#13;
improvement in health status must be through countervailing action on other determinants: lifestyles, the&#13;
51 See Annex 3, Selection among Alternative Project Designs for a more detailed discussion of options considered.&#13;
&#13;
&#13;
&amp;#12;&#13;
- 20 -&#13;
health system and the environment. World Bank efforts are already underway to identify and alleviate&#13;
environmental risks, leaving to this Project the task of reducing the burden of disease through behavioral&#13;
change and improved health services. Rapid assessment of the leading causes of morbidity and mortality&#13;
in FYR Macedonia indicates that no one vertical program would be more cost-effective than broad-based&#13;
primary care in reducing the overall burden of disease--hence support for comprehensive preventive and&#13;
curative primary care. Thought was given to investing solely in health promotion programs (which are&#13;
cost-effective in changing lifestyles in the long run) but ultimately the Project seeks a broader reallocation&#13;
of public resources toward health promotion--not just an IDA investment--which necessitates restructuring&#13;
and investment in the health network as a whole. Furthermore, it was not a politically acceptable option.&#13;
2.26           Promoting reforms to enhance cost effectiveness, fiscal sustainability and patient choice.&#13;
The Government has adopted one alternative to increasing the fiscal sustainability of the health system:&#13;
across-the-board budget cuts which have undermined the cost-effectiveness, quality and availability of&#13;
care. Another alternative--increasing the payroll tax burden--would have a negative impact on the cost&#13;
of labor, and is to be avoided. FYR Macedonia spends a relatively high share of national income (around&#13;
7 percent) on health, pointing to a need for more effective expenditures, not higher revenues. At this&#13;
point, the only alternative to achieving the goals of fiscal sustainability, cost-effectiveness and patient&#13;
choice simultaneously is to reallocate public resources toward more cost-effective health interventions,&#13;
set limits to public sector financial liabilities and create incentives for efficient and competitive behavior&#13;
among health care providers. The Project has been designed to maximize the likelihood of success in&#13;
carrying out these difficult reforms. Each component was designed around a core policy agenda, with&#13;
investments to support implementation of reforms according to a carefully designed sequence.&#13;
Financial Impact&#13;
2.27           Public sector. The project investments generate minimal incremental recurrent costs,&#13;
equal to less than one percent of recurrent health expenditures. Incremental costs associated with the&#13;
Project are dwarfed by the fiscal savings resulting from reforms supported by the Project. Among the&#13;
reform measures which will generate fiscal savings are:&#13;
(a)    definition of a basic benefits package for health insurance within the limits of expected&#13;
payroll contributions (workers, pensioners, registered unemployed);&#13;
(b)    shifting of care to less expensive levels, through an appropriate referral system;&#13;
(c)    reduction of public sector health personnel, and reduction of public sector support for&#13;
medical training;&#13;
(d)    introduction of financial incentives to prevent unnecessary medical procedures and&#13;
excessive lengths of stay;                      I&#13;
(e)    establishment of  lists of essential drugs for procurement and reimbursement, and&#13;
adoption of competitive bidding procedures and reference price reimbursement ceilings;&#13;
(f)    elimination of broad exemptions on copayments and user fees; and&#13;
&#13;
&#13;
&amp;#12;&#13;
- 21 -&#13;
(g)    consolidation of the public sector facilities network (to continue into the next phase of&#13;
reform).&#13;
The extent of fiscal savings will depend on future decisions about the scope of the benefits package, the&#13;
essential drug lists and the reduction in staffing and capacity. Initially, the objective will be to reduce&#13;
public spending for health in line with expected revenues, preventing further accumulation of arrears and&#13;
eliminating the existing stock of arrears. Whether there is a further reduction in public resources for&#13;
health--rather than an expansion of cost-effective interventions--is a political decision. One cannot argue&#13;
on economic grounds that FYR Macedonia is spending "too much" on health, but rather that the country&#13;
is not getting enough for its money. The Project will substantially increase the cost-effectiveness of&#13;
public spending for health, providing the opportunity to reduce the overall resource envelope to a&#13;
sustainable level.&#13;
2.28           Private sector. The reform agenda for pharmaceuticals will lower the cost of drugs (the&#13;
greatest source of private health expenditures) for everyone by creating a more competitive market and&#13;
revising pricing policies. Strengthening of primary care in rural areas will lower the out-of-pocket costs&#13;
of care for rural populations by reducing travel and waiting costs, as well as eliminating hospital&#13;
copayments and fees for routine care. Elimination of broad exemptions on copayments will raise out-of-&#13;
pocket costs for patients in specific groups, but care will be taken to reinforce the progressive nature of&#13;
copayments (higher rates for less essential services) and to define a means-tested basis for guaranteeing&#13;
access to basic services for the poor.&#13;
Rationale for Public Sector Involvement&#13;
2.29           Imperfections and failures in the health care and pharmaceutical markets (externalities,&#13;
uncertainty, asymmetry of information, market power), as well as societal equity considerations, justify&#13;
a strong--albeit changed--role for the public sector in the financing, regulation and, in some cases,&#13;
provision of health services.  Public sector financing of health services allows broad risk-pooling&#13;
(especially in a country as small as FYR Macedonia) to overcome the inefficiency of financial uncertainty.&#13;
It also allows redistribution to achieve equity objectives. Public sector health financing also serves as a&#13;
regulatory tool, through payment mechanisms which curb supplier-induced demand for unnecessary&#13;
services and other inefficient behavior by public and private sector providers. For these reasons, the&#13;
Project supports reform of the existing public sector financing mechanism in FYR Macedonia.&#13;
2.30           Many personal health services can be provided efficiently by the private sector once an&#13;
appropriate incentive structure and regulatory framework are in place. Reforms supported by the Project&#13;
aim to eliminate obstacles and create an environment conducive to privatization and private sector&#13;
development of health services. However, international experience demonstrates that the private market&#13;
will not offer sufficient incentive to provide socially desirable services in poorer, more isolated areas.&#13;
For this reason, most governments offer special incentives and/or direct public sector provision of basic&#13;
health services in poor, rural areas. Likewise, this Project will strengthen public sector provision of&#13;
primary health care only in targeted rural villages, where public sector intervention is justified.&#13;
2.31           The pharmaceutical market is notoriously noncompetitive, particularly in small markets,&#13;
where monopoly or oligopoly is common. The public sector generally relies on both regulation (e.g.&#13;
registration procedures, pricing and substitution policies) and direct provision of essential drugs to create&#13;
competition for the private sector. Unfortunately, the public sector itself is often very inefficient in&#13;
&#13;
&#13;
&amp;#12;&#13;
- 22 -&#13;
providing drugs, so that government failure may equal or exceed market failure. Thus, the Project&#13;
supports not only reforms aimed at creating a more competitive private market, but also measures to&#13;
increase the efficiency of Government procurement and distribution.&#13;
Rationale for IDA Involvement&#13;
2.32           Public sector investment in the health sector is justified on grounds that much of the&#13;
economic benefit of improved health status accrues to society at large, rather than providing a financial&#13;
return to the investor. In the absence of low-cost, domestic capital for public sector investment in human&#13;
development, IDA resources are a good choice for FYR Macedonia. The country has also turned to the&#13;
World Bank for assistance in this area because the Bank can provide high-quality technical advice on&#13;
health sector reform from a broad, international perspective. IDA involvement in health sector reform&#13;
in FYR Macedonia through this Project is consistent with the Country Assistance Strategy (CAS)&#13;
discussed by the Board of Directors during presentation of the Financial and Enterprise Sector Adjustment&#13;
Credit (FESAC; Credit 2721, Report No. P-6539) on April 19, 1995. Key objectives of the CAS include&#13;
maintenance of a fiscally sustainable social safety net during the transition period and restoration of long-&#13;
run economic growth. Broad access to basic health services is an essential element of the social safety&#13;
net, while improvement in health status will increase the productivity of human capital in the long run.&#13;
Health financing reforms also contribute to controlling fiscal deficits which undermine economic growth.&#13;
Hence, a health sector project has been included in the lending program, even under a low-case scenario.&#13;
2.33           Sector work was carried out at an early stage to identify priorities for health sector reform&#13;
and investment.t' Consultant reports produced in collaboration with the technical working groups during&#13;
project preparation addressed the following topics: (i) health finance; (ii) hospital care; (iii) primary health&#13;
care; and iv) health promotion." FYR Macedonia also participated in the Social Challenges of Transition&#13;
Exercise, which has provided a comparative view of health systems in nine other CEE countries, greatly&#13;
facilitating strategy formulation. The resulting health sector reform strategy is now serving not only as&#13;
the foundation for the Health Sector Transition Project, but also as an input in the definition of the&#13;
country's Policy Framework Paper and the proposed Social Sector Adjustment Loan (FY97).&#13;
Cost-Effectiveness of the Project&#13;
2.34           Project components were carefully selected not only for the cost-effectiveness of the&#13;
proposed investments, but also for the impact of associated reforms on the cost-effectiveness of public&#13;
resource use in the health sector as a whole. Rigorous cost-benefit or cost-effectiveness analysis of each&#13;
component was not carried out during project preparation for two reasons: (i) a broader collaborative&#13;
process of assessing health priorities and evaluating cost-effectiveness of alternative interventions is an&#13;
integral part of the Project itself; and (ii) rigorous analysis was deemed unnecessary to provide an&#13;
adequate economic justification for the proposed investments. Justification of each component is as&#13;
follows:&#13;
2.35           Component 1: Health Finance and Management. This component provides economic and&#13;
FYR Macedonia: Health Services in Transition, September 1993.&#13;
Consultants' reports available in the project files.&#13;
&#13;
&#13;
&amp;#12;&#13;
- 23 -&#13;
fiscal benefits through its impact on the allocation of public resources in the health sector. During project&#13;
preparation, a process was initiated to assess health priorities by carrying out a national burden of disease&#13;
analysis, to be followed by use of cost-effectiveness analysis as a tool to define a more appropriate&#13;
benefits package for national health insurance. This, more than any other reform, will channel public&#13;
resources toward more cost-effective health interventions.  The process will continue under this&#13;
component, with the objective of not simply revising the initial benefits package, but of building&#13;
permanent capacity in the MOH to assess health priorities and use cost-effectiveness analysis to make&#13;
choices among alternative treatments. The component also supports the introduction of financial incentives&#13;
for efficient behavior by health care providers, and strengthens the management skills and information&#13;
tools needed to ensure cost-effective use of resources.&#13;
2.36          Component 11: Basic Health Services. The component invests in primary health care as&#13;
the backbone of the health system, strengthening, in particular, disease prevention and health promotion&#13;
activities. The project preparation team assessed the leading causes of morbidity and premature mortality&#13;
in FYR Macedonia--providing a rough indication of the burden of disease. With continued high levels&#13;
of infant mortality due to infectious diseases and maternal mortality due to high-risk pregnancies and&#13;
abortions, as well as rapidly rising premature mortality due to chronic diseases associated with unhealthy&#13;
lifestyles, it was clear that reduction in the burden of disease could be achieved most cost-effectively&#13;
through preventive and curative care at the primary level. The body of international evidence on the cost-&#13;
effectiveness of primary health care in addressing multiple elements of the burden of disease made the&#13;
calculation of potential disability-adjusted life years (DALYs) gained in FYR Macedonia unnecessary.&#13;
Cost-effectiveness of prevention efforts such as childhood immunization, family planning and prenatal&#13;
care--all supported under this component--are well established internationally, and no factors are present&#13;
which would significantly alter in FYR Macedonia the high ratio of benefits to costs.&#13;
2.37          Support for combatting infectious diseases which lead to disability and death in young&#13;
adults--AIDS and tuberculosis--also has a high DALY payoff, particularly given FYR Macedonia's&#13;
elevated incidence of tuberculosis (among the highest in the CEE). A proposal to intervene in the area&#13;
of smoking prevention would have been highly cost-effective, but was rejected by MOH as too&#13;
controversial at this time. The project preparation team (both IDA and client members) believes that&#13;
investment in less controversial disease prevention programs under this first Project, and demonstration&#13;
of success in applying modern social marketing techniques, will build a solid relationship upon which to&#13;
broach the more controversial smoking/tobacco issue under future projects.&#13;
2.38          Component III: Pharmaceutical Policy and Supplv. The benefit of this component lies&#13;
in its economy-wide impact on the price of essential drugs, as well as in the provision of essential drugs,&#13;
vaccines and medical consumables for effective primary care. The second most important determinant&#13;
of quality in primary health care--behind well-trained staff--is the availability of essential drugs. In recent&#13;
years, the Government has relied on humanitarian aid to supplement its own dwindling resources for&#13;
drugs, but these flows have largely dried up as a result of both regional events and resistance by donors&#13;
to continuing the supply in the absence of more meaningful reform of the pharmaceutical sector. The&#13;
Project will provide funding for essential drugs and vaccines--as an input into strengthening primary&#13;
health care--but will link investments to the implementation of a difficult reform agenda.&#13;
2.39          At an estimated three percent of national income, the rate of spending on pharmaceuticals&#13;
in FYR Macedonia is among the highest in the world. More than half of the estimated US$60 million&#13;
per annum in drug spending is funded by the public sector. Market prices of five to twenty times world&#13;
&#13;
&#13;
&amp;#12;&#13;
- 24 -&#13;
market levels indicate a noncompetitive market unrestrained by appropriate public sector regulation or&#13;
intervention. The reform agenda aims at improving the affordability and availability of essential drugs&#13;
by creating a more competitive policy environment and increasing the efficiency of public sector drug&#13;
procurement and reimbursement. If one makes a conservative estimate that implementation of the reform&#13;
agenda will lower prices by one-third, then the economy would save US$60 million during the three-year&#13;
project implementation period alone. Fiscal savings would total around US$30 million, against an initial&#13;
investment cost of US$6.4 million. These large economic and fiscal benefits would continue beyond the&#13;
life of the Project. This high benefit-cost ratio amply justifies the component--although success in&#13;
implementing the reforms may be politically difficult (see Risks, below).&#13;
Impact on Poverty&#13;
2.40          By reallocating public resources towards provision of high-quality basic health services,&#13;
the Project will benefit the poor, who cannot currently afford to pay out-of-pocket for private sector&#13;
services. By creating insurance payment mechanisms which reimburse public and private sector providers&#13;
equally for equal services, the Project gives patients--particularly poor patients--choice, and with choice,&#13;
the power to influence the quality of care provided. Investments in strengthening primary health care in&#13;
rural areas and in disease prevention (equal to 44 percent of the IDA credit) will also benefit the poor,&#13;
who live disproportionately in rural areas. Thus, the proportion of beneficiaries is significantly larger&#13;
than their proportion in the overall population, qualifying the Project for inclusion in IDA's Program of&#13;
Targeted Interventions. Replacing broad copayment exemptions for specific patient groups with a means-&#13;
tested basis for exempting the poor should also result in a better-targeted system of ensuring access to&#13;
basic health services.&#13;
IDnact on the Environment&#13;
2.41          The Project is expected to have a marginally beneficial impact on the environment. By&#13;
providing appropriate equipment for medical waste disposal at the primary care level, the Project will&#13;
have a small positive environmental impact. Otherwise, the Project will not have a direct impact on the&#13;
environment, and has been assigned to Environmental Category C.&#13;
Proeect Risks&#13;
2.42          Sustainabilitv of Political Commitment. The risk which dominates all others vis-a-vis the&#13;
success of the Project is political. It is the risk that the country cannot muster the political will necessary&#13;
to implement fundamental health sector reform, particularly with respect to limiting insurance benefits,&#13;
squeezing economic rents out of the pharmaceutical market and consolidating the public sector facilities&#13;
network. Government has only the health care consumer on its side, facing politically and economically&#13;
powerful medical and pharmaceutical interest groups. One of every seven parliamentarians is a doctor&#13;
which heightens the need for careful marketing of the reform strategy to lawmakers. Much will depend&#13;
on the leadership of the Minister of Health, and his ability to articulate to the public and the parliament&#13;
the objectives and strategies underlying the reform program.&#13;
2.43          To overcome this risk, the following strategy has been pursued. First, technical working&#13;
groups with representatives of relevant ministries, academia and the medical community were formed at&#13;
an early stage. This ensured broader participation of stakeholders in both strategy formulation and project&#13;
preparation. Second, the project preparation team encouraged early interaction with the media, resulting&#13;
&#13;
&#13;
&amp;#12;&#13;
- 25 -&#13;
in MOH press conferences at every stage of project design. Third, early efforts were also made to&#13;
market the emerging reform strategy to key political and economic policymakers. Success of reform will&#13;
depend on support from the highest levels of government, not only the commitment of the MOH.&#13;
Finally, and most importantly, resources have been included in the Project to support a vigorous&#13;
communications strategy, with a full-time consultant to the International Project Unit to assist the MOH&#13;
in designing and implementing effective public information campaigns. The Project will support continual&#13;
opinion research, as well as development of appropriate messages and media approaches for various&#13;
stakeholders, including the general public, the medical community and lawmakers.&#13;
2.44          Institutional Capacity. An additional project risk lies in the weak institutional capacity&#13;
of the MOH, and its limited experience in implementation of large, internationally funded projects. The&#13;
MOH has a direct staff of only 25, mostly with medical--as opposed to managerial--training. The MOH&#13;
is adjusting to its new role in a market-oriented health system, focused more on policymaking and&#13;
regulation than on direct provision of services. There is a tendency to want to exert heavy-handed,&#13;
centralized control rather than to rely on establishment of an appropriate policy environment, regulatory&#13;
framework and incentive structure. This is neither desirable in a mixed public/private health system, nor&#13;
feasible given manpower and financial constraints. Thus, institutional constraints to effective&#13;
implementation are both physical and psychological.&#13;
2.45          Experience in implementing internationally-funded projects has been limited to the&#13;
distribution of humanitarian aid in recent years. To alleviate this and other weaknesses in institutional&#13;
capacity, the Project invests heavily in building managerial capacity within the MOH and NHIF through&#13;
training, study tours and technical assistance. The Project also supplements MOH implementation&#13;
capacity through provision of long-term local management consultants to support the newly-created&#13;
International Project Unit. The IPU will coordinate implementation of this Project, as well as other&#13;
donor-funded investments. Although the reform agenda is substantive, the Project itself was designed&#13;
for easy implementation: simple investments organized into a small number of procurement packages.&#13;
Medical equipment, supplies, drugs and vaccines accounting for more than 60 percent of the IDA credit&#13;
will be procured by a local agent with sophisticated infrastructure and a strong track record on&#13;
international purchasing and nationwide distribution.&#13;
Monitorin2 and Evaluation&#13;
2.46          A detailed description of project monitoring and evaluation--including summary tables for&#13;
inputs, outputs and outcomes--is provided in Chapter IV of the PIP (Annex 2). Project monitoring will&#13;
involve assessment of project inputs and outputs. Monitoring the use of project resources will be done&#13;
by tracking inputs according to component, activity and expenditure category (PIP, Table 9). Monitoring&#13;
outputs under the Project is more complex, involving both implementation of project activities and&#13;
implementation of the policy reform agenda. For the former, key project activities have been identified&#13;
as output indicators (PIP, Table 10). For the latter, progress in implementing reforms will be jointly&#13;
assessed by Government and IDA on an annual basis. A timetable of expected progress, with carefully-&#13;
defined progress benchmarks, has been summarized in the policy matrix attached to the Government's&#13;
Letter of Development Policy (Annex 1). For project evaluation, a limited set of outcome indicators has&#13;
been selected on the basis of relevance to the project objectives, sensitivity to project activities, ease of&#13;
data collection and parsimony (PIP, Table 11). However, it is recognized that changes in some of these&#13;
indicators cannot be causally linked directly to project activities, since the Project is only one of multiple&#13;
factors impacting health status and services during the short (three-year) implementation period.&#13;
&#13;
&#13;
&amp;#12;&#13;
- 26 -&#13;
However, annual monitoring of these indicators will provide evidence of overall trends in the health status&#13;
of the population, the effectiveness of health services and the efficiency of public spending for health--all&#13;
of which the Project seeks to influence positively.&#13;
Overall Coherence and Completeness of the Policy Framework&#13;
2.47          The Health Sector Transition Project has been designed around a core policy agenda for&#13;
health sector reform. This core policy agenda, as summarized in the Letter of Development Policy, is&#13;
a coherent and sound basis for IDA involvement in the health sector. While it does not solve all&#13;
problems in the health sector, this initial phase of reform carefully identifies those measures which will&#13;
have the greatest impact on the efficiency and effectiveness of public spending for health. A careful&#13;
sequencing of reforms within the three-year project implementation period was elaborated by&#13;
Government. Implementation of these reforms--with support from the Project--will lead to the reallocation&#13;
of public resources toward more cost-effective health interventions, introduce incentives for efficiency&#13;
and quality, build managerial capacity, strengthen basic health services in poorer, rural areas, introduce&#13;
modern techniques of health promotion and vastly increase the affordability and availability of essential&#13;
drugs. These outcomes are central to the short- and long-run improvement of health status in FYR&#13;
Macedonia, the objective against which IDA involvement will be evaluated.&#13;
&#13;
&#13;
&amp;#12;&#13;
- 27 -&#13;
111. PROJECT COSTS. FINANCING, MANAGEMENT AND IMPLEMENTATION&#13;
3.1           This chapter provides a summary of the Project Implementation Plan (PIP) prepared in&#13;
collaboration with the Borrower, and reviewed and found satisfactory by IDA. The PIP, attached to this&#13;
Staff Appraisal Report as Annex 2, includes detailed information on:  (i) project implementation&#13;
arrangements and responsibilities; (ii) project cost, financing, procurement and disbursement&#13;
arrangements; (iii) monitoring and evaluation; (iv) supervision and reporting requirements; (v) initial&#13;
project implementation schedules; and (vi) several agreed terms of reference and equipment lists.&#13;
A. Project Cost&#13;
3.2           Total project cost is estimated at US$19.4 million, or MKD 737 million equivalent,&#13;
including contingencies.  Total  base cost is estimated at US$17.4 million.  Physical and price&#13;
contingencies are estimated at US$1.4 million and US$0.6 million, respectively. The foreign exchange&#13;
component is estimated at US$14.5 million, or 75 percent of total cost. All imported goods and services&#13;
destined for health institutions and related purposes--including those financed under the Project--are&#13;
exempt from taxation and customs duties.&#13;
3.3           Project costs include financing for medical and laboratory equipment and supplies,&#13;
essential drugs and vaccines, office equipment, computers, furniture, local and external technical&#13;
assistance and training, minor facilities' rehabilitation, and incremental operating costs (including&#13;
equipment maintenance, supplies and incremental staff salaries). Cost estimates by project component&#13;
are shown in Table 1 of the PIP, and by expenditure category in Table 2.&#13;
B. Project Financing&#13;
3.4           The proposed IDA Credit of SDR 11.8 million (US$16.9 million equivalent) will finance&#13;
87 percent of the estimated total project cost, including 100 percent of the total foreign exchange cost&#13;
(US$14.5 million) and 48 percent of estimated local costs (about US$2.4 million of a total US$5.0&#13;
million). The Government will finance the remaining estimated US$2.5 million in local costs. Table 3&#13;
of the PIP shows the financing plan for the Project, and Table 4 the project cost breakdown by&#13;
component and financier.&#13;
3.5           Project cost estimates include US$0.3 million (1.5 percent of total project cost) in&#13;
incremental operating costs attributable to the Project during the three-year period. These costs comprise&#13;
equipment operation and maintenance, minor operating expenses and supplies, and incremental staff&#13;
salaries. On an annual basis, these incremental operating costs are estimated at MKD 5.0 million, equal&#13;
to less than 1 percent of the recurrent health budget. These costs will be more than compensated by fiscal&#13;
savings from a number of measures being undertaken by the MOH, inter alia, limiting insurance benefits,&#13;
introducing competitive procurement for pharmaceuticals and reducing public funding for medical&#13;
training.&#13;
3.6           Project start-up is being facilitated through a Project Preparation Facility (PPF) Advance&#13;
of US$223,500 (P983-0-MK). The PPF is being used to establish and equip the International Project Unit&#13;
&#13;
&#13;
&amp;#12;&#13;
- 28 -&#13;
(IPU), hire and train key project unit staff, and hire local experts needed for a series of technical studies&#13;
to be carried out with assistance from a team of external consultants.&#13;
C. Project Mana2ement and Implementation&#13;
3.7           The IPU, established in the MOH, is headed by a Director, and supported by several full-&#13;
time staff (long-term local consultants under contract with the MOH for the duration of the Project),&#13;
including: a procurement officer (already in place), disbursement officer/accountant, and office&#13;
administrator/interpreter .&#13;
3.8           The IPU is be responsible for coordination, management and monitoring of the Health&#13;
Sector Transition Project. More specifically, the Unit's responsibilities include: (i) project administration&#13;
and coordination (including liaison with IDA and agencies and institutions involved in implementation&#13;
of the Project); (ii) procurement coordination and follow-up; (iii) maintaining project records and&#13;
accounts; and (iv) monitoring, evaluation, and progress reporting. It is also expected that the IPU will&#13;
provide a focal point for coordination of health sector reform activities, and assist in dissemination of&#13;
information about the reform program to policymakers, interest groups and the general public. Short-&#13;
term local and external consultancy services in areas such as procurement and project management, as&#13;
well as in policy-related areas such as health economics and market regulation, are foreseen to assist the&#13;
IPU in fulfilling its role. With the addition of more full-time staff, the IPU will also serve as&#13;
coordinating agency for other donor-funded activities (e.g., WHO, UNICEF), ensuring consistency with&#13;
the MOH's medium-term strategy for sector reform.&#13;
3.9           Overall responsibility for implementation of each of the components is as follows:&#13;
(i) Health Finance and Management--lead agency, the National Health Insurance Fund; (ii) Basic Health&#13;
Services--lead agency, the Office of the Assistant Minister for Primary and Preventive Health Care; and&#13;
(iii) Pharmaceutical Policy and Supply--lead agency, the Department of Pharmaceuticals in the MOH.&#13;
A thorough discussion of implementation responsibilities is found in Sections B and C of the PIP.&#13;
D. Proiect Supervision&#13;
3.10          The Project is expected to require a total of about 33 weeks of supervision per year&#13;
during the three-year implementation period, including 15 weeks for routine supervision of project&#13;
implementation, and 18 weeks of supervision and continued dialogue and advice on implementation of&#13;
the core policy agenda. Estimated annual supervision requirements are presented in Table 8 of the PIP.&#13;
E. Procurement Arrangements&#13;
3.11          Items to be procured have been grouped into a small number of packages (about eight)&#13;
to encourage competitive bidding and permit bulk procurement. The Bank's standard bidding documents&#13;
will be used for procurement under the Project. Paragraphs 25-34 of the PIP found in Annex 2 provide&#13;
details regarding procurement arrangements envisaged under the Project, and the standard procurement&#13;
information is presented in Table 5. All procurement financed under the Credit will be carried out in&#13;
&#13;
&#13;
&amp;#12;&#13;
- 29 -&#13;
accordance with IDA Guidelines. Details concerning procurement packages, including the nature of the&#13;
package, estimated value and implementation timetable, are presented in Table 6 of the PIP.&#13;
F. Disbursements&#13;
3.12          The proposed Project is expected to be disbursed over a period of three years, which is&#13;
considerably shorter than the All-Regions Profile for health and population projects of 9.5 and 8.5 years,&#13;
respectively. In addition, the country profile is speculative since this Project is only the second operation&#13;
in the human resources sectors in the FYR Macedonia, the first having become effective less than one&#13;
year ago. The shorter implementation period for the Health Sector Transition Project reflects the nature&#13;
of the Project as a source of bridge financing during the initial phase of the transition and in support of&#13;
the first phase of the Government's health reform program. Investments under the Project, and the&#13;
packaging of procurement, have been kept simple to accommodate the shorter timeframe. Implementation&#13;
and related disbursements will be facilitated by having defined equipment lists and agreed terms of&#13;
reference prior to project implementation (see Chapters V &amp; VI of the PIP). Moreover, the use of an&#13;
experienced procurement agency to procure and distribute, on behalf of the MOH, medical equipment,&#13;
supplies and pharmaceuticals procured under the Project (estimated value about US$7 million or 40% of&#13;
the IDA credit) will also simplify implementation. The closing date will be March 31, 2000. Estimated&#13;
disbursements of the Credit by year are shown in Table 7 of the PIP.&#13;
3.13          Implerr.entation will be facilitated by the establishment of a Special Account, opened by&#13;
the Government in a bank and maintained under terms and conditions acceptable to IDA. The account&#13;
will be denominated in US dollars, and will have an authorized allocation of US$1.0 million. Further&#13;
details regarding the Special Account are outlined in para. 36 of the PIP.&#13;
G. Proiect Audits and Reportin2&#13;
3.14          The IPU will be responsible for coordinating annual project audits and for fulfilling&#13;
reporting requirements. With respect to project accounts, including the Special Account, they will be&#13;
audited in accordance with IDA's Guidelines for Financial Reporting and Auditing of Projects Financed&#13;
by the World Bank (March 1982), and will be provided by the Borrower within six months of the end&#13;
of each fiscal yea!. In addition, the IPU will be responsible for preparing semi-annual progress reports,&#13;
which will include:  a sunmmary of progress under each component, proposals for rescheduling of&#13;
activities where necessary, actual disbursements and projections for the subsequent six-month reporting&#13;
period, as well as a thorough analysis of progress in implementation of the health sector reform program&#13;
as outlined in the Letter of Development Policy. Further information concerning auditing and progress&#13;
reporting under the Project is provided in paras. 37-38 of the PIP.&#13;
3.15          During negotiations, Government gave assurances that it will prepare and furnish to&#13;
the Association by January 31, 1998 a report on progress achieved in carrying out the Project up to&#13;
that time and proposing measures to ensure achievement of objectives during the remaining project&#13;
period. It was further agreed that the Association and the Borrower will jointly review this report by&#13;
March 31, 1998 and, on the basis of conclusions from that review, agree on steps to be taken to ensure&#13;
efficient project completion.&#13;
&#13;
&#13;
&amp;#12;&#13;
- 30 -&#13;
H. Status of Preparation&#13;
3.16          During the initial stages of preparation, the Borrower established five technical working&#13;
groups to develop project proposals for each component. That structure--with minor modification--has&#13;
remained in place and has been a principal contributor to the thorough preparation process. Through&#13;
changes in political leadership at MOH, the working groups provided continuity in preparation of both&#13;
the reform strategy and the specific project proposals, leading to an internalization of the Project by MOH&#13;
personnel and participants from the medical community and associated institutions. The close&#13;
collaboration of the working groups with IDA staff and with WHO led to progress in the formulation of&#13;
the Government's medium-term strategy, which has served as the basis for the core policy agenda&#13;
supported under this Project. This agenda has been broadly discussed with a view to achieving the&#13;
consensus necessary for its implementation. The Project Implementation Plan, setting out detailed&#13;
responsibilities and arrangements for carrying out project activities, has been prepared and agreed.&#13;
Lastly, the IPU has been established and key staff appointed to ensure a smooth start-up of project&#13;
implementation.&#13;
&#13;
&#13;
&amp;#12;&#13;
- 31 -&#13;
IV. PROJECT BENEFITS AND RISKS&#13;
A. Benefits&#13;
4.1           The economic benefits of the Project include better quality basic health services and more&#13;
cost-effective use of public resources for health--both of which will counteract the negative impact of&#13;
recent economic and fiscal contraction on the health of the population. Benefits by component are as&#13;
follows:&#13;
4.2           Component I: Health Finance and Management. This component provides economic and&#13;
fiscal benefits through its impact on the allocation of public resources for health.  It will result in a&#13;
reallocation of public resources toward more cost-effective health interventions, as well as limitation of&#13;
health expenditures to fiscally sustainable levels. The component implements a basic benefits package&#13;
for health insurance which is based on cost-effective treatment of national health priorities, and is tailored&#13;
to available resources. It also develops permanent capacity in the MOH to use the tools of burden of&#13;
disease and cost-effectiveness analysis to adjust benefits as health priorities and resource constraints&#13;
evolve. The component will also put in place incentives for efficiency and quality of care, through the&#13;
establishment of new provider payment mechanisms, and will build managerial skills and provide&#13;
management tools--particularly the integrated medical and financial information system--which will result&#13;
in more effective resource management in the health sector&#13;
4.3           Component II: Basic Health Services. Cost-effective reduction in the burden of disease,&#13;
through improved preventive and curative primary care, is the major economic benefit of this component.&#13;
With continued high levels of infant mortality due to infectious diseases and maternal mortality due to&#13;
high-risk pregnancies and abortions, as well as rapidly rising premature mortality rates due to chronic&#13;
diseases associated with unhealthy lifestyles, it is clear that preventive and curative primary care is the&#13;
most cost-effective way to reduce multiple elements of the burden of disease. The component will result&#13;
in adequately staffed and equipped primary health care centers in rural areas, offering a broader approach&#13;
to family medicine with greater emphasis on disease prevention and health promotion. It will also begin&#13;
the process of consolidating staffing and physical capacity in the public sector network in order to use&#13;
resources more efficiently. The component will result in more effective reduction of the leading causes&#13;
of infant, child, maternal and other premature adult mortality through support for prevention programs&#13;
in the areas of childhood immunization, maternal and child health, tuberculosis and AIDs prevention and&#13;
blood supply. Within these prevention programs, a demonstration of the effectiveness of modern, social&#13;
marketing techniques in changing lifestyles to improve health will pave the way for greater investment&#13;
in health promotion under future projects.&#13;
4.4           Component III: Pharmaceutical Policy and Supply. The benefits of this component lie&#13;
in its economy-wide impact on the price of essential drugs, as well as the direct provision of drugs,&#13;
vaccines and medical consumables for more effective primary care. The second most important&#13;
determinant of quality in primary care--behind well-trained staff--is the availability of essential drugs.&#13;
The component will supply drugs and other consumables, linked to implementation of pharmaceutical&#13;
sector reform aimed at increasing the affordability and availability of essential drugs. Legislative reform&#13;
will result in streamlined registration procedures allowing easier market entry for lower-cost generic&#13;
equivalents. It will also allow licensed pharmacists to substitute lower-cost generic equivalents for&#13;
&#13;
&#13;
&amp;#12;&#13;
- 32 -&#13;
prescription specialty drugs. Reform of pricing policies will alter financial incentives to encourage&#13;
marketing of lower-cost drugs. Adoption of essential drug lists for public sector procurement and&#13;
reimbursement, as well as the introduction of competitive bidding for bulk procurement and reference&#13;
price ceilings for public sector reimbursement will lower unit costs for drugs in the public sector, and&#13;
channel public resources toward the most cost-effective drugs. Overall, the economic and fiscal gains&#13;
of this component dwarf the economic costs, with fiscal savings in the three-year project implementation&#13;
period conservatively estimated at ten times the investment cost. These large economic and fiscal benefits&#13;
will continue beyond the life of the Project.&#13;
B. Risks&#13;
4.5            The Project faces two key risks--one political, the other institutional. The political risk&#13;
is dominant in determining the success of the Project. It is the risk that the country cannot muster the&#13;
political will necessary to implement fundamental health sector reform, particularly with respect to&#13;
limiting insurance benefits, squeezing economic rents out of the pharmaceutical market and consolidating&#13;
the public sector facilities network. Government has only the health care consumer on its side, facing&#13;
powerful medical and pharmaceutical interest groups. One of every seven parliamentarians is a doctor--&#13;
heightening the need for careful marketing of the reform strategy to lawmakers. To reduce this risk, the&#13;
following strategy has been pursued. First, technical working groups with representatives of relevant&#13;
ministries, academia and the medical comrnunity were formed at an early stage to ensure broad&#13;
participation in both strategy formulation and project preparation. Second, the project preparation team&#13;
encouraged early interaction with the media, resulting in MOH press conferences at every stage of project&#13;
design. Third, early efforts were also made to market the emerging reform strategy to key political and&#13;
economic policymakers. Finally, and most importantly, resources have been included in the Project to&#13;
support a vigorous communications strategy, including a full-time consultant to the International Project&#13;
Unit assisting the MOH in designing and implementing effective public information campaigns. The&#13;
Project will support continual opinion research, as well as development of appropriate messages and&#13;
media approaches for various stakeholders, including the general public, the medical community and&#13;
lawmakers.&#13;
4.6           A secondary risk lies in the weak institutional capacity of the MOH, and its limited&#13;
experience in implementation of internationally-funded projects. The MOH has a direct staff of only 25,&#13;
mostly with medical--as opposed to managerial--training. Some are having difficulty adjusting to the new&#13;
role of the MOH in a more market-oriented health sector. Indeed, institutional constraints to effective&#13;
project implementation are both physical and psychological. To alleviate this risk, the Project will invest&#13;
heavily in building managerial capacity within the MOH and NHIF through training, study tours and&#13;
technical assistance. The Project also supplements MOH's implementation capacity through provision&#13;
of local management consultants, working full-time to support the newly-created International Project&#13;
Unit. The IPU will coordinate implementation of this Project, as well as other donor-funded investments&#13;
to ensure coherence with the medium term strategy for health sector reform. Although the reform agenda&#13;
supported by the Project is substantive, project activities were designed for easy implementation: simple&#13;
investments organized into a small number of procurement packages. Medical equipment, supplies, drugs&#13;
and vaccines accounting for more than 40 percent of the IDA credit will be procured by a local agent&#13;
with sophisticated infrastructure and a strong track record of international purchasing and nationwide&#13;
distribution.&#13;
&#13;
&#13;
&amp;#12;&#13;
- 33 -&#13;
V. AGREEMENTS REACHED AND RECOMMENDATIONS&#13;
5.1           Prior to negotiations, Government:&#13;
(a)    selected two pilot districts according to agreed upon criteria for testing of: (i) the&#13;
medical and financial management information system; (ii) the health statistics&#13;
information system; and (iii) the capitation payment mechanism for primary care (para.&#13;
2. 10);&#13;
(b)    gained Parliamentary approval for amendments to the Health Protection Law reinstating&#13;
the hospital referral system through annual enrollment with primary care physicians&#13;
(para. 2.14);&#13;
(c)    submitted to IDA a satisfactory draft Drug Bill, reflecting the Government's drug policy&#13;
reform strategy (para. 2.18); and&#13;
(d)    established an International Project Unit within MOH and appointed a full-time director&#13;
and procurement officer with authorization to carry out the project activities (para. 2.22).&#13;
5.2           During negotiations, Government gave assurances that it will:&#13;
(a)    implement the policy reform agenda detailed in the Letter of Development Policy, and&#13;
will review jointly with IDA progress in carrying out the agenda on an annual basis&#13;
(para. 2.4);&#13;
(b)    maintain continuous staffing of the IPU, to include a Director and staff devoted full-time&#13;
to the Health Sector Transition Project consisting of a procurement officer, disbursement&#13;
officer/accountant and office administrator/interpreter (2.23); and&#13;
(c)    prepare and furnish to the Association, by January 31, 1998, a report on progress&#13;
achieved in carrying out the Project up to that time and proposing measures to ensure&#13;
achievement of objectives during the remaining project period. It was further agreed that&#13;
the Association and the Borrower will jointly review this report by March 31, 1998 and,&#13;
on the basis of conclusions from that review, agree on steps to be taken to ensure&#13;
efficient project completion (para. 3.15).&#13;
5.3           As a condition of effectiveness of the proposed Credit, Government will:&#13;
(a)    sign a contract with a procurement agency to ensure procurement and distribution of&#13;
pharmaceutical products, medical equipment and supplies under the Project in accordance&#13;
with IDA's Guidelines for Procurement (January 1995) (para. 2.19).&#13;
5.4           As a condition of disbursement of the Pharmaceutical Policy and Supply component:&#13;
(a)    a Drug Law, satisfactory to IDA, regulating the registration, trade and distribution of&#13;
drugs in the territory of the Borrower, will be enacted, and all provisions for the&#13;
implementation of this legislation completed (para. 2.19).&#13;
Recommendation&#13;
5.4           Subject to the above, the proposed Project provides a suitable basis for an IDA Credit&#13;
of SDR 11.8 million (US$16.9 million equivalent) to the Government of FYR Macedonia.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 1&#13;
Page 1 of 15&#13;
REPUBLIKA MAKEDONIJA&#13;
MINISTERSTVO ZA ZDRA VSTVO&#13;
REPUBLIC OFMACEDONIA&#13;
MINISTRY OFHEALTH&#13;
Letter of Development Policy&#13;
REPUBLIC OF MACEDONIA&#13;
HEALTH SECTOR TRANSITION PROJECT&#13;
Skopje, May 15 1996&#13;
Mr. James Wolfensohn&#13;
President&#13;
International Development Association&#13;
1818 H Street, N.W.&#13;
Washington, D.C. 20433&#13;
Dear Mr. Wolfensohn:&#13;
The Republic of Macedonia inherited from the former Yugoslav federation a publicly-funded and&#13;
publicly-provided health system, organized on the basis of "self-managed communities of interest"&#13;
with decentralized health insurance funds and local networks of health facilities. The system had a&#13;
number of strengths, including universal health coverage, broad access, minimal financial risk for&#13;
individuals, well-trained health personnel and strong epidemiological control. As a result, the&#13;
health system contributed to the long-term improvement in the health of the population, with life&#13;
expectancy rising from 61 years in 1960 to 72 years in 1990--far exceeding the average for&#13;
countries of similar income level, and even surpassing the average for much wealthier countries in&#13;
Central and Eastem Europe. Nonetheless, the health system at independence suffered from long-&#13;
standing weaknesses and inefficiencies. In particular, the system offered no financial incentives to&#13;
health personnel and patients to increase efficiencv, control costs and improve the quality of care.&#13;
Facilities lacked clear ownership as well as managenral autonomy and decision-making skills.&#13;
Excessive decentralization had led to duplication and fragmentation of services, coupled xvith&#13;
regional inequities in the quality of care. The system relied too heavily on hospital-based care, and&#13;
overemphasized curative treatment at the expense of more effective disease prevention programs.&#13;
These problems were underscored during the early years of independence, when severe economic&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 1&#13;
Page 2 of 15&#13;
contraction led to a dramatic decline in public resources for health, which fell by nearly 40 percent&#13;
in real termns between 1991 and 1993. This decline gave greater urgency to the need for reforms to&#13;
increase the cost-effectiveness of health spending.&#13;
Health System Reform Since Independence&#13;
Following independence in 1991, we revised the existing Health Protection Law to address&#13;
certain structural problems in the health system. In particular, we established a single, centralized&#13;
Health Insurance Fund (HIF) to maximize risk-sharing and alleviate regional inequities in the&#13;
quality of care. Socially-owned facilities were transformned into a single network of public sector&#13;
facilities reporting to the Ministry of Health (MOH). Private sector health insurance and health&#13;
services were authorized, along with HIF reimbursement of private services (reimbursement of&#13;
private services has been limited, in practice). Patients were granted free choice of physicians,&#13;
although regulations were not put in place to maintain an appropriate hospital referral system.&#13;
This has since exacerbated the overreliance on hospital-based care. Further revision in 1993&#13;
introduced financial participation by patients in the costs of ambulatory care, hospital care, drugs,&#13;
medical supplies and prosthetic devices (copayments ranging from 10 to 50 percent of the reference&#13;
price).  A  first effort was also made to exclude some health services--largely cosmetic&#13;
interventions--from HIF reimbursement, and to require the uninsured to pay for health services out-&#13;
of-pocket.&#13;
We were obliged to make a rapid and difficult fiscal adjustment in the health system.&#13;
Public sector spending for health declined in line kith real reductions in national income, although&#13;
this was insufficient to prevent the accumulation of arrears. This ad hoc expenditure adjustment&#13;
was not optimal, relying on across-the-board reductions in recurrent spending (for drugs. vaccines,&#13;
medical supplies, maintenance, utilities and staff remuneration) rather than restructuring of the&#13;
public system and reallocation of resources toward more cost-effective types of care. As a result,&#13;
the quality and broad availability of basic health services has been seriously compromised in recent&#13;
years.  We are commuitted to more fundamental restructuring and resource reallocation, but&#13;
recognize the need for strategic planning and technical expertise to define an appropriately-&#13;
sequenced reform program. With financial and technical support from the proposed IDA-funded&#13;
Health Sector Transition Project, ve have already embarked on the process of defimng and&#13;
implementing a medium-term  strategy for health system  reform.  Technical working groups&#13;
established by our MOH to prepare the project have elaborated a number of background papers&#13;
setting out the broad objectives of our health system reform, and outlining a sequence of steps to&#13;
achieve them. Using these documents as a basis, the technical working groups have identified a&#13;
limited number of core policy measures to be implemented during the first phase of reform, with&#13;
support from the proposed IDA-funded health project.&#13;
Strate2'v for Health System Reform. 1996-99&#13;
Our overriding objective is to overcome the current stagnation in health status associated&#13;
w%ith the early phase of the transition, by addressing high-prioritv health problems contributing to&#13;
infant, maternal and premature adult mortality. To achieve this, we will focus on reform of the&#13;
health system aimed at: i) maintaining universal access to basic preventive and curative health&#13;
services and essential drugs; ii) promoting diversitv and patient choice in provision of health&#13;
services; iii) redefining the role of the public sector in health policy and service delivery. and&#13;
establishing a more appropriate public/private mix of health services; iv) improving the fiscal&#13;
sustainabilrx of public spending for health; and v) increasing the efficiency of resource allocation&#13;
2&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 1&#13;
Page 3 of 15&#13;
and use.  An initial phase of reforms will be implemented over the next three years. This core&#13;
policy agenda will focus particularly on: i) health financing and reimbursement; ii) organization&#13;
and management of health service; and iv) pharmaceutical policies and supply.&#13;
Health Financin2 and Mana2ement&#13;
Our objectives for health financing over the next three years are to ensure universal access&#13;
to basic health services while introducing appropriate financial incentives and ensuring fiscal&#13;
sustainability of the Health Insurance Fund. On November 7, 1995, we submitted to Parliament a&#13;
further revision of the Health Protection Law which specifies that out-of-pocket payment is&#13;
required for all health services not explicitly covered by compulsory health insurance, and for&#13;
specialist outpatient and hospital care to which the patient was not referred by his/her primary&#13;
physician. This is part of our effort to reestablish a referral system in order to discourage&#13;
excessive use of hospitals (see para. 11)   for discussion of the referral system), as well as a&#13;
precursor to further limiting compulsory health insurance coverage. In the next three years, we&#13;
will focus our efforts on the followNing core policy agenda: i) definition of a basic package of health&#13;
services for compulsory health insurance coverage; ii) revision of copayment and user fee policies,&#13;
and penalties for non-contribution to insurance, iii) adoption of a capitation payment mechanism&#13;
for public and private sector primary health care; and iv) adoption of an integrated medical and&#13;
financial information svstem (as a prerequisite to defining a case-mix payment mechanism for&#13;
hospital care). PHRD grant resources made availabl by the Japanese Government for project&#13;
preparation will permit us to begin the necessary technical studies shortly. The recommendations&#13;
of these studies will be reviewed by our Government's Technical Committee on Health Finance,&#13;
which will then propose necessary legislative and regulatory changes.&#13;
Basic benefits for comDulsorv health insurance coverage. A technical team of foreign&#13;
and local experts will assess the burden of disease in Macedonia in order to quantitatively evaluate&#13;
health priorities.  They Nvill then use existing information on the cost-effectiveness of various&#13;
treatments along with estimated costs of actual treatment in our country to recommend ways to&#13;
limit basic health insurance coverage in terms of types of services and level and/or lifetime value of&#13;
reimbursements. Their objective N1ill be to define a basic package which is financially sustainable&#13;
Within the expected resources from statutory health insurance contributions. At the same time,&#13;
they w'ill define one or more supplemental premiums and packages for those who desire broader&#13;
coverage. We anticipate that the technical proposal for basic and supplemental packages will be&#13;
ready by December 31, 1996, with Government presentation of the recommended packages to&#13;
Parliament by June 30, 1997. Following Parliamentary discussion and adoption, we expect the&#13;
resulting basic package to be under implementation through the HIF by December 31, 1997.  Its&#13;
presentation to Parliament will- coincide v.ith presentation of proposed revisions to the Health&#13;
Protection Law. These revisions will increase the flexibilitv of the law to permit: i) periodic&#13;
adjustment of the basic package of health services, ii) revision of copayment and user fee policies;&#13;
and iii) introduction of new provider payment mechanisms.&#13;
Couavment and user fee policies. Existing proposals to revise copavment and user fee&#13;
policies will be studied in order to simplify admninistration, eliminate excessive exemptions and&#13;
grant Government flexibility to periodically adjust rates through an appropriate institutional&#13;
mechanism.  Recommendations will be review ed by the Technical Committee on Health Finance&#13;
and then incorporated in revisions to the Health Protection LaN, to be presented to Parliament for a&#13;
first reading by June 30,1997. The revised policy is expected to be implemented by December 31,&#13;
1997.&#13;
3&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX I&#13;
Page 4 of 15&#13;
Capitation pavment mechanism for vrimary health care. In the next few years we wlill&#13;
proceed with the design, testing and nationwide implementation of a capitation payment system for&#13;
primary health care. Currently, salary and material payments to public sector facilities are made&#13;
regardless of service utilization, while payments to the emerging private sector are erratic and&#13;
prone to abuse. Adoption of a capitation system corresponds to our needs to find a payment&#13;
mechanism which: i) emphasizes primary care as the backbone of the health system; ii) rewards&#13;
health care providers for their level of effort and their efficiency; iii) remunerates public and&#13;
private sector providers equally for equal services, iv) allows patient choice of primary physician;&#13;
and v) establishes a predictable financial outflow  from the H1F.  Technical study Will begin&#13;
immediatel. to define the basic package of primarv health services to be included within the&#13;
capitated payment (as part of the larger process of defining basic insurance coverage) and&#13;
estimating the average per capita cost of providing these services. Design and implementation of&#13;
the capitation payment system will be linked to our reinstatement of a referral svstem   and&#13;
restructuring of public sector primary health care teams (para. I 1). Legislative revisions needed to&#13;
allow  introduction of the capitation system  will be included in the proposal  presented to&#13;
Parliament by June 30,1997. Pilot testing of the capitation system in two zones will also begin bv&#13;
June 30 1997 and extend for a full year. Two pilot sites were selected prior to negotiation of the&#13;
proposed health project. By June 30 1998, regulations regarding the capitation system will be&#13;
modified as necessary, with nationwide implementation completed by June 30, 1999.&#13;
Inteerated medical and financial information system for public sector health facilities.&#13;
We intend to design, test and implement for all public sector health facilities an integrated medical&#13;
and financial information system which assists managers in strategic decision-making and permits&#13;
development of a case-mix based payment system for hospital care. The proposed design of the&#13;
integrated management information system (MIS) will be presented to the Technical Committee on&#13;
Health Finance (Information Systems subcommittee) by June 30, 1997. One-year pilot activities&#13;
in two zones, including two medical centers (general hospital and polyclinic) and four associated&#13;
primary care centers, will be underway by June 30, 1997 in order to test and refine the MIS By'&#13;
June 30 1998, a technical review of the pilot phase will be completed, and a plan defined for&#13;
introduction and eventual automation of the MIS nationwide. Data from the pilot phase vAill be&#13;
used to develop a case-mix based pavment system  for hospitals. to steer resources toward&#13;
productive facilities and create incentives for efficiency and cost containment. This will replace the&#13;
current system of allocating resources largely on the basis of staffing. The technical proposal for a&#13;
new  hospital payment system  will be completed by December 31, 1998, with nationlide&#13;
implementation undervay by June 30, 1999.   In addition to the facilities-based NIS, data&#13;
collection for national health statistics (e.g. morbidity, mortality) will be strengthened under the&#13;
proposed Health Sector Transition Project.&#13;
Organization of Health Services&#13;
In an aggregate sense, staffing levels and service capacity in our health system are on par&#13;
with averages in Westem Europe. However, services are not organized for optimal efficiency, and&#13;
the system represents a heavy fiscal burden given our national income level. Duplication and&#13;
fragmentation of services are common, due to the highly decentralized approach of the past. Manv&#13;
facilities are fully staffed, but underutilized. Shortages in drugs and supplies at the periphery&#13;
coupled with a breakdown of the referral system have scnt patients streaming into tertiary care&#13;
hospitals to meet even their basic primary health care nceds. We recognize the need to rationalize&#13;
our public sector health system, shifting the bulk of care to wNhere treatment is most cost effective--&#13;
4&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 1&#13;
Page 5 of 15&#13;
the primary level--and consolidating or liquidating redundant services wvhen they are clearly&#13;
identified. However, rationalization will only be possible with: i) development of accounting and&#13;
payment mechanisms which explicitly link resources to service delivery; ii) reinstatement of an&#13;
appropriate referral system to shift patients to the primary level; and, most importantly, iii)&#13;
provision of high-quality care at the primary level.&#13;
Development of new accounting and payment mechanisms will be supported by the&#13;
proposed health project, and reform measures are described in paras. 9-10 above. Amendments to&#13;
the Health Protection Lawv reinstating a referral system were adopted by Parliament on November&#13;
7, 1995. Under the amendment, individuals select a primary physician (with the option to change&#13;
each year) who is the first point of contact for routine care, and provide the required referral for&#13;
specialist outpatient and inpatient services (except emergency care). Each individual's health&#13;
identity card will include the name of his/her primary physician.  This policy will halt the&#13;
indiscriminate use of specialist and hospital services, particularlv for primary health needs.&#13;
However, implementation of this policy will be successful only if high-quality services are&#13;
available at the primary level.&#13;
Both policy reform and investmnents are needed to improve the quality and ensure the&#13;
financial sustainabilitv of our primary health care system, particularly in rural areas.  We have&#13;
asked the World Bank to support key investments in quality care, including basic reequipping of&#13;
rural primary health centers, development of continuing education programs for health personnel at&#13;
the primary level and establishment of quality assurance standards and monitoring. A critical&#13;
element will also be an affordable supply of essential drugs at the primary level, as described in&#13;
paras. 17-23 below. The core policy agenda will address staffing pattems for primary care as well&#13;
as the overall supply of health professionals in the system, as a main determinant of longer-run&#13;
financial sustainability.&#13;
Staffing of rural orimarv health centers. 250 rural primary health centers xwill receive&#13;
equipment packages under the proposed project. Of these, 150 are currentlv staffed with a full-&#13;
time phvsician, in addition to one or more nurses. These centers will be reequipped in 1996, and&#13;
remain staffed with a full-time physician throughout the 1996-99 period. Of the remaining 100&#13;
primarv health centers which are not staffed with a full-time physician, 50 have been selected by&#13;
the technical working group as requiring full-time physician services, based on the size of the&#13;
population served and proximity to other health services. We will redeplov existing public sector&#13;
staff in order to assign  full-time physicians to these 50 centers by June 30 1997.  This&#13;
redeployment will be a prerequisite to reequipping the remaining 100 rural primary health centers.&#13;
Creation of primary health care teams in urban areas. In urban areas, provision of&#13;
primarv care is excessively fragmented among a number of physicians and health professionals.&#13;
They tend to be overly-specialized according to patient age-groups, leading to inflexibility and&#13;
inefficiency in staff deployment. Pediatricians unnecessarilv limit themselves to treating either&#13;
ages 0-7 or 7-19, dentists focus on either of these age groups or adult care. Workplace physicians&#13;
duplicate basic primarv care services offered in free-standing clinics. We intend to simplify this&#13;
staffing structure, bs realigning public sector health personnel in urban areas into primarv health&#13;
care tcams. A primary liealth care team would consist of a core group of physicians--a general&#13;
practitioner, a pediatrician, an obstetrician-gynecologist and a dentist--plus associated nursing&#13;
persornel. The general practitioner would coordinate the primarv health care team, and serve as&#13;
primary physician for the purposes of referral to specialist services and hospital care. Other&#13;
specialist personnel would continue to offer consulting services by referral, but would fall outside&#13;
5&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 1&#13;
Page 6 of 15&#13;
the core primary health care team. A detailed plan for reorganization of primary care personnel&#13;
into primary health care teams will be prepared by December 31 1996, with implementation&#13;
completed by June 30, 1997.&#13;
Supply of health  professionals.  In order to ease fiscal constraints and prevent&#13;
unnecessary cost escalation through supplier-induced demand for health services, measures will be&#13;
taken to control the future numbers of physicians, dentists and pharmacists trained in the country.&#13;
We already offer no guarantee of public sector employment to graduating health professionals, and&#13;
this policy Will be maintained.  In addition, we will use attrition (normal retirement, voluntary&#13;
privatization, etc.) to reduce the net number of publicly-employed physicians (currently totaling&#13;
4,516) by at least 200 before June 30, 1998. In terms of future supply, we will invoke numerus&#13;
clausus for enrollment in medical training programs, in order to maintain adequate ratios of&#13;
medical professionals to population and reverse excessive expansion of enrollments in recent years.&#13;
Enrollment for physicians' training will be decreased from 120 in academic year 1996/97 bv 20&#13;
percent annually for the next three years (academic v'ears 1997/98, 1998/99 and 1999/2000). The&#13;
1999/2000 enrollment level is consistent with maintaining an adequate ratio of medical&#13;
professionals to population in the longer run, and will be extended over a longer period than the&#13;
proposed project implementation phase. If this limit of medical students per annum is maintained,&#13;
it would permit a ratio of 2.3 physicians per 1,000 inhabitants in the year 2010, given expected&#13;
demographic trends and attrition rates in the profession. This is close to the current ratio of 2.4&#13;
physicians per 1,000 inhabitants in our country, as well as to the current average for OECD&#13;
countries. If recent enrolLment rates of 150-200 students per annum were maintained, the ratio of&#13;
physicians to population would rise rapidly to around 2.6-2.7 by the vear 2010. For dentists' and&#13;
pharrnacists' training, average annual enrolLments have nearly doubled since 1991, and will be&#13;
reduced to an annual total of 75 students for dentistrv and 75 students for pharmacy for the&#13;
academic years 1996/97 through 1998/99 and beyond. Maintaining reasonable ratios will permrit&#13;
better remuneration of highly-trained health professionals--an expected trend as earnings diverge to&#13;
reflect skill levels in the market economy.&#13;
Disease prevention and health promotion. Long-term trends toward better health have&#13;
stagnated in recent years as a result of socioeconomic decline and reduced quality of health care&#13;
services and public health interventions. With an infant mortalitv rate which is twice the average&#13;
for Central and Eastem Europe and four times the average of Western Europe, and rapidly rising&#13;
rates of lifestyle-related chronic diseases (heart disease, cancer, chronic liver disease, etc.), it is&#13;
clear that improvements in health status in our country will depend on a renewed commitment to&#13;
disease prevention and health promotion. Our national prevention programs have been particularly&#13;
hard-hit by recent fiscal contraction. In 1993, legislation was adopted shifting funding of non-&#13;
salary material costs for national prevention programs to the general budget, to relieve financial&#13;
pressure on the Health Insurance Fund. However, budgetary allocations have been insufficient and&#13;
unfulfilled due to general fiscal distress. We have requested bridge financing under the proposed&#13;
IDA project to provide imported materials for five of the highest priority prevention programs: i)&#13;
Childhood Immunization, ii) Matemal and Child Health; iii) Tuberculosis Prevention, iv) AIDS&#13;
Prevention; and v) Blood Donation. In addition, we are committed to providing funding from the&#13;
general  budget for additional material and operating expenses (non-salary) for these five&#13;
programs, in the amounts of US$0.9 million equivalent in 1996, US$1.0 million equivalent in&#13;
1997 and US$1.2 million equivalent in 1998 for budget items agreed with IDA.  In addition to&#13;
these allocations, the general budget vill provide additional funding for the Childhood&#13;
Immunization Program, for timelv purchase of vaccines, syringes and needles as necessary.&#13;
Funding requirements are estimated at US$1.02 million equivalent in 1996, USS1.12 million&#13;
6&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 1&#13;
Page 7 of 15&#13;
equivalent in 1997 and US$1.23 million equivalent in 1998. These finds will be allocated from&#13;
the general budget, unless a firm commitment for external funding is obtained. UNICEF has&#13;
already indicated its willingness to provide vaccines, syringes and needles as necessary for the&#13;
Childhood Immunization Program in 1996 and 1997, and we will cooperate closely with UNICEF&#13;
to ensure continued extemal funding in 1998, as well. Thus, throughout the irutial phase of reform&#13;
(1996-99), wve are committed to providing budgetary or external funding to ensure immunization&#13;
coverage rates of 95 percent or higher for the full range of childhood communicable diseases&#13;
addressed under the Immnunization Program.&#13;
Pharmaceutical Policy and Supply&#13;
At an estimated three percent, the share of national income spent on drugs in our country is&#13;
among the highest in the world. More than half of this is financed by the public sector, through&#13;
HIF reimbursements. Spending is high because prescribing practices favor overconsumption, while&#13;
registration, procurement, pricing and reimbursement policies favor higher-prices specialtv drugs&#13;
and limit competition in the market. Local prices for drugs are frequently five to ten times higher&#13;
than comparable world market prices. Our goals for pharmaceutical reform in the next few years&#13;
are to reduce local prices for essential drugs, facilitate the introduction of high-quality, lower-cost&#13;
drugs, encourage more rational prescribing practices and place appropriate limits on public sector&#13;
reimbursement of drugs to both public and pnrvate sector suppliers. Reforms will focus on the&#13;
following areas: i) revision of the legislative franework. ii) streamnlined registration for equivalent&#13;
products and authorization of generic substitution; iii) implementation of pricing policv which&#13;
favors lower-cost drugs, iv) adoption of essential drug lists for public sector facilities and&#13;
reimbursement, v) introduction of a reference price reimbursement system, vi) development of&#13;
competitive bidding procedures for public sector bulk procurement. and vii) promotion of rational&#13;
prescribing practices.&#13;
Revision of the le2islative framework. The Drug Law wnill be revised to meet European&#13;
standards and to reflect the reform agenda described below wvith respect to registration;,&#13;
substitution, pricing and public sector procurement and reimbursement. A satisfactor., draft Drug&#13;
Law has been submitted to IDA, and will be presented to Parliament for a first reading in coming&#13;
months. as a condition of effectiveness for the Health Sector Transition Project&#13;
Streamlined registration for equivalent products and authorization of zeneric&#13;
substitution.   The Drug Law will be simplified to allow for faster registration of generic&#13;
equivalents and other synonymous substances, particularly through elimination of cumbersome&#13;
requirements for clinical trials (replaced by requirements for bioequivalencv testing), and&#13;
development of an abridged application procedure. No modification will be made to existing&#13;
qualitv standards and controls, ensuring that qualitv requirements remain high regardless of cost.&#13;
In addition, the Drug Law will be modified to authorize and encourage licensed pharmacists to&#13;
substitute lower-cost synonymous substances (e.g. generic or branded-generic drugs) for brand&#13;
name prescriptions, unless specificallk prohibited by the prescribing physician.&#13;
Implementation of pricin2 policies which favor lower-cost dru2s. The Drug Law will&#13;
be modified to eliminate the proposed 20 percent mark-up for drug wholesalers and retailers and&#13;
give the national drug authorities the flexibility to introduce prcing policies which favor low%er cost&#13;
drugs. The earlier proposal, a fixed-proportion mark-up based on production costs, encourages&#13;
both the inflation of production costs and the marketing of higher-priced drugs. The revised Drug&#13;
Law will be submitted to Parliament as a condition of effectiveness of the proposed project. The&#13;
7&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 1&#13;
Page 8 of 15&#13;
national drug authorities will then introduce a new pricing policy based on differential mark-ups&#13;
which favor essential and lower-cost drugs by June 30, 1977.&#13;
Adoption of essential dru2 lists for public sector facilities and reimbursement. The&#13;
MOH will issue a decree establishing essential drug lists for primary and hospital care in public&#13;
sector facilities.  The lists will be established through intensive preparation by our Drug&#13;
Com'ittee, which will also review the lists annually, updating as necessary. Procurement by&#13;
public sector facilities will be limited to the drugs on these lists, which are defined according to&#13;
their International Non-proprietary Names (INNs). Furthermore, reimbursement of drugs by the&#13;
1F will be limited on the basis of these essential drug lists. Adoption of the essential lists for&#13;
public sector procurement will take place by December 31, 1996. Limitations on the range of&#13;
drugs to be reimbursed by the HIF will go into effect, along with the introduction of reference price&#13;
reimbursement ceilings (see belowv), no later than December 31 1997, as part of a comprehensive&#13;
overhaul of HIF reimbursement policy.&#13;
Introduction of a reference price reimbursement system.    Ceilings for drug&#13;
reimbursement by -HF to health facilities and pharmacies will be established using reference prices&#13;
based on low-cost generic products. Additional costs for higher-priced brands will be borne out-of-&#13;
pocket by patients/customers in both public and private sector pharmacies.  Defining the&#13;
methodology for establishing reference prices will be the subject of a study carried out by HIF, to&#13;
be completed by June 30 1997.  Regulations establishing the reference price reimbursement&#13;
system, along *with limitations on the range of drugs to be reimbursed and revisions to copayment&#13;
policy for prescriptions will be adopted by December 31 1997, for immediate implementation.&#13;
Development of competitive biddine procedures for public sector bulk procurement.&#13;
Currently, drug procurement is carried out locally by individual public sector health facilities on a&#13;
relativelv small scale, wvith no common procedures to ensure competitive pricing. With essential&#13;
drug lists for public sector facilities in place, it will become easier to aggregate purchasing for the&#13;
public sector in order to reap the benefits of economies of scale.   We intend to introduce bulk&#13;
procurement for the public sector, and to carrv it out through a competitive bidding process to&#13;
ensure high quality at lower prices. Our Department of Pharmacv in the MOH will be responsible&#13;
for managing a training program to build capacity for competitive bulk procurement, vhile drafting&#13;
the regulations defining a public sector drug procurement process. These regulations will be&#13;
agreed with IDA, and adopted bv June 30 1997, with trial procurement according to regulation&#13;
(financed under the proposed IDA credit) taking place by December 31 1997. By June 30 1998,&#13;
all public sector purchases which can be grouped into bulk lots will be procured through this&#13;
competitive process. wvhile health facilities will be required to engage in comparative pricing for&#13;
small-scale procurement of non-standard items.&#13;
Promotion of rational grescribine Dractices. We intend to establish a National Drug&#13;
Information Center (NDIC) which would act as a clearinghouse for international information on&#13;
pharmaceutical products. as well as direct information campaigns aimed at prescriber, pharmacists&#13;
and the public. The NDIC wvould be established by December 31 1996, and would be responsible,&#13;
inter alha, for educating physicians and pharmacists on the benefits of prescribing bv lnternational&#13;
8&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 1&#13;
Page 9 of 15&#13;
Non-proprietary Name, permitting generic substitution and following optimal prescribing practices.&#13;
It would also inform the public about lower-cost pharmaceutical alternatives. In addition, the HIF&#13;
will do periodic analysis of prescribing patterns for drugs on the reimbursement list, identifying&#13;
and recommending changes in poor prescribing practices.&#13;
Based on the policies and actions described in this Letter, we would like to request IDA's&#13;
support for our health sector reform progran through a credit for the Health Sector Transition&#13;
Project in an amount of US$16.9 million equivalent.&#13;
Yours sincerely,&#13;
H.E. Ilija ilip6e                                             E. Slavjanka Stojanova&#13;
minist ;;f Health                                     4       y   Minmster of Finance&#13;
of      ubt 'puMic of Macedonia                             o wC    ubli  f   edonia&#13;
91 000 Skopje, "Vodnjanska" bb. Tel. N: 389 91 11 34 29    Fax.NG: 389 91 11 30 14&#13;
9&#13;
&#13;
&#13;
&amp;#12;&#13;
FORMER YUGOSLAV REPUBLIC OF MACEDONIA&#13;
PROGRESS BENCHMARKS: HEALTH SECTOR REFORM. 1996-97&#13;
Progress Benclhmarks                     Conditions of    Condition of     Year I Review     Year 11 Review   Year III Review&#13;
Negotiations    Disbursement    (Sept. 1997)'      (Sept. 1998)    (Sept. 1999)&#13;
1.    Health Finance and Management&#13;
A.    Basic benefits package for health&#13;
insurance&#13;
Proposed package presented to&#13;
Parliament for first reading                                        X&#13;
Basic benefits package implemented&#13;
through the Health Insurance Fund                                                     X&#13;
B.    Copayment and user fee policies&#13;
Amendments to Health Protection&#13;
Law presented to Parliament for&#13;
first reading                                                       X&#13;
Revised copayment and user fee&#13;
policies implemented                                                                  X&#13;
C.    Capitation payment mechanism for&#13;
primary health care&#13;
Amendments to health Protection&#13;
Law presented to Parliament for&#13;
first reading                                                       X&#13;
Two pilot districts selected       X                       _         _&#13;
oQ z&#13;
x&#13;
1/    Timing of annual review will depend on date of effectiveness of the IDA credit.&#13;
0&#13;
h1n&#13;
&#13;
&#13;
&amp;#12;&#13;
FORMER YUGOSLAV REPUBLIC OF MACEDONIA&#13;
PROGRESS BENCHMARKS: HEALTH SECTOR REFORM. 1996-97&#13;
Progress Benchmarks                      Conditions of    Condition of     Year I Review    Year 11 Review   Year III Review&#13;
Negotiations    Disbursement    (Sept. 1997)'     (Sept. 1998)     (Sept. 1999)&#13;
Pilot testing launched in two&#13;
districts                                                           X&#13;
Regulations for nationwide&#13;
implementation adopted                                                               X&#13;
Capitation payment imnplemented&#13;
nationwide                                                                                           X&#13;
D.    Integrated medical and financial&#13;
information system&#13;
Proposed system design presented&#13;
to Technical Committee on Health&#13;
Finance (information systems&#13;
(Subconmmittee)                                                    X&#13;
Pilot testing launched in two&#13;
districts                                                          X&#13;
plan for nationwide&#13;
introduction and automation of                                                       X&#13;
system developed&#13;
Technical study for case-mix based&#13;
payment mechanism for hospitals&#13;
completed and implementation                                                                         X&#13;
underway&#13;
x&#13;
1/    Timing of annual review will depend on date of effectiveness of die IDA credit.&#13;
0&#13;
&#13;
&#13;
&amp;#12;&#13;
FORMER YUGOSLAV REPUBLIC OF MACEDONIA&#13;
PROGRESS BENCHMARKS: HEALTH SECTOR REFORM. 1996-97&#13;
Progress Benchmarks                      Conditions of    Condition of    Year I Review     Year II Review   Year III Review&#13;
Negotiations    Disbursement   (Sept. 1997)'      (Sept. 1998)     (Sept. 1999)&#13;
H.    Organization of Health Services&#13;
A.    Hospital Referral System&#13;
-      Amendments to Health Protection&#13;
Law reinstating a hospital referral&#13;
system adopted by parliament      X&#13;
B.    Staffing of rural primary health&#13;
centers (PHCs)&#13;
-     Public sector physicians redeployed&#13;
to provide full-time coverage to 50&#13;
selected rural PHCs.                                               X&#13;
-      Full-time physician services&#13;
maintained at 200 selected rural&#13;
PHCs (including 50 cited above)                                                      X               X&#13;
C.    Creation of primary health care&#13;
teams in urban areas&#13;
Plan for reorganization of primary&#13;
care personnel into teams&#13;
completed                                                          X&#13;
-     Reorganization plan implemnented                                                     X&#13;
1/   nrnug of anmal review will depend on damn of effectiveness of die IDA credit.&#13;
&#13;
&#13;
&amp;#12;&#13;
FORMER YUGOSLAV REPUBLIC OF MACEDONIA&#13;
PROGRESS BENCHMARKS: HEALTH SECTOR REFORM, 1996-97&#13;
Progress Benchmarks                     Conditions of    Condition      Year I Review     Year II Review   Year III Review&#13;
Negotiations    Disbursement   (Sept. 1997)'    (Sept. 1998)    (Sept. 1999)&#13;
D.    Supply of Health Professionals&#13;
-     Enrollments for physician training&#13;
reduced by 20 percent per annum&#13;
from 120 in 1996/97 academic year                                 X                X               X&#13;
-     Enrollments for dentist and&#13;
pharmacist training reduced to 75&#13;
students per annum or less                                        X                X               X&#13;
Number of public sector physicians&#13;
reduced by 200 (net) from 1995&#13;
level of 4,300                                                                     X&#13;
E.    Disease prevention and health&#13;
promotion&#13;
-     Provision of central budget funding&#13;
for non-salary material expenses of&#13;
five high-priority prevention&#13;
programs, as agreed with IDA2                                     X                X               X&#13;
I/    Timing of annual eview will depend on date of effectiveness of die IDA credit.                                           X t&#13;
2d&#13;
2/    See LcUC,o c mi  o p ei. Pdc   fw&amp;mso  utcr.mm(&#13;
0&#13;
?Ln&#13;
&#13;
&#13;
&amp;#12;&#13;
FORMER YUGOSLAV REPUBLIC OF MACEDONIA&#13;
PROGRESS BENCHMARKS: HEALTH SECTOR REFORM, 1996-97&#13;
Progress Benchmarks                      Conditions of    Condition of    Year I Review     Year II Review   Year III Review&#13;
Negotiations    Disbursement    (Sept. 1997)'     (Sept. 1998)     (Sept. 1999)&#13;
Ill.   Pharmaceutical Policies and Supply&#13;
A.    Revision of legislative framework&#13;
-     Satisfactory revised Drug Law&#13;
submitted to IDA.                 X&#13;
-     Enact a Drug Law satisfactory to&#13;
IDA                                                X&#13;
C.    Pricing policies which favor lower-&#13;
costs drugs&#13;
-     Enact a Drug Law satisfactory to&#13;
IDA                                                X&#13;
-     New pricing policy introduced by                                    X&#13;
national drug authorities&#13;
D.    Essential drug lists for public sector&#13;
procurement&#13;
-     Decree issued establishing essential&#13;
drug lists (agreed with IDA) to&#13;
limnit procurement by public sector&#13;
facilities                                                         X&#13;
1/    Timing of annual review will depend on date of effectiveness of the IDA credit.                                             o&#13;
I-n&#13;
&#13;
&#13;
&amp;#12;&#13;
FORMER YUGOSLAV REPUBLIC OF MACEDONIA&#13;
PROGRESS BENCHMARKS: HEALTH SECTOR REFORM, 1996-97&#13;
Progress Benchmarks                          Conditions of     Condition of      Year I Review      Year 1I Review    Year III Review&#13;
l__________________________________________  Negotiations       Disbursement      (Sept. 1997)1      (Sept. 1998)      (Sept. 1999)&#13;
l -    Range of drugs to be reimbursed by                                                           X&#13;
HIF limited on basis of essential lists&#13;
E.     Reference price reimbursement ceilings&#13;
for drugs&#13;
x&#13;
l -    Study on methodology for establishing&#13;
reference prices completed&#13;
-      Regulation adopted and reference price&#13;
reimbursement ceilings introduced&#13;
x&#13;
F.     Competitive bidding procedures for&#13;
public sector bulk procurement of&#13;
drugs&#13;
|      Regulations adopted on procedure for                                      X&#13;
competitive bidding which are&#13;
satisfactory to IDA&#13;
|      Competitive bidding implemented for                                                          X&#13;
all public sector bulk procurement&#13;
G.     rational prescribing policies&#13;
-      National Drug Information Center                                          X&#13;
established&#13;
x1&#13;
0&#13;
1/ Timing of annul review will depend on date of effectiveness of the IDA credit.&#13;
fr-i&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page I of 65&#13;
Former Yugoslav Republic of Macedonia&#13;
Health Sector Transition Project&#13;
Proiect lmvlementation Plan&#13;
Introduction&#13;
This Project Implementation Plan (PIP) reflects the outcomes of the October 1995 pre-&#13;
appraisal mission and its work with the technical working groups of the Ministry of&#13;
Health (MOH)'/, as well as subsequent discussions between the MOH and the Bank in&#13;
December 1995 concerning further refinements to project scope and content. It was&#13;
discussed with the Borrower and refinements made during negotiations in May 1996.&#13;
The PIP presents the overall framework for implementation of the Project by the&#13;
Borrower and outlines in detail activities, arrangements and responsibilities. While the&#13;
implementation environment of the project is inherently dynamic, this PIP seeks to&#13;
clearly outline the general principles, agreed by all parties, according to which the project&#13;
will be carried out.&#13;
A list of working group members is given in Appendix 1.&#13;
&#13;
&#13;
&amp;#12;&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 2 of 65&#13;
Forner Yugoslav Republic of Macedonia&#13;
Health Sector Transition Project&#13;
Project ImDlementation Plan&#13;
Table of Contents&#13;
Pag&#13;
Chapter I:      Project Description, Objectives and Components  ............ .                          3&#13;
Chapter II:  Project Management and Implementation ...............                                      3&#13;
A.      Project Management ...................................  3&#13;
B.      Summary of Implementation Responsibilities ............ .                      7&#13;
C.      Implementation Arrangements by Component  .......... .                          8&#13;
1.     Health Finance and Management  ...................... 9&#13;
2.      Basic Health Services ............................. 9&#13;
3.      Pharmaceutical Policy and Supply ......           ............... 10&#13;
D.      Detailed Cost Tables and Implementation Schedules  .....           ......... 12&#13;
Chapter III:    Project Cost, Financing, Reporting and Supervision  ........            ........... 25&#13;
A.      Project Cost and Financing  .........           ..................... 25&#13;
B.      Procurement Arrangements and Schedule  ....... ..             ............ 29&#13;
C.      Disbursements, Special Account and Audit Requirements ....            ....... 34&#13;
D.      Reporting Requirements .............. .................. 36&#13;
E.      Supervision Requirements .............. ................. 36&#13;
Chapter IV:   Monitoring and Evaluation          ..............................  38&#13;
Chapter V:    Equipment Lists and Terms of Reference    ..........................  44&#13;
Tables:&#13;
Table 1:        Project Cost Summary .       ................................. 26&#13;
Table 2:        Project Costs by Expenditure Category  ......            ................ 27&#13;
Table 3:        Financing Plan by Financier  .........           .................... 28&#13;
Table 4:        Project Costs by Component and Financier .................... 28&#13;
Table 5:        Procurement Arrangements ..........              .................... 30&#13;
Table 6:        Procurement Implementation Summary  ...................... 33&#13;
Table 7:        Estimated Disbursements by Year .......             ................... 35&#13;
Table 8:        Supervision Requirements ..........            ..................... 37&#13;
ARppedices:&#13;
Appendix 1:   Working Group/Technical Committee Members .....                  ............ 55&#13;
Appendix 2:   Matrix of Procurement and Reporting Responsibilities ....            ......... 57&#13;
Appendix 3:   Draft General Procurement Notice ........................    65&#13;
&#13;
&#13;
&amp;#12;&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 3 of 65&#13;
I. Project Description. Objectives and Components&#13;
1.            The primary objectives of the Health Sector Transition Project are to: (i) improve the&#13;
health of the population by improving the quality of basic health services; and (ii) support an initial phase&#13;
of policy reforms to enhance cost-effectiveness, fiscal sustainability and patient choice within the health&#13;
system. These objectives will be achieved through activities and reforms under three project components&#13;
with the specific objectives outlined below:&#13;
(a)    Health Finance and Management: to support (i) the Government's efforts to prepare&#13;
and implement health financing reforms, building on technical work begun during project&#13;
preparation, through policy studies and advocacy/public information campaigns; and&#13;
(ii) the future introduction of a case-mix hospital reimbursement scheme through&#13;
development and testing of an integrated medical and financial management information&#13;
system for public sector facilities.&#13;
(b)    Basic Health Services: to improve the quality and effectiveness of primary health care&#13;
services through (i) the provision of basic equipment kits to 250 rural health centers and&#13;
support for clinicians' continuing education in provision and management of care; and&#13;
(ii) support for selected prevention programs.&#13;
(c)    Pharmaceutical Policy and Supply : to promote more rational use of drugs through&#13;
(i) strengthening local capacity for competitive drug procurement; and (ii) developing&#13;
essential drugs lists for public sector health facilities.&#13;
The project will finance local and external technical assistance, local training, long- and short-term&#13;
fellowships and study tours, medical and laboratory testing and diagnostic equipment and supplies,&#13;
computer hardware and software, reference materials, office equipment, furniture, and minor civil works&#13;
to support the activities described below.&#13;
II. Project Management and Implementation&#13;
A. Project Management&#13;
2.            Overall responsibility for implementation of Health Sector Transition Project rests&#13;
with the MOH, while responsibility for day-to-day coordination, management and monitoring rests&#13;
with the International Project Unit (IPU) established within the MOH. It is expected that the IPU&#13;
will also assume responsibility for the coordination of other donor-funded activities in the health&#13;
sector. In order to carry out its functions, the Unit will be staffed by a full-time Project Director,&#13;
supported by a "core team", financed under the project. This core team is comprised of: (i) a&#13;
procurement officer; (ii) a disbursement officer/accountant; and (iii) an administrative&#13;
assistant/translator. To assist this team, short-term technical support for the IPU will be provided for&#13;
under the project in a number of areas, inter alia, health policy development, procurement of goods&#13;
and services, project management, and administrative support services.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 4 of 65&#13;
3.            Details concerning support to the IPU and estimated costs are presented in the table&#13;
below. Initial start-up costs for appointment of key staff (i.e., the Director and the Procurement&#13;
Officer), equipment of the Unit, and staff training in procurement and project management are being&#13;
financed by a Project Preparation Facility (PPF; P983-0-MK) of US$223,500.&#13;
&#13;
&#13;
&amp;#12;&#13;
FYR MACEDONIA&#13;
Heam Sedor Trnsibon Proec&#13;
Inenaon  Proect Unil (IPU)&#13;
Detailed Costs&#13;
(USS 000)&#13;
Quannltla                                Base Cost                  Totbe Including Coitngtncl_&#13;
Unit   t 1617         97119 31               Total 7697 To b   17    971#1   91     Total    363      376    9119    Tota&#13;
1. Invsbnt Cost&#13;
A IPU Statwbp Fknaced&#13;
byPPF&#13;
1. Ste"n&#13;
Projet Dfector /a                         month             9           -           -          9       27         -        -       27       27         -        -       27&#13;
ProcunutffOwlb                            .onth             6           -           -          6       18         -        -       i8       18         -        -       18&#13;
Inlew eIc                                month             6           -                      6        9         -        -        9        9                           9&#13;
Subttl                                                                                                   54                          54       55         -        -       55&#13;
2 Staff TraIIng&#13;
P.j Mangemn  &amp;&#13;
PnOCvement                               month             2           -           -          2       15         -        -       15       15         -        -       15&#13;
Lanuage Tramig Id                         month              3           -          -          3        3         -        -        3        3         -        -        3&#13;
Sudaol                                                                                                   18         -        -       18       18         -        -       18&#13;
3. Technical Assistance&#13;
Extenal TA le                             mont              2           -           -          2       30         -        -       30       30         -        -       30&#13;
Locd TAIt                                  nth              18          -           -         18       54         -        -       54       55         -        -       55&#13;
Subtl                                                                                                     4         -        -        4       85         -        -       85&#13;
4. Estblish PIU Ocics&#13;
Site Pyspaaon 19                          vaS                                                           5         -        -        5        5         -        -        5&#13;
5. PIU Operaons&#13;
MiisiaNan                                  unit              1           -          -          1       25         -        -       25       25         -        -       25&#13;
Office Equipment ih                       value                                                        20         -                20       20         -        -       20&#13;
Subtotal                                                                                                 45                          45       46_               _         46&#13;
Subtotal                                                                                                   206        -         -     206       208        -               208&#13;
B. Fll-TIm  Staff tor Proect&#13;
Imp _mentato&#13;
Project Director                            month             12         12         12          36       36       36        36      108       38       39        40      118&#13;
Procurement Offier                          month             12         12          12         36       36       36        36      108       38       39        40      118&#13;
Accountant I Disbwsefent Offcer             month             12         12          12         36       36        36       36      108       38       39        40      118&#13;
Administrative AssistanU                                                                                                                                                                   1&#13;
Interpreter                                month             12         12         12          36       18       18        18       54       19       20        20       59&#13;
Subtotal                                                                                                   126      126      126      378       134      137      140      411&#13;
Page 1&#13;
&#13;
&#13;
&amp;#12;&#13;
C. Sbhortd-en Technica AsJttanee&#13;
ExtemalTAAm ntxh                                          4          2          1          7      60       30       15     105       64      33       17      113&#13;
LocalTA4                                 month            18        16         12        48       54       54       36     144       57      59       40      156&#13;
Audior (Local TA)                        ntX4h             1         1          1          3       3        3        3       9        3       3        3       10&#13;
Subtotad                                                                                           117       87       54     258      124      95       60      279&#13;
0. IPU Opesulons&#13;
1. Olw Eqsmw &amp; Supplies                  vaue                                                       -       5        -       5                6        -        6&#13;
E. IPU Stan Traning&#13;
Extmnl Tmungik                          nmxoh              3         2          1          6      23       15        8      45       24       16       8       49&#13;
Local Truaing A                          nxh-                        2          1          3        -       2        1       3        -       2        1        3&#13;
Sutbebl                                                                                             23       17        9      48       24       18       9       52&#13;
Tot Investenft Costs                                                                                 472      235      189     f65      491     256      210      957&#13;
B. Recurren Costs&#13;
A. Opeang Cos&#13;
Vehide O&amp; M                             peryear                                                    3        3        3       8        3        3       3        8&#13;
Office Consumables S Supples            per yea                                                    3        3        3       9        3        3       3        9&#13;
Ovetead hn                              per year                                                    2       2        2       a        2        2       2        6&#13;
Tota Recurent Conta                                                                                    8        8        8      23        a        8       8       23&#13;
Total                                                                                                 479      243     196      918     498      264      218     980&#13;
%a Janury - September 1996&#13;
b March - Septmber 1996&#13;
t March - Sepember 1996&#13;
kd Engteh language training prided ocalNy&#13;
W TA for suport to drug comvonent, PIU, etc.&#13;
Vf Estmted 3 peons for 6 months to support reform (Cotponet 1).&#13;
bg Remodeling of prenmses, installation of phone and fax ines, rnenet hookup, etc.&#13;
%h Compute, wostations, fax, photocopier, etc.&#13;
U For example: procuremnent, project management. short-term technical support..&#13;
Ij For example: Local advsory services for coordination of refomn. health economics, procurement. translationrinterpretation.&#13;
k For example: Bank procurenment, disburement; project management; PCU workshops.&#13;
tI Language, computer sklhs. etc.&#13;
ti DHL, postage. etc.&#13;
Page 2&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 7 of 65&#13;
B. Summarv of Implementation Responsibilities&#13;
4.            The Project will be implemented in close coordination and collaboration with the central&#13;
and district units of National Health Insurance Fund (NHIF), National Institute for Health Protection&#13;
(NIHP), Institute of Pharmacology, health facilities (hospitals, laboratories, PHC units), other donor-&#13;
funded activities in the health sector (e.g., EU/PHARE, UNICEF), and other ongoing projects in related&#13;
sectors (such as the Social Reform and Technical Assistance Project (Credit 2722-MK)2'. The technical&#13;
working groups of the MOH which developed the project proposals for each component will be sustained&#13;
as Technical Committees (TCs) throughout project implementation to provide technical and other support&#13;
(see below). Coordination and communication among the TCs, as well as other concerned parties, will&#13;
be assured by the Project Director through regular implementation summary meetings.&#13;
Responsibilities of the MOH:&#13;
(i)    establish and facilitate the operation of the IPU and TCs, seeking to ensure an atmosphere&#13;
of mutual support, collaboration, and open communication among all concerned parties in&#13;
implementing the project;&#13;
(ii)    monitor the execution of project activities to ensure the successful and timely achievement&#13;
of project objectives;&#13;
(iii)   take the lead in defining appropriate policies, strategies and targets aimed at attaining the&#13;
project's objectives and, particularly, in seeking the commitment of other Governmental and non-&#13;
governmental institutions to the successful implementation of health sector reform activities;&#13;
(iv)   seek to ensure that adequate counterpart financing from the Government budget is made&#13;
available in a timely manner, and that credit proceeds are utilized judiciously and as agreed under&#13;
the project; and&#13;
(v)    ensure availability of staff resources required by the project (in the IPU, as defined&#13;
above, as well as in health facilities involved in implementation), and timely procurement and&#13;
delivery and efficient use of goods and services purchased under the project.&#13;
Responsibilities of the IPU:&#13;
(i)    undertake the planning, coordination, management, monitoring and reporting functions&#13;
described under the Project, including organization of monthly infornation-sharing meetings&#13;
regarding project status for all parties directly and indirectly involved;&#13;
(ii)    monitor project disbursements and expenditures (both local and foreign),  process&#13;
2/     This Project, being implemented by the Agency for Transformation of Enterprises with Social Capital,&#13;
includes the strengthening of revenue collection for the National Health Insurance Fund through improved&#13;
administration of payroll contributions.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 8 of 65&#13;
withdrawal applications in collaboration with the Central Bank of FYR of Macedonia, and track&#13;
disbursements of credit and Government counterpart funds with a view to maintaining up-to-date&#13;
project records and accounts;&#13;
(iii)   ensure compliance with IDA's Guidelines in the procurement of goods and services under&#13;
the project;&#13;
(iv)   ensure the timely preparation and distribution of comprehensive semi-annual Progress&#13;
Reports to the relevant government and other participating institutions, including IDA, reflecting:&#13;
(a) the status of implementation progress, problems encountered and corrective actions needed;&#13;
(b) current expenditures under each project component and disbursement category, with updated&#13;
estimates for completion; and (c) progress in policy reforms supported under the project,&#13;
problems encountered, and corrective steps to be taken.&#13;
(v)    ensure the timely preparation of annual audits of project accounts, including expenditures&#13;
made against Statements of Expenditures (SOEs), and submission of audit reports to IDA and&#13;
the concerned government institutions within six months after the end of the Borrower's fiscal&#13;
year;&#13;
(vi)   oversee the approval and signature processes required for project-related documents and&#13;
contracts, facilitating this process as required with a view to avoiding unnecessary delays in&#13;
project implementation;&#13;
(vii)   with technical inputs from the TCs and technical assistance as required, coordinate&#13;
preparation of specifications and bidding documents for equipment to be procured under the&#13;
project, review of bid packages, evaluation of bids, and drawing up of contracts with winning&#13;
suppliers;&#13;
(viii)  develop administrative procedures to ensure the efficient use of project resources --&#13;
including financial, staffing and time;&#13;
(ix)   liaise with other donor-funded activities to ensure that all externally funded activities are&#13;
in line with the agreed medium-term strategy for health sector reform of the MOH; and&#13;
(x)    ensure the preparation of the Borrower's review of project implementation to be included&#13;
in the Implementation Completion Report (ICR) within six months after project closing.&#13;
C. ImDlementation Arrangements by Component&#13;
5.            The paragraphs below discuss implementation arrangements for each of the three&#13;
components of the project. Detailed cost tables and implementation schedules related to the specific&#13;
components are found in Section D.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 9 of 65&#13;
COMPONENT (1): Health Finance and Management&#13;
6.            Overall responsibility for implementation of this component lies with the National Health&#13;
Insurance Fund (NHIF), a semi-autonomous fund under the supervision of the MOH, the director of&#13;
which reports to the Minister of Health. The NHIF will take principal responsibility for defining and&#13;
implementing the reforms supported under the project. In that capacity, the Fund will manage and&#13;
supervise the work of the foreign and local experts hired to carry out technical studies under the&#13;
component. The NHIF will coordinate and supervise the pilot activities (in capitation payment, integrated&#13;
information systems, etc.) in the two selected districts, collaborating with the District HIF (DHIF) offices,&#13;
the medical centers, PHC centers and District Institutes of Public Health. The Fund will also be&#13;
responsible for identifying qualified fellowship and study tour candidates to be trained as trainers for&#13;
outreach to DHIF and facilities' staff on issues concerning financial and administrative management.&#13;
Implementation of this local management training through seminars will be coordinated by the NHIF.&#13;
With respect to information system activities, the NHIF will oversee the work of the foreign and local&#13;
technical assistance hired to support the design of an integrated information system, the formulation of&#13;
an automation plan, and coordination of testing in selected pilot areas. Lastly, in collaboration with the&#13;
IPU, the NHIF will oversee the development of a public information and outreach strategy with respect&#13;
to the content and implementation of reforms.&#13;
7.            The Technical Committee (TC) for this component (formally the technical working&#13;
group established during project preparation) will be headed by the director of the NHIF. The TC will&#13;
play an important role in reviewing the series of technical studies regarding proposed reforms, and&#13;
making final recommendations to the MOH on the policy reforms. The Committee will advise and assist&#13;
the IPU in developing technical specifications for goods to be procured under this component, as well&#13;
as terms of reference for consultants. Finally, the TC will supervise the work of technical assistance to&#13;
establish a Hospital Management Association which, once operational, will develop and carry out training&#13;
programs for medical professionals. Technical assistance will be provided under the project to give initial&#13;
support to the Association in this task.&#13;
8.            Under the project, pilot activities are foreseen in two selected districts (selection of&#13;
suitable pilots districts is a condition of negotiation). The DHIF offices of the pilots areas will oversee&#13;
implementation of activities, reporting to the NHIF. The DHIFs will also coordinate the distribution of&#13;
equipment to be procured for carrying out pilot activities, and together with the selected medical centers,&#13;
primary health care centers and the district offices of the IPH will be responsible for any necessary site&#13;
preparation (i.e., installation of phone lines, electrical connections, etc. for hardware) and actual&#13;
implementation of activities.&#13;
COMPONENT (2): Basic Health Services&#13;
9.            Primary responsibility for implementation of this component lies with the Office of the&#13;
Assistant Minister for Primary and Preventive Health Care (AMPPHC). This Office will supervise&#13;
the work of the procurement agency, in collaboration with the IPU, hired to ensure the purchase and&#13;
distribution of: (i) basic medical equipment kits for rural primary health centers (PHCs) (to be purchased&#13;
from UNIPAC) as well as other equipment and furniture for rural PHCs (the latter being financed by the&#13;
Government); and (ii) various medical consumables, vaccines, and promotional supplies needed for&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 10 of 65&#13;
prevention programs supported under the project.3/ The AMPPHC will be responsible for selecting&#13;
qualified candidates from within the MOH for training in primary health care strategies and planning, and&#13;
will supervise the development of continuing education programs for PHC physicians and nursing staff.&#13;
Finally, the Office will develop final recommendations to the MOH on quality assurance standards for&#13;
PHC and will approve any action plan for quality assurance monitoring and supervision.&#13;
10.          In developing continuing education programs aimed at broadening the skills of PHC&#13;
personnel, the medical associations (Physicians' and Nurses' Associations) and related medical faculties&#13;
(physicians' and nursing faculties) will play a key role. These programs will seek to give greater&#13;
emphasis to a family medicine orientation in medical education, and to primary and secondary prevention&#13;
strategies. In addition, these associations and faculties will take the primary role in defining--for&#13;
presentation to the Office of the AMPPHC--the action plan for primary care quality assurance monitoring&#13;
and supervision mentioned in the preceding paragraph.&#13;
II.          Implementation of activities supporting priority prevention programs under the project&#13;
will be the responsibility of the National Institute of Public Health (NIPH), reporting to the Office of&#13;
the AMPPHC. The NIPH will assume direct responsibility for carrying out immunization program&#13;
activities, maternal and child health care programs (namely, cervical cancer screening and neonatal&#13;
intensive care support in conjunction with the University Hospital), and AIDS screening activities&#13;
provided for under the project. The Institute will also supervise implementation of project inputs in&#13;
tuberculosis screening and prevention, and blood donation program support through, respectively, the&#13;
National Institutes of Lung Diseases and Tuberculosis and Blood Transfusion. Through representation&#13;
on the TC for basic health services (see below), the NIPH will provide inputs to related equipment&#13;
specifications and consultancy terms of reference under this component. Responsibility for receipt and&#13;
distribution of medical consumables and equipment for implementation of prevention programs will also&#13;
lie with the Institute, as will ensuring the development and dissemination of promotional materials for&#13;
each program.&#13;
12.          The TC for basic health services will be chaired by the Assistant Minister for Primary&#13;
and Preventive Health Care, and will be comprised of representatives from each of the agencies involved&#13;
in carrying out the programs supported under the project (see preceding paragraph). The Committee will&#13;
also provide technical support to the IPU in formulating consultant terms of reference, finalizing&#13;
equipment specifications, and inputs to the development and use of promotional materials.&#13;
COMPONENT (3): Pharmaceutical Policy and SUPDIV&#13;
13.          The Department of Pharmaceuticals (DoP) in the MOH will have overall responsibility&#13;
for implementation of this component. It will play a key role in the reform process, managing each of&#13;
the successive steps of legislative revision and definition of the regulatory framework concerning drug&#13;
registration, pricing, and substitution. While the NHIF will take the lead in managing technical assistance&#13;
for the definition of a reference price reimbursement system for drugs, and for testing and implementing&#13;
3/     The role of the procurement agency in the competitive procurement of pharmaceuticals for the&#13;
public sector is discussed under Component (3), Pharmaceutical Supply.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 11 of 65&#13;
that system, the DoP will provide inputs throughout the process. Moreover, the DoP will take the lead&#13;
role in the formulation of public sector competitive bidding procedures for the procurement of drugs and&#13;
vaccines, including management of training for concerned staff in those procedures. The Department&#13;
will also be responsible for managing the consultants carrying out technical studies pertaining to the&#13;
reforms, developing essential drug lists, as well as promoting rational drug use among prescribers and&#13;
consumers in collaboration with the Drug Information Center to be established in the Institute of&#13;
Pharmacy (see para. 14 below).&#13;
14.           With respect to drug procurement, the DoP will supervise the work of the contracted&#13;
procurement agency selected to procure and distribute drugs, medical equipment and consumables under&#13;
the project according to competitive bidding procedures. The procurement agency, to be selected as a&#13;
condition of effectiveness, will be fully equipped for, and experienced in, accepting and processing&#13;
orders, and ensuring secure warehousing and timely distribution of items purchased through large-scale&#13;
procurement.&#13;
15.           The National Drug Information Center and the Center for Adverse Reactions will be&#13;
established and operated under the responsibility of the Institute of Pharmacy (Faculty of Medicine).&#13;
The Institute will ensure that necessary site preparation is carried out prior to arrival of equipment,&#13;
finalize specifications for required equipment with the IPU, identify and request, with assistance from the&#13;
IPU, appropriate drug information reference materials, and appoint qualified staff to both Centers. A&#13;
public information strategy for drugs will also be developed with some assistance from WHO in addition&#13;
to support provided under the project. The NIPH will oversee the development of the quality control&#13;
laboratory, including provision of support to the IPU on technical specifications for lab equipment, site&#13;
preparation, and the selection of qualified candidates for training to be carried out.&#13;
16.           The TC for pharmaceuticals will review proposals put forward by the technical consultants&#13;
and finalize recommendations for pharmaceutical policy reform for Ministerial improvement. This will&#13;
include recommendations on: drug registration, essential lists, pricing policy, registration and testing,&#13;
substitution policy, reimbursement, and public sector procurement.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 12 of 65&#13;
D. Detailed Cost Tables and Implementation Schedules&#13;
&#13;
&#13;
&amp;#12;&#13;
FYR MACEDONIA&#13;
Healih Sector Transition Project&#13;
Health Finance &amp; Management&#13;
Detiled Costs&#13;
(USS '000)&#13;
QuanUtbs                                    Bats Cost                 Totale Including Contingence.&#13;
Unkt       9697        97/M8       9U199         Total      96S97    97198    SUS9    Total   96S97    97/99    99         Total&#13;
I. Invstment Costs&#13;
A. Heat FInancing Reforms /a&#13;
1. IT EquIpment&#13;
CompuWers   modem, printers              vlue                                                             16        -        -       16       18        -        -       18&#13;
2 Office Equipment &amp; Supples&#13;
General Ofike Equipment                  value                                                             5        -        -        5        6        -        -        6&#13;
3. Advory Servsk&#13;
Long-Term Advisor lb                    month               -           6           -             6                90        -       90        -       98        -      98&#13;
Exlemal TA                              mordh               4           3           1             8       60       45       15      120       64       49       17      129&#13;
LocalTA                                 month              36          15           5            56      108       45       15      168      115       49       17      160&#13;
Subl                                                                                                       168      180       30      378      179      196       33      408&#13;
4. Training&#13;
Study Tours c                           month               8           -           -             8       60        -        -       60       64        -        -      64&#13;
Woukshops for capitation Id             per day             -        640          640          1,280       -       32       32       64        -       35       36       70&#13;
Pilotb awg for Capitation Paymrnt /e    per day            80           -           -            80        4        -        -        4        4        -        -        4&#13;
Subtoa                                                                                                      64       32       32      128       68       35       36      138&#13;
Subtotal                                                                                                     253      212       62      527      270      231       69      570&#13;
B. Stengthn H"lh Insurance Fund&#13;
1. IT Equipment and Software&#13;
Server, conmuters w modems,&#13;
prnters &amp; line connections, routers     value                                                           233        -        -      233      259        -        -     259&#13;
System software. SOt data base&#13;
&amp; licenses                              value                                                           102        -        -      102      114        -        -     114&#13;
Subtotal                                                                                                   335                        335      373                        373&#13;
2. Office Equipnwnt &amp; Supplle&#13;
Fax &amp; su4pies                            value                                                            10        -        -       10      11         -        -       11&#13;
3. AdvIsory Services&#13;
Extemal TA if                           month               4           2           -             6       60       30        -       90      64        33        -      96&#13;
Local TA                                 month             14          10           4            28       42       30       12       84       45       33       13      91&#13;
Subtotal                                                                                                   102       60       12      174      108       65       13      187&#13;
4. Training&#13;
Senars for NHIF Staff&#13;
&amp;DHIFDirectors./g                      perday            490           -           -           490       25        -        -       25       26        -        -      26&#13;
Follow-up traingt for NHIF Staff /h     per day             -          75           -            75        -        4        -        4        -        4        -       4         Q&#13;
Contir Education l                      per day             -         150          90           240        -        8        5       12        -        8        5       13 3Z&#13;
Felowships l                             month             18          18          18            54      135      135      135      405      143      147      150     441        0 Z&#13;
Study Tours for DHIF Managers                                                                         X&#13;
&amp; NHIF Staff                           rn month            9           -           -             9       68        -        -       68       72        -        -       72       Uft&#13;
Subtotal                                                                                                   227      146      140      513      241      159      155      556&#13;
Subtotal                                                                                                     674      206      152    1,032      734      224      169    1,127&#13;
Page 1&#13;
&#13;
&#13;
&amp;#12;&#13;
C. Strengthen Hospial Management&#13;
1. Setup Costs for Hospital Association&#13;
Materials &amp; Software                     value                                                             15        2        2        19       17        2        2       21&#13;
2. Advisory Services&#13;
Extemal TA                               month              4            2           -             6       60       30         -       90       64       33        -       96&#13;
Local TA                                 month              8            4           4            16       24       12       12        48       26       13       13       52&#13;
Subtotal                                                                                                      84       42       12      138       89       46       13      148&#13;
3. TraIning&#13;
Extemal Training (study tours) /A        month              9            9           -            18       68       68         -      135       72       73               145&#13;
Seminars//m                             perday            300          300         350           950        15       15       18       48       16       16       19       52&#13;
Continuing Education /n                  per day             -         200         200           400         -       10       10       20        -       11       11       22&#13;
Subtotal                                                                                                      83       93       28      203       88      101       31      219&#13;
Subtotal                                                                                                       182      137       42      360      194      149       46      389&#13;
D. Public Information Campaign&#13;
Extemal TA                                 month              2            -            -             2       30        -        -       30       32        -         -      32&#13;
LocalTA                                    month             12           12          12             36       36       36       36      108       38       39       40      118&#13;
PR Contractual Services /o                annually                                                           100       80       35      215      106       87       39      232&#13;
Subtotal                                                                                                       166      116       71      353      176      126       79      382&#13;
Total tnvestment Costs                                                                                          1,275     671      326    2,271    1,374      730       363    2,467&#13;
II. Recurrent Costs&#13;
A. Operating Costs /p&#13;
1. Supplies &amp; Expenses to&#13;
Implement Policy Reforms                 annually                                                            19        8        5       32       19        8        5       33&#13;
2. Incremental Staff Salaries              month               -          24          48             72        -        7       14       22         -       7       15        23&#13;
Total Recurrent Costs                                                                                             19       15       19       54        19       16       21       56&#13;
Total                                                                                                           1.294      686      345    2,325    1,393      746      384    2,522&#13;
\a Minimum benefit package, PHC Capitation. Copayment&#13;
\b First 12 months for long-term advisor financed under the Japan Grant.&#13;
\c MOH officials, Parliament, MOF, and working committee members.&#13;
\d Capilation payment. 80 persons x 8 days.&#13;
\e 8 persons x 10 days.&#13;
If For design and implementation of training for HIF &amp; RHIF staff.&#13;
\g Subjects indude, for NHIF: Policy analysis, health econ, insurance, statistical methods (15 persons x 12 days). DHIF: management, insurance, info systems (30 persons x 7 days).&#13;
\h 15 persons x 5 days.&#13;
\i 30 persons x 5 days; 30 persons x 3 days.&#13;
j Long-temm (9 mos.) &amp; short-term (3 mos.) fellowships.&#13;
\k 12 persons x 3 weeks.&#13;
\1 12 persons x 3 weeks.&#13;
\m 25 persons x 12 days. each year for 2 years; 50 persons x 7 days for one year.                                                                                                        IV&#13;
\n 50 persons x 4 days.                                                                                                                                                                  at&#13;
\o Survey, program design, materials development, coordination of media activities. etc.                                                                                                  f &#13;
\p Supplies &amp; expenses for implementation of studies, Ad Hoc Committee operations, etc. Financed by Gvt.&#13;
Pae 2&#13;
&#13;
&#13;
&amp;#12;&#13;
FYR MACEDONIA&#13;
Health Sector Transition Proped&#13;
Health Finance &amp; Management&#13;
Detiled Costs&#13;
(USS 0'0)&#13;
QuantIiss                              Base Cost                 Totals Including Contingencbs&#13;
Unit       96197     971S8     98/9       Total    96197    97/98    98/9S    Total   96U97    97199    9J/99    Total&#13;
I. Investment Costs&#13;
A. Study and Design of FAS &amp; HIS&#13;
External TA                                 month            12                   -         12      180        -        -     180      191         -        -     191&#13;
Local TA                                    month            12         1         1         14       36        3        3      42       38         3       3       45&#13;
Subtotal                                                                                              216        3        3     222      230         3        3     236&#13;
B. Site Preparations a&#13;
1. CMIYI Works&#13;
HIF National Center                       value                                                    2         -        -       2        2         -        -       2&#13;
HIF District Offices (2 pilot sites)      value                                                    10        -        -      10       10             -           10&#13;
Hospitals (2 pitot sites)                 value                                                    18        -               16       16         -               16&#13;
NIPH National Center /b                   value                                                     4                         4        4                          4&#13;
NIPH District Offices (pilot shes)        value                                                    6         -        -       6        6         -        -       6&#13;
NIPH Local Offices (2 pilots sits)        value                                                     4                 -       4        4                   .      4&#13;
Subtotal                                                                                             42                        42       43         -        -      43&#13;
2. Telephone Line Installation /c           value                                                    35        -        -      35       35    _             -      35&#13;
Subtotal                                                                                               77                         77       78        -        -      78&#13;
C. Staff Training&#13;
Central Level Staff /d                     workshop           2         2         2          6        0        0        0        0        0        0       0        0&#13;
Regional HIF staffle                      workshop            1         1         -          2       10       10        -      19       10        10        -      21&#13;
Regional Heafth Care institutes f         workshop            1         1         -          2       12       12        -      24        13       13        -      26&#13;
Hospital Administrators /g                workshop            1         1         1          3       18       18       18      53        19       19      20       57&#13;
Hospital Medical Directors /h             workshop            1         1         1          3       18       18       18      53        19       19      20       57&#13;
PHC Staff i                               workshop            1         1         -          2        2        2        -        3        2        2        -       3&#13;
Subtotal                                                                                               59       59       35      152       62       64       39     165&#13;
D. Cornputer Systens&#13;
1. MOH&#13;
Computer equipment /j                     value                                                     -        5        -       5                 6         -       6&#13;
2. Financial Accounting System&#13;
HIF Nabonal Center hk                     value                                                             10                10               11                11&#13;
2 pilts sites HIF Regi. Offices A         value                                                     -       50        -       50        -       57        -      57&#13;
2 pilot sites: HIF Local Hospttals /m     value                                                     -      240        -     240         -      274        -     274&#13;
2 pilot sites: PHC Centers /n             value                                                     -       40        -      40         -       46               46&#13;
Uninterrupted Power Supply&#13;
(UPS) Equipment                          value                                                     -      40         -      40         -      46         -      46&#13;
Modems for other regional offices         value                                                     -       48        -      48         -       55        -      55              SQ&#13;
FAS Application Software for&#13;
Pilot Sites                              value                                                     -       60               60         -      68        -       68&#13;
Subtotal                                                                                              -      488        -     488         -      556        -     556&#13;
Page 1&#13;
&#13;
&#13;
&amp;#12;&#13;
3. Health Information System&#13;
NIPH National Center /o                    value                                                      -      80         -      80         -       91        -       91&#13;
NIPH District Offices (2 pilot sites) /p   value                                                      -      80                80         -       91        -       91&#13;
NIPH Local Offices /q                      value                                                      -      40         -      40         -       46                46&#13;
Uninterrupted Power Supply&#13;
(UPS) equipment                          value                                                              50         -      50         -      57         -       57&#13;
Statistical Software Products              value                                                      -       8         -        8        -        9        -        9&#13;
Subtotal                                                                                                -     258         -     258         -      294        -      294&#13;
4. Nationwide Extension&#13;
Computer Equipment /r                      value                                                      -        -     167       167        -               195      195&#13;
5. Initial Consumable Products&#13;
Tapes, diskettes, printer cartridges,&#13;
paper for pilot sites                     value                                                      -      30         -       30                34        -       34&#13;
Produce &amp; print new forms&#13;
for non-pilot sites                       value                                                      -      50         -       50        -       57        -       57&#13;
Subtotal                                                                                                -      80         -       80        -       91        -       91&#13;
Subtotal                                                                                                  -      831      167      998        -      947      195    1,142&#13;
Total lnvestment Costs                                                                                    352      893      205    1,449      370    1,014      238    1,621&#13;
II. Recurrent Costs&#13;
A. Maintenance Contracts&#13;
Computer systems hardware&#13;
&amp; software                                per year                                                     -        -       50       50        -        -       53       53&#13;
FAS &amp; HIS Application Software&#13;
Systems                                   per year                                                     -        -        1        1                          1         1&#13;
Total Recurrent Costs                                                                                       -        -       51       51         -        -       54       54&#13;
Total                                                                                                     352      893      256    1,500       370    1.014      292    1,676&#13;
\a All site preparation work to be financed by Gvt.&#13;
\b National Institute for Public Health.&#13;
\c About 31 lines. Financed by govemment.&#13;
\d 10 persons x 4 days.&#13;
\e 48 persons x 4 days.&#13;
\f 30 persons x 8 days.&#13;
\g 44 persons x 8 days.&#13;
\h 44 persons x 8 days.&#13;
\i 4 persons x 8 days.&#13;
1; 1 pc, 1 printer, software&#13;
\k 2 PCs, 1 printer &amp; software.&#13;
U Small LAN with 4 workstations&#13;
\n LAN with 10-30 workstabons&#13;
\n 2 PCs, printer &amp; modems.                                                                                                                                                               V&#13;
\o LAN with 4 workstations, large data base, and server.                                                                                                                                 Q&#13;
\p LAN with 6 workstations, data base, software&#13;
\q LAN with 3 workstations, data base, software                                                                                                                                          O  Z&#13;
\r This activity contingent upon submission of satisfactory automation plan.&#13;
Page 2&#13;
&#13;
&#13;
&amp;#12;&#13;
FYR MACEDONIA&#13;
Heafth Sector Transition Project&#13;
Priority Preventon Programs&#13;
Detailed Costs&#13;
(US$ '000)&#13;
QuantHies                                        Base Cost                  Totals Including Contingencies&#13;
Unit          96197          97198           98199           Total       96197    97198    98/99    Total   96197    97198    91199    Total&#13;
1 Investnlnt Costs /a&#13;
A. Immunization Program&#13;
1. HepatitisBVaccne/b                      per dose            12.000          7,000          5,000           24,000      24       14       10       48       27       16       12       5.4&#13;
S. Tubmrculoes Preention&#13;
1. Equipment requirements&#13;
707O mm film                              rot                  370            280            185             835        9        7        5       21       10        8        5       24&#13;
Replacenernt X-ray equipmenl              value                                                                        231      231         -     462      257      263         -     520&#13;
Mobile Cnicic                              unit                   -              1                               1        -     360         -     360         -     410        -      410&#13;
Promotional Materials /d                  value                                                                           6       5        3       14        7        5        4       15&#13;
Subtotl                                                                                                                  246      603        8      856      274      687        9      970&#13;
C. AIDS Prewntion&#13;
Tes Kits                                    value                                                                         175      175        -     350      195      199         -     394&#13;
Promotional Materials                       value                                                                          10       5        5       20       11        6        6       23&#13;
Subtota                                                                                                                     185      180        5      370     206      205        6      417&#13;
D. BWod Donation Program&#13;
1 Promotional Matenals&#13;
&amp; ID Cards                                 value                                                                         135     100       72      307      150      114       84      348&#13;
E.  rnal and Child Care&#13;
1. Neonal Intenslve Care&#13;
Civil Woks (neonatal unit)                value                                                                        500         -        -     500      506         -        -     506&#13;
Intensive Care &amp; Therapy Undts (3)        value                                                                           -     270         -     270         -     308        -      308&#13;
Subtotal                                                                                                                 500      270         -     770      506      308        -      814&#13;
2. Reproductive Health Supplies&#13;
RHOGAM                                   perunit             10,000          7,500           5.000          22,500      150     113       75      338      167      128       88      383&#13;
RHTesting                                 perunit            15,000         11,250           7,500          33,750      45       34       23      101       50       38       26      115&#13;
Oral Contraceptives                      per cyce           120.000         90,000          60,000         270.000      60       45       30      135       67       51       35      153&#13;
Inecdables                               per dose             3.000          2,250           1.500           6,750       14      10        7       30       15       12        8       34&#13;
IUDs                                      perund              3.000          2,250           1,500           6.750       21      16       11       47       23       18       12       54&#13;
Subtal                                                                                                                    290     217      145      651      322      248      169      739&#13;
3. Cancer Screening Suppibe&#13;
Speculum                                   und                  110            110                            220         7        7        -      13        7        8                15   =&#13;
Sterlizer                                  und                   11             10               -              21        7        6        -       13       7        7         -      14   co&#13;
Microscopes                                und                    3              2              1                6       60      40       20      120       67       46       23      136  &#13;
ALutomatic Slide Strainer                  unit                   1                              -               1       40                 -      40       45         -        -      45&#13;
Automalt Coverglaass Spper                 und                    1               -                              1       70        -        -      70       78                 -       78    0 rm&#13;
Glassware                                 vailue                                                                         10        5       5       20        11       6        6       23   crX&#13;
Page 1&#13;
&#13;
&#13;
&amp;#12;&#13;
Sides &amp; Cover sip le                        vatue                                                                            30       23        15       68       33        26       18       77&#13;
Optical Scanner                              unit                    1               -               -               1       10         -         -      10        11        -        -       11&#13;
Ayre spatuias /f                            value                                                                             10        8        5       23        11        9        6       26&#13;
Chemicals &amp; slains                          value                                                                             8         4        4       16        9         5        5       18&#13;
Vehicdeig                                    unt                     1               -               -                1      15         -         -      15        17        -         -      17&#13;
Subtotal                                                                                                                      266        92       49      407      296       105       57      459&#13;
4 Pro4liconal labriels&#13;
Posters, leaflets /h                        value                                                                            27        19       13       59       30        22       15       67&#13;
S Software                                    value                                                                             13       13       13       38        14       14       15       43&#13;
Subtotal                                                                                                                       1,095      611      219    1.925    1,169       696      256    2,121&#13;
F. Laboratory Diagnostics&#13;
Laboratory equipment &amp; related&#13;
supplies                                     value                                                                           120       100       60      280      134       114       70      318&#13;
Total Investment Costs                                                                                                           1,805    1,607       374    3.787    1,959    1,832       436    4.228&#13;
It. Recurront Costs&#13;
K Cytology Screening&#13;
1. Management Center&#13;
Secretary (2)                               month                   24             24              24               72        5         5        5       14         5        5        5       15&#13;
Paper, postage, etc                         value                                                                            15        15       15       45       15        16       16       47&#13;
Overhead r,                                 value                                                                             3         3        3        8         3        3        3        8&#13;
Vehide 0 &amp; M                               per year                                                                            -        2        2        3         -        2        2        3&#13;
Subtotal                                                                                                                       22        24       24       70        23       25       25       72&#13;
2. Cytology Lab&#13;
Screeners (5) &amp; adrnmn staff (2)           annually                                                                          44       44        44      131       44        45       46      130&#13;
Total Recurrent Costs                                                                                                               66       68        68      201       67        70       72      209&#13;
1,872    1,675      441    3,988    2,026    1,902       508    4,436&#13;
Page 2&#13;
&#13;
&#13;
&amp;#12;&#13;
FYR MACEDONIA&#13;
Heanh Sector Transiion Promed&#13;
Prmary Health Care (PHC)&#13;
Detailed Costa&#13;
(USS '000)&#13;
Quantitis                                Base Cost                Totals Including Contingencebs&#13;
Unit       96197      97198       9U/99       Total     9697    97/98    9U199    Total   9697    97198   98U9    Total&#13;
I. InVeWMnt Costs&#13;
A. Equipment of Rurl Healt Centers (RHC)&#13;
1. RHCs with full-time MDla&#13;
Medical equipment                      per RHC            60         110         30         200      450     825      225    1,500      501     940      263    1.704&#13;
Fumitute/b                             perRHC             60        110          30         200      132     242       68      440      147     276       77      500&#13;
Subtotal                                                                                               582    1,067     291    1.940      648    1,216     340    2.204&#13;
2. RHCs wlth part-dam MD Ic&#13;
Medicalequspment                       perRHC              -         50            -         50        -      100        -     100        -      114       -      114&#13;
Fumiture /d                            per RHC             -         50            -         50        -       75        -      75        -      85                85&#13;
Subtotal                                                                                                 -      175        -     175        -      199       -      199&#13;
3. 30 RHCs (more than I MD)&#13;
Complementary Medical Eqmt. /e           value                                                       170      255        -     425      189     291        -      480&#13;
Complementary Fumdure /f                 value                                                         4        6        -       9        4       6        -       11&#13;
Subtotal                                                                                               174      261        -     434      193     297        -      491&#13;
Subtotal                                                                                                 756    1,503     291    2.549      841    1,713     340   2.894&#13;
B. Capacity Building (PHC &amp;&#13;
Proventwy Progranm)&#13;
1. Staff Training&#13;
2-3MonthCourses(extemal)/g               month             8           8          8          24       60       60      60      180       64      65       67      196&#13;
2. Study Tours &amp; Seminarm h&#13;
SludyTours(30persons)ri                 month             10           5           -         15       75       38        -     113       80      41        -      120&#13;
TA for Planning &amp; Followup               month             3         1.5         1.5          6       45       23      23       90       48       24      25       97&#13;
Localseminarsforstafffj                 perday           150         450         150        750        8       23       8       38        8      24        8       41&#13;
Subtotal                                                                                               128       83      30      240      135      90       33      259&#13;
3. EquIpnent&#13;
Computer, printer, photocopier           value                                                         -       10        -      10        -       11       -       11&#13;
Subtotal                                                                                                 188      153      90      430      199      166     100      466&#13;
Total Investment Costa                                                                                     943    1.655     381    2,979    1,041    1,879     440    3,360&#13;
II. Recurrent Costa&#13;
A. Operating Costs (cap bldg.) /k           annually                                                       -        2       2        4        -        2       2        4&#13;
Total Recurrent Costa                                                                                        -        2       2        4                 2       2        4&#13;
Total                                                                                                      943    1,657      383    2,983    1,041    1,881     442    3,364&#13;
\a About 200 facilities.                                \i Average two-weeks per person x 30= 15 training months.&#13;
\b Financed by Gvt.                                     \j Average 3 days, 50 participants each. Year 1: 1 workshop; Year 2: 3 workshops, Year 3: 1 workshop.                         :5.&#13;
Xc About 50 faciliies.                                  %k Financed by Gvt.&#13;
\d Financed by Gvt.                                                                                                                                                                Otl&#13;
ve 30 of 150 MDs have more than 1 MD                                                                                                                                                - &#13;
\f Financed by Gvt                                                                                                                                                                 '  '&#13;
\g Areas indude: health planning, MCH. PHC management.&#13;
\h 3 categories: conlinrang education; quality assurance; PHC skills strengthening.   Page 1&#13;
&#13;
&#13;
&amp;#12;&#13;
FYR MACEDONIA&#13;
Heatth Sector Transition Project&#13;
Supply and Distribution of Pharmaceuticals&#13;
Detailed Costs&#13;
(USS '000)&#13;
QuantUUs                             Base Cost                 Totals Including Contingencies&#13;
Unit      96/97     97198    91/91      Total    96197    97198    98/99    Total   96197   97)S8   88/99    Total&#13;
I Investment Coets&#13;
A. Drug Procurement &amp; Capacity Building&#13;
1. Procure Drugs &amp; Consunables la&#13;
Drugs &amp; Consumables                     per year                                             1,000     900      775    2,675    1,113    1,026     905    3,044&#13;
2. Capdaty Building lb&#13;
ExternalTraining                         month            4        4         2         10       30      30       15       75      32       33       17      81&#13;
Reference pricing study (extemal TA)     month            2        1         -          3       30      15        -       45      32       16        -      48&#13;
Advisory Services (extemal TA)           month            3        2         1          6       45      30       15       90      48       33       17       97&#13;
Local Traming /c                       workshop           2         1        1          4        5       3        3       10       5        3        3       11&#13;
Office Equipment/d                      package           1         -                   1        5        -       -        5       6         -       -       6&#13;
Subtotal                                                                                         115      78       33      225     122       84       36     243&#13;
3. Procuremnt a Distribution Services&#13;
Local TA/e                              fees/year                                              310     310      130      750     314      321      138     773&#13;
Subtotal                                                                                         1,425    1,288     938    3,650    1,549    1,432    1,079    4,060&#13;
B. Drug Control Laboratory&#13;
1. NPH Control Lab&#13;
Civil orks If                            value                                                 201        -        -     201     203         -       -      203&#13;
Lab equipment                            value                                                   -   1,280         -   1,280        -   1,459        -   1,459&#13;
Laboratory Engineer (Local TA)           month            -         2                   2        -       6                 6        -       7                 7&#13;
Staff trahinng (extemal) /g              month            2        2          -         4       15       15    _          30       16      18    _           32&#13;
Subtol                                                                                           216    1,301        -   1,517      219    1,482            1,701&#13;
C. Pr.clinical &amp; Clinical Pharmncology&#13;
and Toxicokogy&#13;
1. Bloequivalence Equipment &amp;&#13;
LabConsumables/h                          value                                                 133                 -     133      148        -       -      148&#13;
2. Phannacodynamics Equipment              value                                                 175        -        -     175      195        -       -      195&#13;
3. Advere Drug Reactions&#13;
Equipment                                value                                                  25        -        -      25      28         -       -       28&#13;
ReJerence Materials                      value                                                   1        -        -       1        1        -                I&#13;
Office equipmentri                      package           1         -         -         1        3    _                    3        3        -   _            3&#13;
Subtotal                                                                                          29        -               29       32        -       -       32&#13;
Subtotal                                                                                           337                       337      375                       375&#13;
D. Drug infowmation A RaUonal Us.&#13;
1. Drug Inomnaion Center/&#13;
Computer equpment                       package           1         -         -         1        3                 -       3        3        -       -        3&#13;
On-line network connections/k            vaue                                                   10        -        -      10       11        -       -       11&#13;
Page 1&#13;
&#13;
&#13;
&amp;#12;&#13;
Software applications                      value                                                    3                          3        3                          3&#13;
Seminars in Rabonal Drug Use A           workshop           4         4         2         10       24       24       12       60       26       26       13       65&#13;
Reference Materials                        value                                                   25       25        -       50       28       28        -       56&#13;
Audiovisual equipment                     package           1         -         -          1        5        -        -        5        6                  -       6&#13;
Public Informationr/m                      value                                                    -       50       50      100        -       57       58      115&#13;
Subtotal                                                                                             70       99       62      231       77      112       72      260&#13;
Total                                                                                                  2,048    2,688    1.000    5,735    2,221    3,025    1,151    6,396&#13;
\a Vaccines incduded under Prevention Programs subcomponent. Incdudes synnges, needles, &amp; sterle gloves&#13;
for prevention programs.&#13;
lb Drug procurement, legislation, regulation.&#13;
kc 10-15 persons for 1 week.&#13;
vd Computer, pnnter, photocopier.&#13;
\e Contractual services lor procurement &amp; distribubon of medical equipment &amp; supplies for prevenbon programs, rural health centers, and drugs/consumables procured under the project.&#13;
Financed by Gvt.&#13;
Uf Sie preparabon for control lab and constructon of animal house; financed by Gvt&#13;
%g Advanced methodology.&#13;
\h Year 1: S10,000 lab consumables; Year 2: 5123.000 equipment.&#13;
U Computer, printer.&#13;
\ WHO contrbuting 510,000 for 2 workshops and insttutional support.&#13;
Xk Internet, Medline, other health institutions&#13;
I Prescriber,s. heath professionals, etc. 10-15 persons/workshop; US$80 / day.&#13;
\m Promobonal materials, disseminaton to prescribers and pharmacists.&#13;
IV&#13;
o C&#13;
Pap2&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 22 of 65&#13;
Component: Health Finance &amp; Management&#13;
Year 0      Year 1           Year 2        Year 3&#13;
Activity                Strt r      Finish   Q3 04  Q1  Q2 03 Q4 Q1'Q2 Q3 Q4 1Q102 03  Q4&#13;
I Health Finance Reforms&#13;
Consultants hired and studies underway   May-961 Sep-96_                                         _&#13;
Advisory services, continued             _ Sep-96  Mar-97&#13;
2 Benefits package defined                  Dec-96  Dec-96_&#13;
Submit to Parliament                     Jun-97  Jun-97&#13;
Implement through NHIF                   Dec-97  Dec-97 _                    __            ___&#13;
3 copaymentiUiser fees                       _____&#13;
Submit to Parliament                     Jun-97f Jun-97                     -&#13;
Implement   ~       --                  Dec-97i Dec-97                   T   |__;__&#13;
4Capitation~                     -            __   ______            __ _                    -__&#13;
Present to Pariament                   - Jun___  Jun-97 J&#13;
Begin pilots (see below)                 Jun-97  Jun-98&#13;
51 integrated WiS&#13;
Present to technica-committee         _Jun-   Den-97c&#13;
Begin pilots (see below)           ____Jun-97i Jun-98&#13;
6 Design FAS i5HS_                                                     &#13;
TORs &amp; shortlist                         Sep-96  Sep-96   __&#13;
Solicit proposals_ ___                 :-Oct-96 Nov-96&#13;
Evaluate 8 award                         Nov-96 Dec-96&#13;
TA underway                                 Jan-97  Sep 98&#13;
,Site preparation for pilots (NHIF, DHIF,                                                    - &#13;
7 hospitals)&#13;
* Select contractors                       Jan-971 Feb-97             _                 ___I&#13;
Carry out work          _Mar-97May97_&#13;
8 Procure IT equipment for pilots&#13;
Prepare specifications and bid documents  Dec-961 Jan-97              __i____&#13;
Bidding process                          Jan-97tMar-97                            T&#13;
Evalute bids and award                   Apr-97  Apr-97&#13;
Deliver, install, train staff            May-97  Jun-97&#13;
9 Pilots underway                           Jun-97  Jun-98&#13;
Evaluate pilots                           Jul-98' Dec-98_&#13;
Implement nationwide                     Jun-99i                                        | &#13;
10 Capacity Building                                  ____'_I_____j&#13;
Training for NHIF staff &amp; DHIF Directors  Jan-977Jun-97&#13;
Folowup training NHIF staff              Oct-97  Feb-98&#13;
Continuing Education                      Oct-97  Mar-99&#13;
Long- &amp; short-term fellowships  -&#13;
1st cohort:&#13;
Identify candidates &amp; institutions      Oct-96  Dec-96                                 _&#13;
Training implemented                    Jan-97  Aug-97            =__                                    _&#13;
2nd cohort                                                                             _ _ _&#13;
* Identify candidates &amp; institutions      Oct-97  Dec-97&#13;
* Training implemented                   Jan-98 Aug-98&#13;
3rd cohort:                                                              I _&#13;
, Identify candidates &amp; institutions       Oct-98 Dec-981             ____i_j____&#13;
Training implemented                    Jan-99 Aug-99                      _       &#13;
I !Public Information Campaign&#13;
tHire experts to design campaign                                                     -       t-&#13;
_   TORS &amp; shortlist                     Oct-96 Dec-96 &#13;
Invite proposals                        Jan-97  Mar-97 _7!_                                             _&#13;
_   Evaluate &amp; select experts   -        Mar-97  Mar-97&#13;
Implement campaign                       Apr-97  Jun-99&#13;
12 Set up hospital association                                                1&#13;
Procure matenals                         Dec-96FDec-96,&#13;
Select short-term experts to assist      Dec-96  Dec-96                 !_;_'_:_;_j&#13;
Organize study tours                     Jan-97  Jun-98&#13;
Organize local seminars                  Jan-97  Jun-99-&#13;
Continuing education                     Jun-98' Jun-99         __L_-__&#13;
' Pre-effectiveness                                                                  _      _       ,_      _&#13;
Assumes effectiveness by Sept. 1996: 3-year implementation; closing Sept. 1999.&#13;
mA\machealtUmpsched.xbs&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX2&#13;
Page 23 of 65&#13;
Component: Basic Health Services             _&#13;
______                 _      _    _,Year 0          Year I           Year 2       Year 3&#13;
Activity                  Start    Finish   Q3 04 Q1  Q2 03 '04 01 02 03 04 Q1iQ2Q03  Q4&#13;
PRIMARY HEALTH CARE&#13;
I Procure equipment for rural PHC*              Aug-96  Jun-99&#13;
Finalize list of requirements                Aug-96  Sep-96&#13;
Submrit to UNIPAC for pricing          --    Oct-96   Dec-96 -                               ___,__&#13;
Delivery Lot 1, Lot 2. Lot 3                 Mar-97   Jun-99             ,                  -&#13;
2 Procure furniture for rural PHCs              Aug-96   Jun-99&#13;
Prepare list of requirements             _ Aug-96   Sep-96                             _____i&#13;
Prepare_bid documents (GVT procedures)       Oct-96  Nov-96&#13;
Bid process           _      ___ __            Dec-96   Mar-97&#13;
Evaluate&amp; Award                              Mar-97  May-97&#13;
tDelivery Lot 1, Lot2. Lot 3                    Jul-97   Jun-99&#13;
3  aacity Bulding       =                       Jan-97   Dec-98                           ____ __           _&#13;
Shl-term external training                   Jan-97   Dec-98&#13;
*Select candidates                           Jan-97   Feb-97            _        _                   _&#13;
Sele,_cniae ___                               Ma-9    Apr-97_                                      __  &#13;
_1 st group. 2nd group, 3rd group              Apr-97   Dec-98  _             _   _                              __ &#13;
Study Tours                                  Mar-97  Dec-98                                                       I&#13;
Select cadidate-s_        _      - _        Mar-97   Ar9 &#13;
1 st group, 2nd group      _           _   May-97   Sep-98          ____________&#13;
Local seminars                               Jun-97   Dec-98&#13;
PREVENTION PROGRAMS ____;__&#13;
4Tmrrmunizatilon program _      _     _         Mar-97  Mar-99                          - ,&#13;
Define_quantities &amp; procure Hep b vaccine    Mar-97  May-97 ____*=_&#13;
* Deliver: lot 1, lot 2. lot 3               Jun-97   Mar-99&#13;
5 AIDS Prevention                          _ Jun-97  Sep-98&#13;
7Test1 kits-___               _     _         Jun-97   Sep-98 _       ________&#13;
6 Tuberculosis prevention                       Sep-96   Oct-98                 _       __&#13;
Procure Mobile Clinic&#13;
Specfications &amp; bidding documents           Mar-97  May-97    ,                                        - _  -&#13;
_Bidding process                             Jun-97   Sep-97                                         -        -&#13;
' Evaluation &amp; award                         Sep-97   Oct-97                      , ___&#13;
Deliver &amp; train staff                       Dec-97  May-98                 __i_|_--&#13;
Procure other equipment                          __I&#13;
'xray film_                                  Se_ Sep-96   Oct-98&#13;
replacement xray equipment&#13;
- Prepare specifications &amp; bid documents    Dec-96   Feb-97&#13;
- Bdding process                            Feb-97  May-97                           __ r&#13;
iEvaluation &amp; award                           May-97   Jun-97&#13;
- Deliver &amp; train staff                     Aug-97   Dec-97        _      ____|&#13;
7 Maternat and Chid Health                      Dec-96  Dec-98             _  _             _ _               I&#13;
Neonatal lntensiveCare                                                                           -&#13;
Site preparation                           May-97  Aug-97                      _&#13;
-Procure IC &amp; therapy units                  Jul-97  Dec-98    ;                                       _&#13;
- Prepare specifications                     Jul-97  Sep-97 ___ T__&#13;
- Prepare bfdding documents                 Sep-97   Dec-97&#13;
- Bidding process                           Jan-98   Mar-98              _  __&#13;
- Evaluatiorn of offers                     Apr-98   Jun-98         __-____&#13;
- Select &amp; award                            Jun-98   Jun-98                                   _    _&#13;
- Deliver, install, train staff             Aug-98  Dec-98&#13;
Reproductive health supplies-                Dec-96  May-97&#13;
* Determine types &amp; quantities (annually)    Dec-96  Dec-96&#13;
*Order, deliver &amp; distribute                Jan-97  May-97&#13;
Cancer screening&#13;
* Procure_supplies and chemicals             Jun-97  Dec-97&#13;
Procure vehicle for stain collection        Apr-97  Sep-97                     _&#13;
Proimotional materbials AIDS, blood&#13;
8  donationa,reproductive health, TB)           Dec-96  Aug-99 _-&#13;
Develop &amp; disseminate                       Dec-96  Aug-99&#13;
9 Laboratory Dtagnoatica                        Mar-97  Dec-98  =        -&#13;
- Prepare specifications                    Mar-97  May-97 g      _    _                Ii&#13;
- Prepare bidding documents                 Mar-97  May-97   T_______i&#13;
- Bidding process                           May-97   Jul-97&#13;
- Evaluation of offers                  _Aug-97  Aug-97&#13;
Select &amp; award                __           Sep-97  Sep-97   _      -                      1 _&#13;
DelFvery/insFallafion                      Sep-97   De98               ____i&#13;
Pre-effectiveness&#13;
Assumes effectiveness by Sept. 1996: 3-year implementation; closing Sept. 1999.&#13;
m \imachealtUimpachedxbs&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 24 of 65&#13;
Component: Pharmaceutical Supply and Distribution&#13;
YearO     Year 11         Year 2      Year 3&#13;
Activity                  Start   Finish   03  0Q4 QIQ2 03 04 QI 02 03 04 01 Q203 04&#13;
1 New Drug Legislation                     _-Oct-995 sep-96&#13;
Finalize drug bill (condition of nego)  __ Oct-95 -May-96                     - ,        _         _ &gt;__  ___&#13;
Submit drug bill to Parliament                                           ______-&#13;
(condition of effectiveness)                Sep-96  Sep-96 __                 _&#13;
2 Drug Procurement Capacity        e__   _       p-96  Mar-97        _             _            =           __- &#13;
External training                           Dec-96   Jun-98       _                      V       - F&#13;
Purchase equipment (shopping)     -         Sep-96r  Oct-96_&#13;
Short-term_TA                               Mar-97  Mar-98 __                   _&#13;
Local training                              Jun-97  Sep-98                                           ________&#13;
3 Procurement of Drugs                         Mar-97  Sep-98 ___&#13;
Tender Process                              Mar-97  Sep-98                            i _&#13;
' Schedule of requirements                    Mar-97  Jun-97           _                           -&#13;
Prepare bid documents                    - J-un--977  Sep-97____&#13;
Clear bid documents                        Sep-97  Sep-97   _            _&#13;
' Go to bid   ____                           Oct-97  Dec-97&#13;
Evaluation8&amp; Contract Award--              Dec-97   Mar-98&#13;
_    Delivery                               Apr-98   Sep-98 _          t _&#13;
4 Quality Control Laboratory                   Mar-97  Sep-98 ,            _                           _&#13;
Hire Lab Engineer (Local TA)                Jan-98   Mar-98 &#13;
' Prepare TORs &amp; shortlist          _       Nov-97  Nov--97                    ______                      -&#13;
_ ' Invite proposals &amp; evaluate                 Dec-97  Dec-97&#13;
* Engineer on board                         Jan-98   Mar-98      __     _-                          ___&#13;
Site Preparation                            Mar-97  i Jun-97         ____|&#13;
Procure equipment                           Jun-97  Aug-97&#13;
= Schedule of requirements       |Jun-97, Jul-97                  =                - '              _&#13;
' Prepare bid documents                     Jun-971  Jul-97               _&#13;
Clear bid documents                        Aug-97 r Aug-97&#13;
Goto bid                                   Sep-97   Dec-97          _&#13;
Evaluation &amp; Contract Award                Jan-98   Feb-98          =    I_ _&#13;
' Deliver, Install &amp; Train Staff            Mar-98  Aug-98                                  _       _&#13;
Staff Training (external)                   Mar-97  Dec-97      _        -                       -&#13;
5 Pharmacology Lab &amp; Adverse Reactions         Jun-97  Aug-98&#13;
Procure equipment (bioequivalence,&#13;
pharmodynamics, adverse reactions)          Jun-97  Aug-97&#13;
' Schedule of requirements                  Jun-97   Jul-97   _     -        __              ,&#13;
F  Prepare bid documents                      Jun-97   Jul-97 -t          t-____&#13;
_ * Clear bid documents                 A_Aug-97  Aug-97               _                       - j&#13;
* Go to bid                                 Sep-97  Dec-97   i                        -            - _&#13;
' Evaluation &amp; Contract Award                    Jan-98   Feb-98         -                        -     _&#13;
* Deliver, Install &amp; Train Staff            Mar-98  Aug-98  __,__                  -                     _&#13;
f Establish Drug Information Center            Sep-96  Dec-98           _______&#13;
Select &amp; Prepare Site (including internet)  Sep-96   Mar-97&#13;
Purchase equipment (IT, software, AV,&#13;
materials)                                  Sep-96  Dec-98                                  I&#13;
' Schedule of requirements                  Sep-96   Oct-96&#13;
* Tender &amp; Award                            Oct-961  Jan-97                                         ___|____&#13;
' Deliver, Install                          Feb-97i Mar-97&#13;
Conduct local workshops for prescribers     Jun-97; Dec-98&#13;
Disseminate information                     Sep-97  Dec-98&#13;
' Pre-effectiveness                                                                   '__&#13;
Assumes effectiveness by Sept. 1996; 3-year implementation: closing Sept. 1999.!&#13;
mArnachealthimpsched.xis&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 25 of 65&#13;
III. Project Cost and Financing, Procurement Arrangements,&#13;
and Disbursements&#13;
A. Project Cost and Financing&#13;
17.          Total project cost is estimated at US$19.4 million (or MKD 737 million equivalent)&#13;
including contingencies. An estimated US$16.9 million equivalent (or 87% of total costs) will be&#13;
financed by the IDA credit of SDR 11.8 million (including a PPF (P-983-0-MK) totalling US$0.2 million&#13;
equivalent). The Credit will finance 100% of the estimated foreign exchange cost (US$14.5 million) and&#13;
48 % of estimated local costs (US$2.4 million). The remaining 13 % of total project costs will be financed&#13;
by the Government (US$2.5 million). All imported goods and services destined for health institutions&#13;
and related purposes--including those financed under the Project--are exempt from taxation and customs&#13;
duties. Any local taxes which may be incurred on locally purchased project items will be financed by&#13;
the Government.  Incremental recurrent costs included in the project (estimated US$0.3 million)&#13;
comprising operating costs, equipment maintenance service contracts, incremental staff salaries, and&#13;
supplies will be financed by the Government. A PPF (P-983-0-MK) of US$223,500 is supporting the&#13;
establishment of the IPU and training of IPU staff; and a PHRD Grant financed by the Government of&#13;
Japan totalling US$0.6 million equivalent has been used to support project preparation, including&#13;
preparatory studies for health financing reform.&#13;
18.          Estimated project costs by component are shown below  in Table 1 (MKD and&#13;
lS$equivalent). Table 2 presents project costs by expenditure category (including contingencies).&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 26 of 65&#13;
Table 1: Project Cost Summary&#13;
MKD Million                  US$million&#13;
Local  Foreign  Total       Local  Foreign Total&#13;
A. Health Finance &amp; Management             45.6    99.9  145.5           1.2     2.6   3.8&#13;
B. Basic Health Services                   62.8  202.1  264.9            1.7     5.3   7.0&#13;
1. Primary Health Care                     21.7    91.7  113.4           0.6     2.4   3.0&#13;
2. Prevention Programs                     41.1   110.4  151.5           1.1     2.9   4.0&#13;
C. Pharmaceutical Supply                   39.2   178.7  217.9           1.0    4.7   5.7&#13;
D. International Project Unit              26.0     8.9   34.9           0.7     0.2   0.9&#13;
Total Baseline Costs               173.6  489.6  663.2            4.6    12.9  17.5&#13;
Physical Contingencies               6.7   44.8   51.5           0.2      1.2   1.4&#13;
Price Contingencies                  5.2    16.5   21.7          0.1     0.4   0.6&#13;
Total Proiect Cost                 185.4  550.9  736.5            4.9    14.5  19.4&#13;
NOTE: Numbers may not total due to rounding.&#13;
* includes US$0.2 million PPF.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 27 of 65&#13;
Table 2: Proiect Costs by Expenditure Categorv&#13;
---------- MKD -------------  ----------US$----------------&#13;
Expenditure Category       Local  Foreign   Total      Local Foreign  Total&#13;
Goods&#13;
Medical Equipment&#13;
&amp; Supplies                  -      206.0  206.0       -      5.4   5.4&#13;
Pharmaceuticals &amp; Consumables   -    127.9  127.9       -      3.4   3.4&#13;
Reference Materials          -         1.9   1.9        -      0.1   0.1&#13;
Other Equipment             15.7      14.9  30.6        0.4   0.4    0.8&#13;
Vehicles                     0.1      14.2   14.3       0.0   0.4    0.4&#13;
Computers                    -        44.2  44.2        -      1.2    1.2&#13;
Furniture                   19.9       -    19.9        0.5    -      0.5&#13;
Subtotal             35.7    409.1  444.8        0.9   10.8   11.7&#13;
Civil Works                 29.6       -    29.6        0.8    -      0.8&#13;
Subtotal             29.6       -    29.6        0.8    -      0.8&#13;
Technical Assistance&#13;
External Experts             -        35.3  35.3        -      0.9    0.9&#13;
Local Experts               74.2       -    74.2        2.0    -      2.0&#13;
Subtotal             74.2      35.3  109.5       2.0   0.9    2.9&#13;
Trainin2&#13;
External                     -        42.2  42.2        -      1.1    1.1&#13;
Local                       16.7       -    16.7        0.4    -      0.4&#13;
Subtotal             16.7      42.2  58.8        0.4    1.1    1.5&#13;
Total Investment           163.4    489.2  652.6        4.3   12.9  17.2&#13;
Incremental Operating Costs&#13;
Supplies                    3.4       -     3.4        0.1    -      0.1&#13;
Incremental Salaries        6.4       -     6.4        0.2    -      0.2&#13;
Equipment Maintenance       2.3       -     2.3        0.1    -      0.1&#13;
Other                       0.5       -     0.5        0.0    -      0.0&#13;
Total Recurrent             12.6       -    12.6        0.3    -      0.3&#13;
TOTAL BASE COSTS           173.6    489.2  663.1        4.6   12.9  17.5&#13;
Physical cont.        6.7      44.8  51.5        0.2    1.2   1.4&#13;
Price cont.           5.2      16.5  21.7        0.1    0.4   0.5&#13;
TOTAL COSTS                185.4    549.9  736.5        4.9  14,5  19.4&#13;
NOTE: Numbers may not total due to rounding.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 28 of 65&#13;
19.   Table 3 shows the project financing plan by financier, and Table 4 project financing by&#13;
component and financier.&#13;
Table 3: Finaning Plan by Financer&#13;
(US$million)&#13;
Financier    Local (%)      ForeiRn  (%)        Total (%)&#13;
IDA           2.4 48.0       14.5  100.0       16.9  87.0&#13;
Government   2.5 52.0         0.0   0.0         2.6   13.0&#13;
TOTAL       4.9 25.5       14.5  74.5        19.4  100.0&#13;
NOTE: Numbers may not total due to rounding.&#13;
Table 4: Proiect Costs by Component and Financier&#13;
(US$million, including contingencies)&#13;
*Component                 IDA          Government          TOTAL&#13;
A. Health Finance &amp;&#13;
Management               4.0                0.2               4.2&#13;
B. Basic Health Services   6.5                 1.3              7.8&#13;
C. Pharmaceutical Supply   5.4                 1.0              7.0&#13;
D. IPU                     0.9                 0.1              1.0&#13;
TOTAL               16.9                2.5             19.4&#13;
NOTE: Numbers may not total due to rounding.&#13;
20.   Basis for cost estimates. Cost estimates are derived from those assumed under other projects in&#13;
the Eastern and Central Europe Region, including FYR Macedonia. Additional sources include relevant&#13;
equipment catalogues and supplier quotations, as well as technical estimates for applications software and&#13;
hardware. Estimates for consultant and training costs also reflect experiences in the Region. Incremental&#13;
staff salaries included in the project are based on current government rates. Project costs have been&#13;
estimated in US dollars, with the local equivalent calculated on the basis of the February 1996 exchange&#13;
rate of 38 MKD/US$1.&#13;
21.   Contingency Allowances. Project costs include contingencies for unforeseen physical variations&#13;
(totalling US$1.2 million) equivalent to 5% for technical assistance and training, and 10% for other&#13;
project items. Annual inflation of 2.4% is assumed for both foreign and local costs during the three-year&#13;
implementation period.&#13;
22.   Foreign Exchange Component. The foreign exchange component is estimated at about US$14.5&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 29 of 65&#13;
million including contingencies, or 75% of total project cost. Calculations of the foreign exchange&#13;
component are based on the following assumptions: (i) 100% for medical equipment and supplies,&#13;
reference materials, computer software and hardware, external technical assistance and training; (ii) 60%&#13;
for office equipment; (iii) 90% for vehicles; and (iv) 0% for furniture, local technical assistance and&#13;
training.&#13;
23.    Customs Duties and Taxes. The Ministry of Finance has confirmed that imported goods destined&#13;
for health-related institutions and purposes are exempt from taxes and duties. However, locally purchased&#13;
medical and computer equipment is taxed at 5%; and office equipment at 25%. Under the project, it is&#13;
expected that most medical and computer equipment will be imported, as will most office equipment (with&#13;
the exception of about US$400,000 of goods purchased through local shopping). Given the small amount&#13;
involved, no estimation of taxes has been included in project costs. The Borrower does recognize that&#13;
it will be responsible for meeting all duty and/or tax obligations should they arise.&#13;
24.   Incremental Recurrent Costs. Project cost estimates include US$0.3 million (2% of total project&#13;
cost) in incremental operating costs attributable to the Project during the three-year period. These costs&#13;
comprise equipment operation and maintenance, minor operating expenses and supplies, and incremental&#13;
staff salaries. Annual incremental operating costs are estimated at MKD 5.0 million or less than 1% of&#13;
the recurrent health budget. These costs will be more than compensated for through a number of&#13;
measures being undertaken by the MOH, inter alia, savings generated by competitive procurement of&#13;
pharmaceuticals and reductions in public funding for medical training.&#13;
B. Procurement Arrangements and Schedule&#13;
25.    Project inputs, estimated costs, and proposed procurement arrangements for those inputs&#13;
financed under the IDA Credit are summarized in Table 5 below. Incremental recurrent costs, civil&#13;
works, and furniture, all of which are financed 100% by Government counterpart funds, are shown&#13;
under the Non-Bank Financed (NBF) column.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 30 of 65&#13;
Table 5: Proposed Procurement Arrangements '&#13;
(US$million)&#13;
ICB            Other bl        NBF cs          TOTAL&#13;
1. Civil Worksd-                                        -               0.8            0.8&#13;
2. Goods&#13;
2.1  Medical Equipment &amp; Supplies  3.9               2.2              -             6.1&#13;
(3.9)           (2.2)             -             (6.1)&#13;
2.2  Drugs &amp; Consumables            3.8              -                -             3.8&#13;
(3.8)            -                -             (3.8)&#13;
2.3  Reference Materials                             0.1              -             0.1&#13;
(0.1)            -             (0.1)&#13;
2.4  Other Equipment "                               0.9              -             0.9&#13;
-              (0.9)             -             (0.9)&#13;
2.5  Furniture                                       -               0.6             0.6&#13;
2.6  Vehicles                       0.4 f"           0.0              -             0.5&#13;
(0.4)           (0.0)             -             (0.5)&#13;
2.7  Information Technology         1.3              0.1              -              1.3&#13;
(1.3)           (0. 1)            -(1.3)&#13;
3. Consultancies &amp; Training&#13;
3.1  Project Management             -                0.7              -             0.7&#13;
-              (0.7)             -             (0.7)&#13;
3.2  Specialist Services                             1.5             0.8 hb        2.3&#13;
(1.5)            -             (1.4)&#13;
3.3  Training                                        1.7              -             1.7&#13;
-              (1.7)             -             (1.7)&#13;
4. Incremental Recurrent Costs " -                                     0.3             0.3&#13;
5. PPF Refinancing                                      0.2              -             0.2&#13;
(0.2)            -             (0.2)&#13;
Total                          9.4              7.5             2.5           19.4&#13;
(9.4)           (7.5)             -            (16.9)&#13;
Note:  Figures in parentheses are the respective amounts financed under the IDA Credit.&#13;
a/      Figures may not total due to rounding. Figures include contingencies.&#13;
b/     International Shopping (IS), estimated US$0.6 million; National Shopping (NS), estimated USS0.4&#13;
million (office equipment, promotional materials, computer peripherals and supplies).&#13;
Direct Contracting (DC), estimated US$0.1 million (e.g., reference materials, manuals); and medical&#13;
equipment for rural primary health centers, estimated US$2.2 million purchased from UNIPAC&#13;
catalogue. Consultant services (estimated US$2.2 million) and training (estimated US$1.7 million) to&#13;
be procured in accordance with IDA Guidelines.&#13;
c/      Non-Bank Financed. Financed 100% by Government.&#13;
d/      Includes site preparation for information technology installation (e.g., communication lines), neonatal&#13;
care unit, drug control laboratory and animal house. All Civil Works financed by the Government.&#13;
e/     Includes promotional materials for prevention programs, office equipment, computer peripherals and&#13;
supplies.&#13;
f/     US$0.4 million for mobile clinic for tuberculosis screening.&#13;
g/     One vehicle for cancer screening activities (about US$15,000); purchased through NS.&#13;
h/      Procurement services contract (estimated US$0.8 million), financed by the Government.&#13;
i/     Including equipment maintenance and service contracts, incidental supplies, incremental staff salaries.&#13;
All recurrent costs financed by the Government.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 31 of 65&#13;
26.    Civil works (including site preparation for information system pilots, neonatal care unit, and drug&#13;
control laboratory and animal house) totalling an estimated US$0.8 million will be financed entirely by&#13;
the Government and procured according to its procedures.&#13;
27.    Goods to be procured include medical and laboratory equipment and supplies, drugs and&#13;
consumables, computer hardware and software, office equipment, furniture, promotional materials for&#13;
prevention programs, and vehicles (one mobile clinic for tuberculosis screening, and one vehicle for&#13;
cancer screening activities).&#13;
28.    Furniture amounting to about US$0.6 million will be financed by the Government and procured&#13;
through relevant local procedures. For other goods under the project, equipment contracts of a value&#13;
exceeding US$200,000 equivalent per contract will be procured following International Competitive&#13;
Bidding (ICB) procedures in accordance with the IDA's "Guidelines for Procurement Under IBRD Loans&#13;
and IDA Credits" (January 1995). Equipment and supplies will be grouped into a small number of&#13;
packages (about nine) to be procured through ICB to encourage competitive bidding and permit bulk&#13;
procurement, including: laboratory and diagnostic equipment and supplies (two packages); neonatal&#13;
intensive care unit equipment; other medical equipment; replacement x-ray equipment; drugs and&#13;
consumables; reproductive health supplies (including contraceptives); mobile clinic for tuberculosis&#13;
screening; and computer hardware. Computer hardware and peripherals (representing about US$1.3&#13;
million) will be procured with careful consideration of compatibility and availability of maintenance&#13;
services. Equipment procured through ICB will account for about 70% (US$9.4 million) of total goods&#13;
to be procured under the project. Domestic preference would not be applied.&#13;
29.   Other procurement procedures. Contracts for equipment estimated to cost less than US$200,000&#13;
per contract, not to exceed an aggregate amount of US$0.6 million equivalent, will be awarded through&#13;
International Shopping (IS) procedures, based on comparing price quotations obtained from at least&#13;
three suppliers from two eligible countries in accordance with IDA guidelines. Items that cannot be&#13;
grouped, or groups of items estimated to cost less than the equivalent of US$50,000 per contract, or off-&#13;
the-shelf items, amounting to about US$0.4 million, will be awarded through National Shopping (NS)&#13;
by comparing price quotations obtained from at least three local suppliers, in accordance with IDA&#13;
Guidelines. About US$2.2 million in basic medical equipment (e.g., stethoscopes, scales) destined for&#13;
rural primary health centers will be purchased as catalogue items from UNIPAC (UNICEF). Other&#13;
contracts for goods which IDA agrees are of proprietary nature (e.g., unique reference materials,&#13;
technical manuals, software), amounting to about US$0.1 million may be awarded after direct&#13;
negotiations with suppliers, in accordance with procedures acceptable to IDA.&#13;
30.    Consultants for technical assistance services financed under the project (totalling about US$2.2&#13;
million) will be selected in accordance with the "Guidelines for the Use of Consultants by World Bank&#13;
Borrowers and by The World Bank as Executing Agency" (August 1981). It is estimated that five&#13;
packages for technical assistance will be required (see Procurement Schedule in Table 6 below), including&#13;
specialist services for: health financing and management, reference pricing, pharmaceutical advisory&#13;
services, procurement and distribution services (financed by Government), as well as project management&#13;
support. As needed, the services of individual specialists (e.g., to develop computer applications software&#13;
or technical specifictions for medical equipment) (estimated total value US$250,000) will also be&#13;
contracted on the basis of shortlists of eligible candidates and comparison of at least three curricula vitae.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 32 of 65&#13;
Local training under the project is estimated at US$0.5 million, and external training at US$1.2 million.&#13;
Approximately US$0.7 million of this training under the Health Finance &amp; Management Component will&#13;
be provided as one component of the related consultant services contract. For other external training,&#13;
institutions will be selected through shortlisting in accordance with IDA procedures.&#13;
31.   Table 6 below summarizes the procurement packaging and estimated timetable for goods and&#13;
services under the project.&#13;
l&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 33 of 65&#13;
Table 6: Procurement ImDlementation Summary&#13;
------ - -Estimated Timing --&#13;
Base      Proc.   Prepare                      Complete&#13;
Item                  Cost      Method   Tender Invitation  Award  Contract(s)&#13;
(US$M)&#13;
Civil Works                   0.8       Gvt. financing and procedures, appropriately timed with&#13;
related activities.&#13;
Civil Works: Total    0.8&#13;
Goods&#13;
1. Medical Equipment for RHCs 2.0       DC       1/97     Place order w/ UNIPAC.6/99&#13;
2. Lab Testing Equipment      1.6       ICB      6/97     9/97       2/98    8/98&#13;
3. Lab Diagnostic Equipment    0.3      ICB      3/97     6/97       9/97    12/98&#13;
4. Neonatal Equipment         0.3       ICB      9/97     11/97      3/98    12/98&#13;
5. Replacement x-ray eqmt.    0.5       ICB      12/96    2/97       5/97    12/97&#13;
6. Reproductive health supplies  0.6    ICB      1/97     3/97       6/97    6/99&#13;
7. Drugs &amp; consumables        3.4       ICB      6/97     9/97       12/97   6/99&#13;
8. Mobile Clinic              0.4       ICB      5/97     8/97       10/97   1/98&#13;
9. Reference Materials        0.1       DC       Place orders to coincide with related activities.&#13;
10. Furniture                 0.5       Gvt. financing and procedures, appropriately timed with&#13;
related activities.&#13;
11. Information Technology    1.2      ICB       3/97     6/97       9/97    6/98&#13;
12. Other equipment (e.g., office&#13;
equipment, promotional materials, 0.8   IS/NS    9/96     -          -        12/97&#13;
vehicle)&#13;
Goods: Total          11.7&#13;
Technical Assistance &amp; Tralninz&#13;
Specialist Services:&#13;
1. Health Fin. &amp; Managemt. a/  2.0      SL       3/97     6/97       8/97    10/97&#13;
2. Reference pricing          0.05      SL       12/96    2/97       3/97    6/98&#13;
3. Pharm. advisory services   0.05      SL       12/96    2/97       3/97    12/98&#13;
4. Proc. &amp; Distribution Services 0.9    Gvt. financing and procedures. Signature of contract with&#13;
qualified agent is a condition of effectiveness.&#13;
Project Management:&#13;
5. Project Management Support  0.6      Includes full-time core staff on long-term contracts. Other short-&#13;
term assigmnents filled through SLs of qualified persons&#13;
individuals as required during implementation (est. $250,000).&#13;
Training:&#13;
6. Other training &amp; fellowships  0.8    External training: Consultant guidelines.&#13;
Local training: Seminar &amp; workshops.&#13;
TA &amp; Training: Total   4.4&#13;
NOTE: Numbers may not add due to rounding. Figuret represent estimated base cost.&#13;
a/ Single package to include capacity building in PHC services, research studies in health reform, health reform&#13;
advisory services, FAS and HIS development, hospital autonomy study, public information campaign. Package&#13;
also includes all related training activities (estimated US$0.7 million).&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 34 of 65&#13;
Table 6, continued: Legend&#13;
DC = Direct Contracting                 SL = Shortlist           NS = National Shopping&#13;
ICB = International Competitive Bidding    IS = International Shopping&#13;
32.    In compliance with IDA procedures, standard bidding documents will be used for all ICB&#13;
procurement. IDA will review all final equipment lists, technical specifications, packaging of bids, and&#13;
updated package values. With respect to contracts for goods estimated to cost US$200,000 or more, the&#13;
procedures set forth in paragraphs 2 and 4 of Appendix I of the Guidelines shall apply. Prior review&#13;
(including requests for direct contracting) is expected to cover over 85 % of the total estimated base cost&#13;
for goods procured under the project. Remaining contracts will be subject to selective post award review.&#13;
Consultant contracts, with the exception of contracts with firms not exceeding US$100,000 each in value,&#13;
and for individuals not exceeding US$50,000 each in value, will be subject to prior review. The Bank&#13;
will, however, review terms of reference, short lists, and consultants' profiles for all individual&#13;
consultants.&#13;
33.    The IPU will coordinate and monitor all procurement activities for goods and services under the&#13;
project, including tracking of those activities carried out by the selected agent for procurement and&#13;
distribution of drugs and consumables. In addition, information technology equipment will be procured&#13;
with the assistance of external experts under the related subcomponents, in collaboration with the IPU.&#13;
Short-term technical assistance (both external and local) is included in the project to assist the IPU in&#13;
performing these functions, including preparation of bidding documents and technical specifications. The&#13;
procurement officer has already received training in equipment procurement funded under the PPF, and&#13;
further training for IPU core staff in procurement and project management principles is foreseen under&#13;
the project. The IPU will also be responsible for informing IDA of contract awards, and would include&#13;
the following procurement-related information in periodic progress reports: (a) updated cost estimates,&#13;
by component and category of expenditure, for the project; (b) updated procurement timetable for goods&#13;
and equipment; and (c) status of aggregate limits on specified methods of procurement.&#13;
34.    Procurement and distribution of drugs, consumables, and medical equipment for rural primary&#13;
health centers will be carried out by the local procurement agency selected by the Government. It is&#13;
envisaged that procurement of these items will be carried out in accordance with IDA's Guidelines for&#13;
Procurement (January 1995). The MOH will enter into a cont-act with the selected agency to ensure the&#13;
procurement and distribution of these items, and all fees related to performance of these services will be&#13;
financed by the Government (an estimated US$0.8 million) as part of its counterpart contribution to the&#13;
project. Signing of this agreement, the provisions of which will be acceptable to IDA, is a condition of&#13;
effectiveness.&#13;
35.    A General Procurement Notice was prepared and finalized for publication during negotiations (see&#13;
Appendix 3). A Project Launch Workshop will be held prior to effectiveness (tentatively scheduled for&#13;
July 1996).&#13;
C. Disbursements, Special Account, and Audit Requirements&#13;
36.    Disbursements. The proposed Project is expected to be disbursed over a period of three years,&#13;
considerably shorter than the relevant sector profile in the Region of about seven years. This project is&#13;
the second operation in the human resources sectors in the FYR Macedonia, the first having become&#13;
effective less than one year ago. Therefore, the country disbursement profile is speculative. However,&#13;
the shorter implementation period for the present project reflects the nature of the project as a source of&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 35 of 65&#13;
bridge financing during the initial stages of the transition and in support of the first phase of the&#13;
Government's health reform program, as well as the simplicity of the project's design. The closing date&#13;
will be March 31, 2000. Estimated disbursements are shown in Table 7 below.&#13;
Table 7: Estimated Disbursements by Year&#13;
(US$rnillion)&#13;
IDA Fiscal Year             1996            1997        1998&#13;
Annual                       6.2            8.2           2.6&#13;
Cumulative                  6.2            14.4          16.9&#13;
Cumulative as % of total    37.0           85.0         100.0&#13;
The IDA credit will be disbursed as follows:&#13;
(a)    for equipment: 100% of foreign expenditures, 100% of ex-factory local costs, and 85%&#13;
of other items procured locally;&#13;
(b)    for technical assistance, local and external training: 100% of all expenditures; and&#13;
(c)    repayment of PPF.&#13;
All disbursements will be fully documented with the exception of: (i) goods contracts of a value less than&#13;
US$200,000 equivalent; (ii) contracts with consulting firms of a value less than US$100,000 equivalent&#13;
and with individual consultants of a value less than US$50,000; and (iii) local training--for which&#13;
disbursements will be made on the basis of Statements of Expenditure (SOEs). The required supporting&#13;
documentation will be retained by the IPU for at least one year after receipt by the Bank of the audit&#13;
report for the year in which the last disbursement was made. This documentation will be made available&#13;
for review by the auditors and by visiting staff upon request.  The responsibility for monitoring&#13;
disbursements of the IDA credit, as well as Government counterpart financing, will lie with the IPU.&#13;
37.    Special Accoun.. To facilitate project implementation, the Government has established, under&#13;
terms and conditions acceptable to IDA, a Special Account in US Dollars in the National Bank of&#13;
Macedonia. Payments for eligible expenditures may be made by the IPU out of this account. The&#13;
Special Account will have a total authorized allocation of US$1.0 million. The initial deposit will amount&#13;
to US$500,000 until the aggregate amount of withdrawals from the Credit Account plus the total amount&#13;
of all outstanding special commitments shall be equal to or exceed the equivalent of US$5.0 million. The&#13;
Special Account will be replenished on a monthly basis or whenever the undisbursed balance falls below&#13;
an amount equal to 50% or less of Authorized Allocation, whichever occurs first. Monthly bank&#13;
statements of the Special Account which have been reconciled by the Borrower will accompany all&#13;
replenishment requests. The Special Account funds should be used for all payments of a value less than&#13;
20% of the Authorized Allocation.&#13;
38.    Audit Requirements. The IPU will maintain separate accounts, in conformity with international&#13;
accounting practices. Project accounts, including the Special Account, will be audited in accordance with&#13;
the Bank's "Guidelines for Financial Reporting and Auditing of Projects Financed by the World Bank"&#13;
(March 1982). The Borrower will provide to IDA (within six months of the end of each fiscal year) an&#13;
audit report of such scope and detail as IDA may reasonably request, including a separate opinion by an&#13;
independent auditor acceptable to the Bank on disbursements against certified SOEs. The separate&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 36 of 65&#13;
opinion should mention whether the SOEs submitted during the fiscal year, together with the procedures&#13;
and internal controls involved in their preparation, can be relied upon to support the related withdrawal&#13;
applications.&#13;
D. Reporting Requirements&#13;
39.    The PCU will prepare semi-annual descriptive and financial reports on each project component,&#13;
objective and activity (beginning from the date of Credit Effectiveness). These reports will be due in&#13;
January and July of each year, and will describe: (a) current status; (b) deviations, if any, from the&#13;
implementation plan; and (c) the reasons for deviations and corrective actions being taken. These reports,&#13;
in addition to the SAR and PIP, will form the basic documents for supervision of the project. Project&#13;
reporting, as well as supervision, will also focus on in-depth reviews of the agreed policy agenda (see&#13;
Letter of Development Policy, Annex I to the SAR), the consistency of activities for each component and&#13;
subcomponent with agreements reached at negotiations, performance of the implementing agencies,&#13;
assessment of emerging needs for adjustments to project parameters, and possible follow-up operations&#13;
which could be supported by the Bank. Project supervision will also include a review of project&#13;
expenditures and availability of financial resources, substantive discussions with technical assistance&#13;
groups implementing and/or assisting in the implementation of various components, and discussions with&#13;
responsible authorities. A mid-term review of progress under the project will be conducted by IDA and&#13;
the Borrower by March 31, 1998.&#13;
E. Supervision Requirements&#13;
40.    Supervision. Recognizing that the Health Sector Transition Project is a first generation project&#13;
in the health sector in FYR Macedonia, and that the implementing agency and related institutions have&#13;
no previous experience in carrying out an investment project of this magnitude, the supervision effort&#13;
required during the initial phases of implementation will inevitably be higher than average. Furthermore,&#13;
in planning for project supervision, it is important to distinguish between time spent on routine&#13;
supervision matters, and time spent providing substantive policy advice to the Government and other&#13;
institutions on implementing its reform agenda. In the given implementation environment, the provision&#13;
of both types of assistance will put a heavy demand on resources.&#13;
41.    Table 8 below provides an estimate of the volume and type of supervision inputs envisaged under&#13;
the project. Resident Mission support through local staff is not presently feasible since the Resident&#13;
Mission in Skopje is newly established. However, once operationally staffed and trained, efforts will be&#13;
made to involve local staff in supervision activities. Delegation of specific supervision responsibilities&#13;
to permanent field staff would likely not be feasible until at least the second year of the project, with&#13;
substantive and operational backstopping support continuing to be provided by Headquarters staff and/or&#13;
the Budapest Human Resource Hub.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 37 of 65&#13;
Table 8: Supervision Requirements&#13;
(weeks)&#13;
Staff InDuts           Year 1                 Year 2                 Year 3              Total&#13;
of which              of which                of which           of which&#13;
HO*   Field            HO*   Field            HO*   Field         HO*       Field&#13;
Task Management         6       4              4       4              4       2         14      10&#13;
Operations/Implemen-    6       4              6       4              4       2         16      10&#13;
tation Officer&#13;
Primary Health Care&#13;
Specialist              1       4              0       2              0       2          1       8&#13;
Health Policy/Finan-&#13;
cing Specialist         2       4              2       4              1       2          5      10&#13;
Pharmaceutical Policy&#13;
Specialist              2       2              1       3              1       2          4       7&#13;
Information Technology&#13;
Specialist              1       4              2       4              1       2          4      10&#13;
Total (breakdown)      18      22             15      21             11      12         42      55&#13;
Total Requirements&#13;
Per Year               40                     36                     23                 99&#13;
* HQ includes all non-field inputs, i.e., Bank staff or consultants.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 38 of 65&#13;
IV. Monitoring And Evaluation&#13;
Project Monitoring&#13;
42.    Monitoring is a continual process of assessing whether project resources (inputs) are being used&#13;
as planned to carry out project activities (outputs). Monitoring the use of project resources will be done&#13;
by tracking inputs according to component, activity and expenditure category, as outlined in Table 9:&#13;
Input Indicators. Updated disbursement information will be provided in this format in the project's semi-&#13;
annual Progress Reports, to be prepared by the IPU. Monitoring outputs under the project is more&#13;
complex, involving both implementation of project activities and implementation of the broader policy&#13;
reform agenda. For the former, completion of key project activities will be monitored as indicated in&#13;
Table 10: Output Indicators, and summarized in the semi-annual Progress Reports. For the latter,&#13;
progress in implementing reforms will be jointly assessed by Government and IDA on an annual basis.&#13;
A timetable of expected progress, with carefully defined progress benchmarks, has been summarized in&#13;
the policy matrix attached to the Government's Letter of Development Policy (Annex 1).&#13;
Project Evaluation&#13;
42.    Evaluation is a process of assessing the extent to which a project achieves its objectives. The&#13;
objectives of the Health Sector Transition Project aim to affect outcomes related to health status, services&#13;
and financing. Broad outcome indicators have been selected in each of these areas. The indicators were&#13;
selected on the basis of relevance to the project objectives, sensitivity to project activities, ease of data&#13;
collection and parsimony. It is recognized that changes in most of these indicators cannot be causally&#13;
linked directly to project activities, since the project is only one of multiple factors impacting on health&#13;
status and services during the short (three-year) implementation period. However, annual monitoring of&#13;
these indicators will provide evidence of overall trends in the health status of the population, the&#13;
effectiveness of health services and the efficiency of public spending for health--all of which the project&#13;
seeks to influence positively.&#13;
&#13;
&#13;
&amp;#12;&#13;
TAk 9-.PROJECr MtrrONITG&#13;
INPUT INDICATORS: DISBURSEMENTS&#13;
(USSWD's equivale)&#13;
ConptJExpendiur Caey             T        Feb. 1997'             Sep. 1997              Feb.1996              Sqe9  1998             Feb 1999                Sepi. 1999          Ttzl Expaled&#13;
|         I|ec|E Acnal J|p Ie      A          Expected |Actaled    E E4ced   |Acn          Expeed  | AcJ  u     | Exp  ed      Actnul&#13;
1.    Hel1 Fimu  ta  Map&#13;
A    Heath fumitte eel&#13;
B.   Health Iuw. reut&#13;
Cml waft&#13;
EWW-&#13;
A&amp;mwy wvw&#13;
B.   1WW  1mm    FEW&#13;
Advimy srtcs&#13;
C    H1spit Ma1m          Eq_-0&#13;
Advuy-&#13;
Civil works&#13;
T-g&#13;
I I I (A L)&#13;
CDdil works&#13;
Eqq-&#13;
ATvny u  r"&#13;
T crit n.&#13;
I.wm   m(AD&#13;
E.   ldwnwm sysam~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~J&#13;
Civd works ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~~~~0&#13;
Eq*       ae- fsm-mn  rgrs  eot  ilb  dute  ae  nte  fefcrsrs  fteIAcei                                                                                                                                     t&#13;
A*mwy mr"m ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~~~~~~~~~~0&#13;
Training ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~  ~     ~    ~    ~    ~    ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~~~~~~j &#13;
&#13;
&#13;
&amp;#12;&#13;
PROJECT MONITORING&#13;
INPUT INDICATORS: DISBURSEMENTS&#13;
(USSOOO's equivalent)&#13;
C    _I _/Expencl     Cacgey                             Feb. 1997        |       Sep. 1W7                   Feb. 1997                Sept 199h                 Feb 1999                Sep. 1999             Totl Exy&#13;
E_v_       | ACml         Eye.    [AcI              E  e          Afi         Expect   | Acl           Expct      | Actwu       Expect         Actwl&#13;
I1.   Bai Hnldh Ses&#13;
A.   Pniw  blWe&#13;
Chei wai&#13;
t -a&#13;
EWW&#13;
Advioy sv&#13;
Rral cn&#13;
4.  I      uel.  P c  lih&#13;
Ceil4 works&#13;
EqNp.mem&#13;
Tra*aq&#13;
Anvni&#13;
Tmnu&#13;
Rea'.m  cw a -5&#13;
CmVl wmrh1                                                                                                                                                                                                                       B&#13;
RawrTeJ ommts&#13;
2. T4ufuJloel 1is    eat&#13;
CTn work&#13;
ARn a-s cm&#13;
Rer cA     , P 1e.aO,&#13;
Smi B.Dmtttml q&#13;
Tmin.&#13;
Reaffem cmLs&#13;
CeI works&#13;
A&amp;,nwy scyss&#13;
Trmiting&#13;
ERWm%e  ot  IS&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 41 of 65&#13;
&#13;
&#13;
&amp;#12;&#13;
Tab 1: RwECwr doNRrORM&#13;
OUTPUT INDIATORS'&#13;
Coinponc-liCkilipid                     Feb.1997                 SqpL 1997               Feb. 1995               Sqi. 995                 Feb. 1999               Sep. 199               TeAl Ee&#13;
-   ACbW   E    A_-I  F.   A   F                                                      A_-I E_                 _ Adb   Eal A_                                            I&#13;
1.    Hal F_ae -a     1&#13;
A.   Tl    samhs cn_ad (            )&#13;
11    HIF aaff trid (. er)&#13;
C.   PAW    lI        amid (_MA)&#13;
D.   Dbkic pil asiie&#13;
I  E _  ,-hSd:&#13;
DHin (_       aMe)&#13;
cs (_i"i)&#13;
2    Sfid  _amd m DMFs (         )&#13;
Mew  Cen   (_mc)&#13;
PH         ((Moher&#13;
3    MI S           Rqo r itm&#13;
n.   Bnmr Hal   Seev,m&#13;
A      wal  lCs sufail web MIt-am pkyPsr&#13;
B.   Rko  PHC% which eceiwsd bic equr c_&#13;
ki (r)&#13;
C     Feevmm iu Pranus&#13;
1. Hqpiks B swcirs given&#13;
2 TB  sm  p    a&#13;
3. AIDs te pnrfcrmnd&#13;
4 Family Plamumg cadWtmu&#13;
5. Cerveb anc  x nu&#13;
IlI    1 _nm Icul Pdlicy ae Supply&#13;
A.   Refreence pre snedy&#13;
B.    Staff ntid in ienuuiwl&#13;
-mmnm (mutbs)&#13;
C     F1nk  asimd in nurm&#13;
D     Laboratory eqtapinera unts&#13;
itsalled (nMes)&#13;
1/        Dates of semi-annual Progress Reports will be adjusted based on date of Effectiveness of the IDA cmrdit.                                                                                                        az&#13;
O m&#13;
08 &#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX2&#13;
Page 43 of 65&#13;
'SE-&#13;
z~~~~~~~~~~~~~~~~~~~~~~&#13;
&#13;
&#13;
&amp;#12;&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 44 of 65&#13;
V. EOUIPMENT LISTS AND TERMS OF REFERENCE&#13;
&#13;
&#13;
&amp;#12;&#13;
ITRM                    H  U1pIAC    Unit       1iC       tic        Cost I      Cost 2      APPROV.&#13;
Cost     I MD   noi 1D9I M                 no MD&#13;
790.29       763.,&#13;
1 . WtASUR4EK101TS&#13;
- Scale and Iteolgit meanurifng forV&#13;
edult (140kg x 1009 / 2 matron)              -20                   1      1              250         250     UIVAC&#13;
- Scale intant clinic metric&#13;
15,5 ig x 5 a                           01-455-20    114.41       1       1          114.41       114.41     UNIVAC&#13;
- Infant/cliild height measuring&#13;
board                                   01-145-00    279.04       1       1          279.04       279.04.    UNIVAC&#13;
- weight for height chart                  01-455-70       10.3      1       1            30.3         30.3     UNIVAC&#13;
- Tap-measure 1.SM4/60  vinyl&#13;
coated fibreglams                       05-670-00       0.42      2       1            0.04         0. 42    E(NrPAC&#13;
- Sphygmomanometer 300 194 with            OG-ltl-00      30.22      2       2           60.44       60.4'.    U"iPrc&#13;
cuff, adult size                        0-3-0          3.2        2       26.4                     6.4       UIL&#13;
- Cuff spare for sphygmomanometcr                                    2       1             C.9          C.9     UNiPAC&#13;
adult size lused with item n  21        OG-044-00       i.        2&#13;
- Cuff spare for sphygoofnometer&#13;
child size (used with item n-2          OG-850-00       3.06      2       2            7.72         7.72     UNIPAC&#13;
- spare bulb for *phygmanometer            06I43-00        1.24      2       2            2.48        2.40      UNIVAC&#13;
- Th1erometer clinic oral/rectal&#13;
celsius                                 04-810-60       0.68     10       5             6.3          3.4     UNIVAC&#13;
- relvimter collyer external               0C-C70-00       C.0C      I       1            6.06        C.OC      EIPAC&#13;
1000    3aduated  ith handle00                            2.5       1       1            2:53        2.53      UNIPAC&#13;
- Timer stopclock 60 minutes                             22.77       1       0           22.77           0      u4srAC&#13;
x imsecond spring-wound                 09-034-05&#13;
2. DIAGNOSIS AND TREATHIT                                      .,7.7S                               173.51&#13;
- Tubing medical rubber 150 CH             03-320-00       0.06      2       1            .1.72        0.06     UNIVpe&#13;
- Pump breast hand rubber bulb&#13;
glass bell                              03-450-00       3.09       3       1            9.27        3.OP     UNIPAC&#13;
- Scissors all-purpose 100 M44             22-105-00       3.04      2       2            6.03         c.oe     UNIPAC&#13;
3- MINOR SLIEROY                                                                          59.04       29.52&#13;
- llolder needle, curved jaw..&#13;
M4ayo-ilegard 160 MM                    07-429-05       2.25       2       1             4.5        2.25     uNrVAc&#13;
Forceps dressing spring-type&#13;
155 HHI 5S                              07-210-00       0.09      2       1            1.73         0.09     UNIPAC&#13;
Forceps hemostat straight Kelly&#13;
140 994 S3                              07-245-00       1.75      4       2                7         3.5     UNIPAC                                      A Z&#13;
-  Knife handle surgical for minor                                                                                                                             Z&#13;
surgery n-l                             07-450-00       1.72      2       1            3.44         1.72     UNIPAC                                       m&#13;
-  Probe grooved point &amp; tongue tie&#13;
145 M4M                                 07-590-10       0.72      2       1            1.44         0.72     UNIVAC                                      (it&#13;
-  Scinsors surgical straight&#13;
145 MM S/B S                           07-735-00       1.43      2       1            2.96         1.48     UNIPAC&#13;
-  Idem 145 M64 n/0 55                     07-745 00       1.46      2       1             2.92        1.46     UNIPAC&#13;
-  Forceps sterilizer (titlity)&#13;
200 964 Vaughin 8S                      07-l60-01       1.93       2       1            3.86        1.93     UNIPAC&#13;
- Brush hand surgeon's white&#13;
nylon bristles                          05-140-00       0.57       2       1            1.14        0.57     UNIPAC&#13;
Instrument box f222x122x60W43 SS             -            1S      2        1              30          1S     ?iR&#13;
&#13;
&#13;
&amp;#12;&#13;
4. bASINS, FRAYS, JARS. etc                                                               51.59        14.19&#13;
Danin kidney 82s ML SS                  02-11o-0o       2.29       3       1            6.07         2.29     UNIPAC&#13;
Tray instrumcnt shallow (400 x&#13;
330 x 19 mm) S5                        2ni-,n0-0o       G.51      2        1           13.06        6.53      UNIPAC&#13;
Idem (313 x 247 x 16 MM) 55              2-!5-0o                  1        0            s.97            0     UNI'AC&#13;
Tray instrument covered (225 x&#13;
125 x 50 MM) SS                         02-700-00       5.45       1       0            5.45            0     UNrPhd&#13;
Jar dres-ing with covk!r capAcity&#13;
of 0.945 1. 5S.                         02-s4s-00       4.l5       2       0             9.5            0     UNIPAC&#13;
Stheto9eope binaural complete           06-nsa-00       3.74       2       1            7.40         3.74     UNIPAC&#13;
Ophtamoscopa, basic, for clinic         06-615-00      50.63       1       0           50.63           0C    UNIPAC&#13;
Otoscope net, basic, for clinic         06-00-50      31.49       1       0           31.49            0     UNIPAC&#13;
Speculum ear Gruber net of 4            OG-715-00       2.01       3       o            G.03            0     UNIPAC&#13;
Syringe irrigating Kramer 90 ml              -            15       1       1              15           i5     TENDER&#13;
Speculum nasal Dosworth wire SS         06-000-00       0.91       2       0            1.02            C     IJNIPAC&#13;
Speculum nasal child-size Vienna        06-010-00       4.17       2       0            0.34            0     UNIPAC&#13;
Aspirator nasal infant size             03-100-00       Q.54       1       1            0.54         0.5.     UNIPAC&#13;
Laryngeal mirror                             -           4 .4      1       0             4.4            0     TENDER&#13;
llead mirror with light                      -            25       1       0              25           r'    TENDER&#13;
lRechargeable battery size AA           10-022-17       1.27       6       0            7.62            0     UNIPAC&#13;
Battery charger, combi 110/220 V        10-022-19       6.69       1       0            6.69            C     UNIPAC&#13;
Fork tuning C 256 CPS Ralks&#13;
aluminium alloy (diapazoni              06-320-00       11.0       1       0            11.D            0     UNIPAC&#13;
llammer reflex testing Taylor&#13;
solid rubber head                       OG-400-00       1.29      1        0            1.29            0     UNIPAC&#13;
- Tongue depreosor 165 W4 Metal            06-200-00       0.61     10      10              6.1         6.!      UNIPC&#13;
- Magnifying-glans withi handle 3x&#13;
diam. 75 MM                             46-470-00       4.47      1        0            4.47            0     UNIPAC&#13;
- Light examining floor stand&#13;
type 220 V                              01-111-00      92.11      1       1            92.71       92.71      UNIPAC&#13;
- Vision-testing-chart                     06-100-00       1.72      1       1             1.72        1.72      UNIPAC&#13;
- Forceps tongue-holding rubber&#13;
jaws youg 170 M4M                       07-405-00       3.75       1       1            3.75        3.75      UNIPAC&#13;
- Forceps splinter spring-type&#13;
points 90 W4                            07-349-00       0.54       1       1            0.54        0.54      UNIPAC&#13;
- Forceps splinter/epilation&#13;
spring type 105 1W4                     07-349-15       0.69      1       1             0.69        0.69      UNIPAC&#13;
- set of anti shock therapy                    -              5      1       1                s           5      T eR&#13;
- Oxygenator (humidifying L admin.&#13;
,of oxygen / 2 bottles with valve            -            300      1       0              300           0      TENDER&#13;
- Mouth gag                                    -            2.5      2       1                5         2.5    TUNDER&#13;
'Cat. Ur. Nelaton set of 12 nOn.         02-234-00      12.46       1      0            12.46            0     TENDER&#13;
Rectum speculum SS                          -           47.3      1       0             47.3           0      TENDER&#13;
Obotetrical athetoncope                 oc-050-00      24.31      1       1            24.33       24.33      UNIPAC&#13;
Specuiu- vaginal bi-valve Craven                                                                                                  g&#13;
medium 5S                               07-'71-00       3.20      2       0             6.76          .C      UNlPA .             o&#13;
Tube stomach Pauchier Ch.24(G M1M)&#13;
X 150 Cm                               03-000-00       11.uC      2       1           23.72   ; I.ec      UIpAC&#13;
&#13;
&#13;
&amp;#12;&#13;
- Idem capacity of 2.13 1. SS             02-ssa-00       5.37       2       1           10.74        5.37      UNItPAC&#13;
S. MEDICAL FURNITURE AND OTIIER EQUIPMENT                                               3005.3      521.93&#13;
- Gynecological table                          -           1750      1       0            1750            0     TENDER&#13;
- Stool revolving ndjustable              01-690-00        57.4      1       0            57.4            0     UNIPAC&#13;
- Ilasin 4 1. SS                          02-160-00       4.93       1       1            4.93        4.9       U14IPAC&#13;
- Haste receptacle 13 1. capacity         01-900-00      10.97       1       1           10.97       10.97      UNIPKC&#13;
- Dry sterilizer 4006330*400 /220V        01-G40-00    399.23        1       1          399.23      399.23      UNIPAC&#13;
- Drums, gterilizing, cylindrical,&#13;
diam. 240 MM                            01-0n7-00      16.97      2       2           33.94        33.94     UNIPAC&#13;
- tetrigerator 140 1. witli&#13;
freezing compartment App. 15 1.             -                     I00  1  0             700            0     TENDER&#13;
- vaccine carrier 2.0 1. neL cap.         11-050-05      25.29       1       0           25.29            0     UNIPAC&#13;
- Bag for physician                       05-120-00      30,60       1       0           30.60            o     UNIPAC&#13;
- Strecher folding                       O0-O00-oo       72.06       1       1           72.0,6      72.06      UNIPAC&#13;
6. CONSUMALLES                                                                          151.65       74.38&#13;
- Needle suture, surgeons regtilar,&#13;
3/0 circle, size 12, pkt of 6           07-593-32       0.99      5       0            4.95            0     uNPrAC&#13;
- Needle suture, surgeons regular,&#13;
3/0 circle, size 10, pkt of 6           07-591-40       1.05      5       0            5.25            e     UirPAC&#13;
- Suture silk black with needle,&#13;
size 00 USP, box of 36                  05-640-01       0.51      5       0            2.55            0        rI PAC&#13;
- Suture silk black nize I USP,&#13;
j       2 x 76 CM, without needle               05-GS0-02       0.4f      5       0              2.4           0      UNIPAC&#13;
L  Idem, size 3 USP                        05-650-04       U.61      5       0             3.05           0      UNIPAC&#13;
I - Knife blade surgical for minor&#13;
suirgery n-10, pkt of 5                07-460-00        0.35      5       0            1.75            0     UNIPAC&#13;
Cloven surgeon's latex nize 7&#13;
disposablc, pair                        03-21IS-O1      0.20     25      to                7         2.0     UNrPAC&#13;
- Idem, size 0                            01-2JS-U1       0. 211    25      10               7         2..0    MPI P.AC&#13;
C Gloves examination latex non&#13;
sterile size medium, box of 20         03-300-01       0.n3       5       1            4.;5         0.03     ,UN1PAC&#13;
S Syringe hypo 2 MI. Luer                                                                    I&#13;
disposable, box of 100                07-022-05         2      5       5             10          10    1U4IPAC&#13;
- Idem S ML, box of 100                 07-024-05       3.24    10      10            32.4       32.4      UNIPAC&#13;
- Needle hypo 1.0 x 30 MM diapos.&#13;
Luer, box of 100                      07-474-20      1.60    10      10            16.0        16.C    tiJNPAC              &#13;
- Needle IM, size to be defined                _                                                                                          Om&#13;
box of  0O0                                          1.75      5       5           0.75        0.75     UNIPAC                          CX&#13;
- Cainlula IV luer 1OG disposable       07-092-10       0.51    50       0            20.5          0      UNIPAC                         t &#13;
- Cnnula IV cNild Luer 20C disp         07-092-20       0. 5)    30      0            17.1           0     tjNIPAC&#13;
&#13;
&#13;
&amp;#12;&#13;
7. LABORATORY                                                                           1400.9         G2.5 S&#13;
- Microncope Ibinocular inclilzed&#13;
without illumination                    u9-'i7l-04    420.G7      1       0          420.G7            0      UNIPAC&#13;
- Illuminator for microncope                   -             20      1       0              20            0     lENDER&#13;
- Centrifuge for 6*15ml.                  09-256-00    735.03        1       0          735.03            0     U11IPAC&#13;
- Tube for centrif. lSml gratl.           09-265-00       0.f62    12        0            7.14            e     UNIPAC&#13;
- Tube for centrif. 15 ml tingradl.        09-26G-00      0.I6    36         0            5.16            0     UNIIAC&#13;
- Westergreen rack and pipettee                -             iS      1       0              15            0     ThNDER&#13;
- Set of pipettes (0.1 ml - 50 ml)             -             30      1       0              30            0     TENDER&#13;
- Set of teot tubes&#13;
din. 12naa, L. 100mm lbox of 100)           -             10      1       0              10            e     TENDEn&#13;
dia. 16nm,, L. 160n  (box of 100)           -             10'     1       0              10            0     TENDEIlt&#13;
- 2 stands for test tubes                      -             10      1       0              10            0     TECDER&#13;
- Set of flanks, conical&#13;
erlenmeyer type (25 - 1000 ml)              -             35      1       0              35            0     TEINDER&#13;
- Flask, conical (1000 ml)                     -              5      5       5              25           25     TENDEIt&#13;
Set of bruslhen, pipettes clean.            -             10      I       0               10           0     TErDER&#13;
Multistix N. Reagent strips,&#13;
box of 100                                  -            7.5    10        5              75         37.5     TENDER&#13;
TOTAL (1 -&gt; 7)                                                                      6284.52     1644.73&#13;
+ llandling (5t)                                                                    314.226     02.2iGS&#13;
t Insurance A transport (101)                                                       620,452     164.473&#13;
Total basic costs                                                                    7227.2     1091.44&#13;
rounded down/up to                                                                          7500         2000&#13;
0. COMPLEMENTARY EQUIPMENT&#13;
uinit cost  Quiantity                                         i&#13;
EKG for RIIC with &gt;1 doctor (30)               3750          30                           112500&#13;
Complete dental unit  (20)                    12500          20                           250000&#13;
Stethoscope (50 doctors)                        3.7'4        50                              107&#13;
Sphygmomanometer (25 doctora)                 30.'1'        2?5                           9G9.25&#13;
lIlamner (25 doctors)                           1.29         25                            32.25&#13;
Otoscope (25 doctors)                         11.49          25                           707.25&#13;
Ophtalmoscope  (25 doctors)                   50.63          25                         1465.75&#13;
nag for doctors  (7 bags)                     30.60           7                          214.76&#13;
la&#13;
TOTAL (0)                                                                                3GG16 6                                       eQ&#13;
+ lhandling (S5)                                                                        10307. 0                                        0 M&#13;
t Insurance &amp; transport (10:)                                                           3G615 .6                                          X&#13;
Total basic costs                                                                        421000&#13;
nounded down/up to                                                                       425000&#13;
&#13;
&#13;
&amp;#12;&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 49 of 65&#13;
HEALTH SECTOR TRANSITION PROJECT&#13;
TERMS OF REFERENCE&#13;
PROJECT UNIT DIRECTOR&#13;
The following Terms of Reference define the primary responsibilities of the Director of the International&#13;
Project Unit (IPU) of the Ministry of Health of FYR Macedonia.4/ This Unit will be responsible for&#13;
coordination and implementation of activities under the proposed Health Sector Transition Project.&#13;
The Director will oversee the establishment, and ensure the sustainability, of a project management&#13;
structure with adequate and sufficient material and human resources for effective implementation of&#13;
project activities. The Director will be responsible for overseeing the establishment of the IPU, ensuring&#13;
that its agreed roles, functions, and staffing are met and carried out. The staff of the IPU (including&#13;
long- and short-term consultants) will report to the Director, who will in turn report to the Minister of&#13;
Health for all matters related to the project. All salary and other expenses related to this post will be&#13;
financed by the World Bank through an IDA Credit.&#13;
The Director will lead and manage the team of staff in the IPU in carrying out the day-to-day activities&#13;
in support of implementation of the Health Sector Transition Project. Specific responsibilities include,&#13;
but are not limited to, those listed below:&#13;
*      ensure first-line contact between the Ministry of Health and the World Bank team for all&#13;
matters related to activities under the Health Sector Transition Project.&#13;
*      ensure first-line contact and conmmunications with other entities (for example, Project&#13;
working  groups,  Beneficiary  institutions,  etc.) and  agencies  (other  donors,&#13;
nongovernmental organizations, etc.) involved in the health sector to ensure cooperation&#13;
and coherency in planned and ongoing programs, as well as regular exchanges of up-to-&#13;
date information regarding the project.&#13;
-      acquire adequate facilities, equipment and other resources to ensure the efficient operation&#13;
of the Project Unit and fulfillment of its responsibilities.&#13;
-      select and hire core staff (procurement officer, accountant/disbursement officer,&#13;
administrative assistant) on the basis of profiles and responsibilities acceptable to the&#13;
Ministry of Health and the World Bank.&#13;
-      arrange and approve short-term staff training, as needed, for IPU staff in areas such as&#13;
4      Given that a project's implementation environment is a dynamic one, the responsibilities outlined here will&#13;
likely evolve over time and thus may require reassessment and modification as implementation progresses.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 50 of 65&#13;
planning and organizational skills, English language, procurement under World Bank&#13;
Guidelines, and other areas as may be considered appropriate.&#13;
supervise daily activities of the Project Unit, evaluating performance and operating&#13;
effectiveness (including ongoing staff performance evaluations and feedback), making&#13;
recommendations for change as necessary.&#13;
oversee the selection and hiring of short- or long-term technical assistance (for example,&#13;
auditors, translators and interpreters, project management support, health economists,&#13;
etc.) to the IPU, including approval of Terms of Reference and shortlists of candidates&#13;
and supervise the work of such contractual assistance.&#13;
with the assistance of concerned IPU staff, develop and oversee the implementation of&#13;
standardized administrative and operating procedures for the Unit, including, but not&#13;
limited to, recordkeeping and filing systems -- with the administrative assistant; reporting&#13;
formats for financial transactions under the project (credit and counterpart fund accounts)&#13;
-- with the accountant/disbursement officer; procurement and contracting tracking system&#13;
*- with the procurement officer, etc.&#13;
ensure that goods and services under the Credit are procured in accordance with World&#13;
Bank Guidelines, providing assistance as needed and together with the procurement&#13;
officer, to project working groups, etc., in drafting terms of reference, defining technical&#13;
specifications, negotiating of contracts, etc.&#13;
together with the procurement officer, provide first-line contact with interested suppliers&#13;
of goods and services regarding the status of project-related activities, and planned or&#13;
ongoing procurement.&#13;
together with any other individual(s) the Ministry of Health may appoint, serve as&#13;
authorized signatory to documentation regarding procurement of goods and services (e.g.,&#13;
final approval of bidding documents, signing of contracts, etc.), withdrawal applications,&#13;
and other documentation or correspondence concerr ing project activities.&#13;
ensure regular monitoring of the status of project activities (through the preparation and&#13;
updating of implementation plans and schedules, disbursement projections, etc.),&#13;
including preparation and transmission of comprehensive progress reports as required&#13;
under the conditions of the Credit Agreement, and any other reporting requirements&#13;
under the Project (for example, annual audits).&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 51 of 65&#13;
HEALTH SECTOR TRANSITION PROJECT&#13;
TERMS OF REFERENCE&#13;
PROCUREMENT OFFICER&#13;
The following Terms of Reference outline the primary responsibilities of the Procurement Officer of the&#13;
International Project Unit (IPU) of the Ministry of Health of FYR Macedonia.5' This Unit will be&#13;
responsible for coordination and implementation of activities under the proposed Health Sector Transition&#13;
Project.&#13;
The Expert will provide assistance to the IPU of the Ministry of Health in the execution of international&#13;
and local procurement of goods and services under the Health Sector Transition Project. The Expert will&#13;
work as part of a core team of staff in the IPU, under the supervision of, and reporting to, the IPU&#13;
Director. All salary and other expenses related to this post will be financed by the World Bank through&#13;
an IDA Credit.&#13;
The Procurement Officer will:&#13;
ensure the procurement of goods and services in accordance with World Bank guidelines for all&#13;
items financed through the Credit, using standard World Bank documentation.&#13;
establish and maintain in the IPU/MOH a data base of letters of interest received from suppliers&#13;
of goods and services for purposes of their possible inclusion on future shortlists or for future&#13;
consultation.&#13;
- work with concerned technical working groups in the preparation of technical specifications for&#13;
agreed lists of equipment (including medical equipment and supplies, information technology,&#13;
office equipment, vehicles, etc.) to be purchased under the project according to various&#13;
procurement methods.&#13;
assist the IPU/MOH  and concerned technical working groups in formulating appropriate&#13;
evaluation criteria, preparation of draft bidding documents, and transmission of those documents&#13;
to the World Bank in a timely fashion for review and no objection, in accordance with World&#13;
Bank requirements outlined in the Credit Agreement and the Staff Appraisal Report.&#13;
monitor receipt of proposals and ensure their safekeeping until bid opening.&#13;
carry out public bid openings and draft minutes of these openings.&#13;
Given that a project's implementation environment is a dynamic one, the responsibilities outlined here will&#13;
likely evolve over time and thus may require reassessment and modification as implementation progresses.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 52 of 65&#13;
assist the concerned technical working groups, or other individuals comprising the evaluation&#13;
committee for a given tender, in the evaluation of proposals received, on the basis of criteria&#13;
stipulated in the bidding documentation.&#13;
ensure preparation of comprehensive evaluation reports according to World Bank standard&#13;
formats and timely transmission of evaluation reports to the World Bank for review and no&#13;
objection.&#13;
notify winning bidders in a timely fashion, and draw up contracts for approval and signature by&#13;
those individuals authorized to sign on behalf of the MOH, ensuring transmission to the World&#13;
Bank of draft contracts requiring prior review and no objection.&#13;
establish and maintain on the premises of the IPU efficient procurement and contracting tracking&#13;
system (noting important approval dates, awards, contract amounts, etc.), as well as a proper&#13;
filing system to ensure quick retrieval of procurement information by Unit staff, visiting&#13;
supervision missions, annual auditors, etc.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 53 of 65&#13;
SAMPLE TERMS OF REFERENCE&#13;
FOR THE AUDIT OF AN IDA-FINANCED PROJECT&#13;
Objective&#13;
I.            The objective of the audit is to enable the auditor to express his professional opinion on&#13;
the financial position of the Health Sector Transition Project (Cr . ...... ) at . 199.. and of the&#13;
resources and expenditures for the accounting period ended on that date, as presented by the audited&#13;
financial statements of the project.&#13;
2.            The audit will be carried out in accordance with International Standards on Auditing and&#13;
will include such tests and controls as the auditor considers necessary under the circumstances.  The&#13;
opinion of the auditor will include specific references as to whether:&#13;
(i)     all external funds provided have been used in accordance with conditions of the relevant&#13;
financing agreements, with due attention to economy and efficiency and only for the&#13;
purposes for which the financing was provided;&#13;
(ii)    counterpart funds have been provided and used in accordance with the relevant&#13;
financing agreements, with due attention to economy and efficiency and only for the&#13;
purposes for which they were provided;&#13;
(iii)    goods and services financed have been procured in accordance with the relevant&#13;
financing agreements;&#13;
(iv)    all necessary supporting documents, records and accounts have been kept in respect of&#13;
all expenditures, including Special Account payments and expenditures made on the&#13;
basis of Statements of Expenditure (SOEs), for which separate audit reports have&#13;
previously been submitted (see below);&#13;
(v)     where Special Accounts have been used, that they have been maintained in accordance&#13;
with the provisions of the Credit Agreement;&#13;
(vi)    the financial statements audited, including the Special Accounts, have been prepared in&#13;
accordance with consistent!y applied International Accounting Standards and give a true&#13;
and fair view of the financial situation of the project at .......... 199.. and of resources&#13;
and expenditures for the year ended on that date.&#13;
Audits of Statements of Expenditure (SOEs)&#13;
3.             In addition to the audit of the financial statements, the auditor is required to audit all&#13;
Statements of Expenditure (SOEs) used as the basis for the submission of withdrawal applications.&#13;
4.             Audits of SOEs will be carried out within the framework of and under the same&#13;
guidelines as the audits of the annual financial statements and will include such tests and controls as the&#13;
auditor considers necessary in the circumstances.  The auditor will be required to express his opinion&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 54 of 65&#13;
as to whether:&#13;
(i)     the SOEs audited have been prepared in accordance with the provisions of the&#13;
Credit\Loan Agreement;&#13;
(ii)    all expenditures have been made wholly and necessarily for the realisation of project&#13;
objectives and with due attention to economy and efficiency;&#13;
(iii)    all information and explanations necessary for the purpose of the audit have been&#13;
obtained;&#13;
(iv)    all supporting records and documents necessary for the purposes of the audit have been&#13;
retained; and&#13;
(v)     the SOEs audited can be relied upon to support the related withdrawal application\s.&#13;
Reports&#13;
5.             The annual audit report should be received no later than six (6) months after the end&#13;
of the accounting period to which the audit refers. The SOE reports should be attached to each&#13;
withdrawal application made on the basis of an SOE.&#13;
6.             In addition to the audit "opinion" report, the auditor will prepare a "management letter".&#13;
In this letter the auditor will:&#13;
(i)     present his comments and observations on the accounting records, systems and controls&#13;
that he has examined during the course of his audit;&#13;
(ii)    identify specific deficiencies and areas of weakness in systems and controls that have&#13;
come to his attention and make recommendations for their improvement;&#13;
(iii)    report on the degree of compliance of each of the financial covenants of the Loan\Credit&#13;
Agreement and give comments on internal and external matters affecting such&#13;
compliance;&#13;
(iv)    communicate matters that have come to his attention during the audit that might have&#13;
an impact on future audits; and&#13;
(v)     bring to the borrower's attention any other matters that the auditor considers pertinent.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 55 of 65&#13;
APPENDIX 1:  WORKING GROUP MEMBERS&#13;
Republic of Nlacedonia&#13;
Mlinistry of Healti&#13;
No. 12-7029&#13;
September 19, 1995&#13;
In accordance with Article 165, Act I of the Law for Management Bodies (Official&#13;
Bulletin of the Republic of Macedonia no. 40/90 and 63/94), the Minister of Health has&#13;
reached the following:&#13;
D E C I S I O N&#13;
For establishiing cooperation withi the World Bank for Reconstructioni and&#13;
Development for the Project: Tranisition of the Healthi Sector&#13;
1. A committee is appointed for cooperation with the World Bank for Reconstruction and&#13;
Development (hereinafter: the Committee) for the Project- Transition of the Health Sector.&#13;
The following members will constitute the Committee:&#13;
For the sub-proiect: Health Finance and Nlanagerment&#13;
1. Vancho Uzunov, 1M.A., Research Associate, Transformiation and Restructuring&#13;
Sector, Macedonian Agency for Privatization of Social Capital Enterprises;&#13;
2. Tome Anakiev, econoinist, Advisor of the Director of OOZT Kliniki, College of&#13;
Medicine, Skopje,&#13;
3. Gordana Pecelj, Mi.A., Assistant Director for Economy and Financing in the&#13;
Health Care Insurance Fund (HCIF);&#13;
4. Prof Dr. M4iodrag Vrchakovski, Director of tihe Institute of Radiology. College of&#13;
Medicine, Skopje;&#13;
5. Jordan Dimovski, economist, Commercial and Financial Director of OOZT&#13;
Kliniki, Faculty of Medicine. Skopje;&#13;
6. Blaze Brsakovski. Head of the Regional HCIF Office in Prilep.&#13;
7. Ratko Kardalev, %M.A., Assistant Minister of Science. Nlinistry of Science, Skopje.&#13;
8. Shulevski Zlate, economist, HCIF Skopje;&#13;
9. Dr. Liljana Ivanovska, HCIF, Skopje.&#13;
For the sub-proiect: Basic Health Services:&#13;
10. Dr. Violeta MNlalinska-Petrushevska. Undersecretary in the MOH, Skopje;&#13;
I I. Dr. Elisaveta Stikova, Director of the Republic Health Care Institute. Skopje;&#13;
12. Prof. Dr. Dimche Ivanovski;&#13;
13. Dr. Janko Obochki, Director of the City General Hospital "'lMosha Pijade",&#13;
Skopj e,&#13;
14. Dr. Marika Karanfilova, Assistant Professor, Institute for Social Medicine,&#13;
Skopje,&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 56 of 65&#13;
For the sub-project Pharmaceutical Policy and Supply&#13;
15. Nenad Popovski, VI.A., Assistant Minister of Health -- Pliarmaceutical Sector,&#13;
MOH, Skopje;&#13;
16. Dr. Ljubica Shuturkova, Assistant Protessor, Department of Plarmaceutidal&#13;
Chemistry, Faculty of Pharmacy, Skopje;&#13;
17. Prof. Dr. Stojmir Petrov, Director of OOZT Instituti, Faculty of Medicine,&#13;
S ko pje;&#13;
18. Danica Zimbakova, M.A., Director of the Pharimiaceutical sector, "Replek&#13;
Makedonija", Skopje.&#13;
19. Venko Temelkovski, NM-A., Assistant General Manager, Alkaloid AD - Skopje,&#13;
Pharmaceutical Division,&#13;
20. Svetlana Karcheva, N[.A., Advisor for International Cooperation, MIOH, Skopje;-&#13;
For Legal Support to the Project:&#13;
21. Jordan Mishkovski, Lawyer, Assistant M9inister of Health -- Health Insurance and.&#13;
Property and Legal Affairs, MOH, Skopje;&#13;
22. Angelina Bachvanovich. Lawyer, Advisor of the Minister-- Normative-&#13;
Provisional and Legal Affairs, MOH, Skopje;&#13;
23. Anka Georgievska, Lawyer, Assistant Mllinister of Health -- Private Health&#13;
Sector, MOH, Skopje.&#13;
2. The Committee Head Coordinator will be Vanciho Uzunov.&#13;
3. The Secretary of the Sub-Project: Finances and Management in the Health Sector will be&#13;
Gordana Pecelj.&#13;
4. The Secretary of the Sub-Project: Basic Health Services will be N'larika Karanfilova.&#13;
5. The Secretary of the Sub-Project: Reforms in the Pharinaceutical system will be Slavica&#13;
Tudzarova.&#13;
6. The Committee will work according to the dynamics agreed at the meetings with the&#13;
representatives of the World Bank for Reconstruction and Development.&#13;
7. The Committee will cooperate with the WHO. Coordinator of this cooperation will be&#13;
Svetlana Karcheva.&#13;
8. The duties and the responsibilities of the Committee are preparation of a final document:&#13;
Strategy of the Reforms in the Health System -- Proposed Measures. Dynamlics of&#13;
Effectuation, Executors and Effects. These originate from the r eforming directions in the&#13;
entire Health system in the Republic of Macedonia, and are based on the establishment of a&#13;
more efficient and more rational health care.&#13;
Ninister&#13;
Prof Dr. Ilija Filipchie&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 57 of 65&#13;
APPENDIX 2: MATRIX OF PROCUREMENT AND REPORTING RESPONSBIILITIES&#13;
The following matrix seeks to clarify responsibilities for key steps in procurement and reporting during&#13;
implementation among the various players involved in the project. The following definitions are used&#13;
in the matrix:&#13;
(a)    International Project Unit (IPU) refers to the unit in the MOH responsible for the&#13;
general administration of the credit and coordination of project activities. The IPU is&#13;
comprised of a project director, procurement officer, disbursement officer/accountant,&#13;
and administrator/translator. The IPU may be supported by short-term consultants in&#13;
specific areas in order that it be able to more efficiently fulfill its role.&#13;
(b)    Technical Committee (TC) refers to the technical working groups established during&#13;
project preparation for each subcomponent and maintained throughout implementation to&#13;
provide technical support to the IPU.&#13;
The IPU is encouraged to organize regular meetings of representatives of the TCs, as well as any other&#13;
individuals involved in project activities both within and outside of the MOH, in order to keep all parties&#13;
up-to-date on project status and identify obstacles earlv on in order to seek mutually agreeable solutions.&#13;
Meetings should ideally be organized around an established agenda, with time allotted for questions or&#13;
other open discussion. The IPU Director will be responsible for keeping the Minister of Health informed&#13;
of the outcome of these meetings, and will seek his guidance in resolving issues if necessary.&#13;
&#13;
&#13;
&amp;#12;&#13;
A&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 58 of 65&#13;
PROCUREMENT OF GOODS THROUGH COMPETITIVE BIDDING&#13;
(Goods requiring prior review)&#13;
ITEM/ACTIVITY                  REVIEW              CLEARANCE/DECISION                COMMENTS&#13;
Equipment Lists. The       Lists are discussed and    IPU  verifies conformity of  IDA reviews and&#13;
concerned TC prepares      agreed with concerned      lists with component         provides comments&#13;
list of requirements in    parties, seeking technical    objectives, agreements    and/or no objection.&#13;
consultation with technical  inputs as necessary. TC   reached during project&#13;
colleagues, as necessary.    ensures conformity of     preparation, and estimated    (NOTE: ALL&#13;
("Schedule of              equipment lists with agreed  budgets. Lists are         correspondence will be&#13;
Requirements" in the       project inputs, budget     submitted to IDA for         channeled through IPU,&#13;
Standard Bidding           estimates.                 review. Major issues or      which will be responsible&#13;
Documents)                                            other relevant points are    for sharing information&#13;
highlighted in IPU          with concerned technical&#13;
transmittal correspondence    colleagues/TCs.)&#13;
to IDA.&#13;
Equipment                  The technical              IPU ensures accuracy and    Bid specifications must&#13;
Specifications. TCs        specifications are discussed  completeness of           be "vendor-neutral " to&#13;
prepare draft technical    and reviewed as necessary   specifications. IPU         ensure fairness to all&#13;
specifications in          with MOH and/or other      forward specifications to    bidders.&#13;
consultation with technical  experts.                 IDA for review. Major&#13;
specialists as needed, and                            issues or other relevant&#13;
with inputs from the IPU                              points are highlighted in&#13;
procurement officer.                                  IPU transmittal&#13;
correspondence to IDA.&#13;
Bidding Documents. IPU    IPU collaborates as         Before submitting bidding    Use of IDA's Standard&#13;
prepares complete bidding   necessary with TCs in      documents for IDA review    Bidding Documents is&#13;
documents with technical    drafting final bidding    and clearance, IPU ensures   mandatory.&#13;
assistance if required, and   documents.              their accuracy, conformity&#13;
technical inputs from the                             with Bank standards and&#13;
TCs if required, especially                           completeness.&#13;
with respect to final&#13;
Schedule of Requirements&#13;
(equipment lists);&#13;
Technical Specifications;&#13;
and Special Conditions of&#13;
Contract.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 59 of 65&#13;
Bid Invitation. The IPU                                Prior to invitation of bids    IPU keeps TC and MOH&#13;
invites bids through                                   which will necessitate local   officials concerned&#13;
advertisements in local                                currency budgets (e.g., for   informed about the&#13;
papers and, in the case of                             taxes or duties, for site   progress of bids.&#13;
ICB, through notification                              preparation, for&#13;
of all embassies/legations                             installation), the IPU will&#13;
of member states of the                                ensure the availability of&#13;
Bank (and Taiwan, China)                               those funds.&#13;
in Skopje. The IPU may&#13;
also wish to publish bid&#13;
notices in Development&#13;
Business by transmitting&#13;
draft notices to the Task&#13;
Manager at IBRD&#13;
headquarters, requesting&#13;
publication.&#13;
Bid Opening Procedures.                                                            These procedures should&#13;
Before bid invitation, the                                                         inter alia include the&#13;
IPU prepares a draft                                                               stipulation that the bid&#13;
protocol of its proposed                                                           opening takes place&#13;
bid opening procedures,                                                            immediately after the&#13;
including the composition                                                          closing time for bid&#13;
of the bid opening                                                                 submission (no later that&#13;
committee and the                                                                  1/2 hour).&#13;
procedures to be followed&#13;
during bid opening.&#13;
Bid Opening. The IPU       During bid opening, the                                 Completeness of bids,&#13;
arranges for the bid       IPU Director and/or                                     bid amounts and names&#13;
opening to take place with  procurement officer                                    of the bidders are&#13;
representative(s) who      verifies the completeness                               announced and recorded&#13;
would like to attend (e.g.,  of submissions (e.g., that                            in written minutes of the&#13;
TCs, any participating     all requested items, such                               bid opening.&#13;
bidders, etc.              as the bid security, have&#13;
been submitted).&#13;
Bid Evaluation/            Award recommendations      IPU verifies format and      A suggested standard&#13;
Recommendation. IPU        are discussed and reviewed   quality of evaluation report  format for bid evaluation&#13;
assists TCs in carrying out  as necessary within the  and recommendations for    reports has been provided&#13;
technical evaluation of    MOH and with concerned    award, and submits to IDA    by IDA.&#13;
bids received on the basis  technical experts (TCs).    for review and no-&#13;
of criteria stipulated in the  All parties seek to ensure    objection.            IDA reviews report,&#13;
bidding documents, and in  that the evaluation was                                 providing comments or&#13;
preparing the bid          properly carried out on the                             observations and/or no&#13;
evaluation report.         basis of established                                    objection to&#13;
evaluation criteria.                                   recommnendation for&#13;
award.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 60 of 65&#13;
Contract Award. After    IPU staff prepares draft    IPU forwards the draft     IDA provides comments&#13;
receipt of IDA no-        contract(s)(in line with   contract(s) to IDA for no-    and/or no objection.&#13;
objection, IPU initiates  IDA's standard             objection, confirming in&#13;
preparation of contract(s)   documents).             covering letter that as&#13;
with winning bidder(s).                              concerns the contracting&#13;
parties, the contract is in&#13;
order.&#13;
Contract Signature and    Signature of contracts apd   Payments made through     IPU ensures that one&#13;
Payments. IPU arranges   payment authorization       special account. Any        original signed copy of&#13;
contract signature with   provided by IPU Director   counterpart financing       contract(s) is forwarded&#13;
appropriate parties and   and/or his/her designated    obligations (such as the  to IDA for project files.&#13;
initiates payment through    authority.              amounts for customs duties&#13;
appropriate procedures.                              and taxes) are also&#13;
processed in a timely&#13;
fashion.&#13;
Customs Clearance,                                                               Inclusion in the contract&#13;
Delivery and Installation.                                                       of adequate provision for&#13;
IPU will coordinate with                                                         assistance in installation&#13;
appropriate officials to                                                         and training, if needed,&#13;
ensure that goods                                                                is verified by IPU in&#13;
imported under the project                                                       consultation with&#13;
are cleared through                                                              concerned technical&#13;
customs in a timely                                                              colleagues/TC.&#13;
fashion. IPU coordinates&#13;
with receiving entities for&#13;
ensuring timely delivery&#13;
and installation.&#13;
PROCUREMENT OF GOODS THROUGH SHOPPING AND DIRECT CONTRACTING&#13;
ITEM/ACTIVITY                  REVIEW             CLEARANCE/DECISION              COMMENTS&#13;
Equipment list (Schedule   Lists discussed and agreed   IPU verifies conformity of   IDA reviews and&#13;
of Requirements). The    with concerned parties,     list with component         provides comments&#13;
concerned TC prepares     seeking technical inputs as  objectives, agreements    and/or no objection.&#13;
list of requirements.     necessary. TC ensures      reached during preparation,&#13;
conformity of list of     and estimated budgets. IPU&#13;
requirements with agreed    submits list to IDA for&#13;
project inputs, and budget   review.&#13;
estimates.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 61 of 65&#13;
Solicitation of Suppliers.   IPU reviews quotes and   IPU selects lowest cost      IDA's standard format&#13;
IPU contacts a minimum     ensures with TC that       supplier who meets           for shopping will be used&#13;
of 3 eligible suppliers,   goods offered meet          requirements.               by IPU.&#13;
shares with them the list    necessary requirements.&#13;
of requirements, and                                                               IPU informs IDA of&#13;
obtains quotes.                                                                    outcome of shopping&#13;
process.&#13;
Contract with Supplier                                 IPU and supplier sign       IPU maintains&#13;
and Payment. IPU                                       contract. IPU initiates     documentation on tile for&#13;
draws up contract with                                 payment through special     post-reviews during&#13;
selected supplier.                                     account.                    supervision mission.&#13;
CONSULTING SERVICES&#13;
ITEM/ACTIVITY              REVIEW                     CLEARANCE/DECISION  COMMENTS&#13;
Terms of Reference.                                                                During the course of&#13;
TORs for major packages                                                            project implementation&#13;
are substantially agreed                                                           any revisions to agreed&#13;
upon at negotiations.                                                              TORs may be proposed,&#13;
discussed and agreed&#13;
between MOH and IDA.&#13;
Short Lists. IPU assists                              IPU submits shortlist for    IDA may assist in&#13;
TCs in preparation of                                 IDA review and no            compiling a shortlist&#13;
representative shortlists                             objection.                   under certain&#13;
for consulting assignments                                                         circumstances.&#13;
(refer to IDA's guidelines&#13;
concerning hiring of&#13;
consultants).&#13;
Letter of Invitation.                                 IPU submits the LOI to       Standard LOI will be&#13;
Letter of Invitation (LOI)                            IDA for review and no        provided to IPU.&#13;
prepared by IPU in                                    objection.                   Particular thought should&#13;
consultation with                                                                  be given to statement of&#13;
TCs/technical colleagues.                                                          evaluation criteria in&#13;
LOI.&#13;
Transmission of LOI                                    Authorized IPU              IPU forwards copy of&#13;
package. IPU ensures                                  representative signs LOI     final package to IDA for&#13;
transmission of LOI                                   before transmission.         project files.&#13;
package (including LOI,&#13;
TORs, supplemental&#13;
information, and draft&#13;
contract form) to each&#13;
shortlisted firm/consultant/&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 62 of 65&#13;
Bid Evaluation/            The evaluation findings    IPU forwards evaluation      IPU will format the&#13;
Recommendation. IPU        and resulting award        report and recommendation   evaluation report along&#13;
assists TCs in evaluation    recommendations are      to award to IDA for review   the lines of the standard&#13;
of proposals received in    discussed and reviewed as   and no objection.          provided by IDA.&#13;
accordance with            necessary within the MOH&#13;
evaluation criteria outlined  and among technical&#13;
in LOI, and in preparation   colleagues/TCs.&#13;
of evaluation report.&#13;
Invitation to Negotiate.    IPU and concerned TC                                   Note: TA contracts are&#13;
Upon receipt of IDA no     expert(s) negotiate contract                           the result of extensive&#13;
objection to the selected  details with selected                                   negotiations between&#13;
consultant(s) or firm, IPU    consultant(s) or firm,                               parties, which is&#13;
invites selected           including payment terms                                 distinctly different from&#13;
consultant(s) or firm to   and work plan for carrying                              equipment contracts,&#13;
negotiate a contract.      out planned activities.                                 where negotiation with&#13;
suppliers is not allowed&#13;
under IDA-financed&#13;
procurement.&#13;
Contract Award. Draft   IPU ensures agreements of  IPU forwards draft contract&#13;
contract is prepared by    all parties on draft       to IDA for review and no-&#13;
IPU, on the basis of       document.                  objection, confirming in the&#13;
IDA's standard contract                               covering letter that the draft&#13;
form for consultants,                                 has been agreed by all&#13;
reflecting agreements                                 parties concerned.&#13;
reaching among all parties&#13;
during negotiations.&#13;
Contract Signature and                                 IPU ensures that payments   IPU forwards one&#13;
Payment. IPU ensures                                   are made in a timely        original copy of the&#13;
signature of contract by                              fashion.                     signed contract to IDA&#13;
authorized representatives                                                         for project files.&#13;
and processes payment(s).&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 63 of 65&#13;
AUD)ITING&#13;
ITEM/ACTIVITY                  REVIEW             CLEARANCE/DECISION               COMMENTS&#13;
IPU will maintain separate  Project accounts will be  IPU forwards Audit         Note: Under its Articles&#13;
project accounts: for     audited annually by        Reports to IDA within six    of Agreements, the Bank&#13;
expenditures through the    external auditors, financed   months after the closing of   must assure itself that&#13;
IDA credit, as well as    by the project. For local   the Government's fiscal    project funds are&#13;
expenditures from         expenditures. normal       year.                       appropriately spent,&#13;
Govemrnent counterpart    Government financial                                   hence the importance of&#13;
financing. A Special      regulations will apply.                                timely, good quality&#13;
Account will be                                                                  audits.&#13;
established to allow timely&#13;
payments of expenses                                                             Sample terms of&#13;
from loan funds.                                                                reference for hiring a&#13;
IPU is responsible for                                                           consultant auditor are&#13;
hiring auditor(s) in a                                                           provided in the PIP.&#13;
timely fashion so as to&#13;
ensure up-to-date&#13;
reporting.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 64 of 65&#13;
PROGRESS MONITORING AND REPORTING&#13;
ITEM/ACTIVITY                   REVIEW              CLEARANCE/DECISION               COMMENTS&#13;
IPU coordinates            Comprehensive progress     Semi-annual progress         The importance of&#13;
preparation of a semi-     reports are finalized by the  reports are transmitted to    action-oriented progress&#13;
annual progress report on   IPU, and reviewed by the   IDA for observation and     reports (PRs) cannot be&#13;
project implementation, as  Minister before           comment, according to the   overstated. PRs are a&#13;
well as on the status of   transmission to IDA.        timetable for submission    useful for sharing&#13;
sector reform activities.                             established in the credit    information with&#13;
Collaboration with                                     agreement. IPU notes in    concerned parties&#13;
concerned TCs and                                      covering correspondence     regarding overall status&#13;
inclusion of their inputs                             that concerned technical     of project and reform&#13;
will be essential.                                    colleagues/TCs and the       activities, difficulties&#13;
Minister have endorsed the   encountered, progress&#13;
report.                     made, problems solved&#13;
IPU ensures circulation of    or solutions proposed for&#13;
progress reports to         unresolved issues. PRs&#13;
members of TCs and other   should include a&#13;
inierested parties.         discussion of, inter alia:&#13;
(a) physical progress&#13;
(bidding invitations,&#13;
awards, TA progress&#13;
etc.); (b) financial&#13;
progress (status of&#13;
budgets, commitments,&#13;
and local and foreign&#13;
currency expenditures);&#13;
(c) project outcomes&#13;
(fulfillment of legal&#13;
covenants, changes in&#13;
monitoring indicators and&#13;
other measurable&#13;
indicators of change);&#13;
and (d) frank assessments&#13;
of progress on&#13;
implementation of the&#13;
agreed sector reform&#13;
agenda.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 2&#13;
Page 65 of 65&#13;
ARpendix 3: General Procurement Notice&#13;
GENERAL PROCUREMENT NOTICE&#13;
FORMER YUGOSLAV REPUBLIC OF MACEDONIA&#13;
HEALTH SECTOR TRANSITION PROJECT&#13;
The Government of the Former Yugoslav Republic of Macedonia (FYR Macedonia) is expected to&#13;
receive a Credit from the International Development Association (IDA) in an amount equivalent to SDR 11.8&#13;
million (US$16.9 million equivalent) to support a Health Sector Transition Project. The objectives of the&#13;
project are to improve the health of the population by improving the quality of basic health services, and to&#13;
support an initial phase of policy reforms to enhance cost-effectiveness, fiscal sustainability and patient choice&#13;
within the health system.&#13;
The project is comprised of the following components:&#13;
(a)    Health Finance and Management: to support (i) the Government's efforts to prepare and implement&#13;
health financing reforms, building on technical work begun during project preparation, through policy&#13;
studies and advocacy/public information campaigns; and (ii) the future introduction of a case-mix&#13;
hospital reimbursement scheme through development and testing of an integrated medical and&#13;
financial management information system for public sector facilities.&#13;
(b)    Basic Health Services: to improve the quality and effectiveness of primary health care services&#13;
through (i) the provision of basic equipment kits to 250 rural health centers and support for clinicians'&#13;
continuing education in provision and management of care; and (ii) support for selected prevention&#13;
programs.&#13;
(c)    Pharmaceutical Policy and Supply: to promote more rational use of drugs through (i) strengthening&#13;
local capacity for competitive drug procurement; and (ii) developing essential drugs lists for public&#13;
sector health facilities.&#13;
The Government intends to apply the proceeds of the Credit to finance local and foreign technical&#13;
assistance, local training as well as long- and short-term fellowships and study tours, medical equipment and&#13;
supplies, computer hardware and software, reference materials, and office equipment, in support of the above&#13;
components. All goods and services to be procured under the project would be tendered through procedures&#13;
in accordance with the procurement guidelines of the International Development Association. Among the&#13;
items to be procured through International Competitive Bidding are laboratory testing and diagnostic&#13;
equipment, medical equipment and consumables, selected pharmaceutical products, and computer hardware&#13;
and software. Advertisement of initial tenders is expected by December 1996.&#13;
Interested contractors and suppliers desiring further information may write to:&#13;
The Ministry of Health&#13;
Attn: Ms. Vesna Bisheva, Director, International Project Unit&#13;
Vodnjanska bb, 91000 Skopje&#13;
FYR Macedonia&#13;
Fax: 389-91 [IPU to provide by mid-June]&#13;
m:\machealt\pip\buff.pip&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 3&#13;
Page I of 6&#13;
Selection Amona Alternative Project Designs&#13;
1.     The project's objectives--to improve the health of the population by enhancing the quality of basic&#13;
health services and support an initial phase of policy reforms to increase cost-effectiveness, fiscal&#13;
sustainability and patient choice within the health system--complement and help achieve the Government's&#13;
overall economic reform strategy. The Government has sought to maintain basic social services in order&#13;
to maintain stability and avoid entanglement in the war in the former Yugoslavia while beginning the&#13;
process of building a modern growing economy. The Government has been successful in achieving this&#13;
goal in spite of a recent assassination attempt on the President's life. The proposed project supports this&#13;
effort by preventing the deterioration in basic health services and beginning the process of policy change&#13;
that is necessary to build an efficient, high-quality health care system.&#13;
2.     The proposed project has three components. Alternatives considered for each component are&#13;
presented below and are evaluated in terms of achieving the project's objectives.  Assessment of&#13;
alternatives to health care investment--such as education--were beyond the scope of the work undertaken&#13;
for this project, but were considered by Government in defining priorities for World Bank assistance.&#13;
As a practical matter, the Government has weighed sector alternatives and selected this project as one that&#13;
meets its overall policy objectives and criteria for World Bank assistance.&#13;
3.    In all cases the status quo is used as one alternative and depending on the component or sub-&#13;
component other reasonable alternatives were considered. Factors which determined the selection of the&#13;
proposed activities included, in no particular order: 1) programs most likely to achieve the project's&#13;
objectives; 2) activities that lay the foundation for sustained change; 3) alternatives likely to be achieved&#13;
within the budget and human resource constraints of the country and the health care system; 4) the cost-&#13;
effectiveness of the alternatives; and 5) politic.al and implementation feasibility.&#13;
Component 1: Health Finance and Managemnent&#13;
4.     Activities in Component I consist of 1) health financing reforms, 2) information systems, and 3)&#13;
building the technical capacity of the NHIF and health care managers.&#13;
Health Financing Reforms&#13;
5.     All of the health financing reforms are interrelated, and along with the other activities are&#13;
designed as a package to lead to a more efficient health care financing system.  Many of these&#13;
investments, such as the accounting and information systems, lay the ground work for the adoption of&#13;
new ways to pay for services which relate costs to services provided, and which introduce incentives in&#13;
the system for efficient and effective behavior by health care providers. The ultimate success of these&#13;
policy reforms can be measured by indicators of efficiency (e.g. length of stay and costs per patient day)&#13;
and quality (e.g. readmission rates, infection rates, and patient satisfaction).&#13;
6.     Revision of user fees - The first policy reform envisions revision of the user fees and co-payment&#13;
policy. A technical study will be followed by specific reform options including a reevaluation of&#13;
exemptions granted and the establishment of lump sum user fees. Exemptions under the present system&#13;
are extremely broad, and subject to abuse, leading to inequity in the application of fees, and exacerbating&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 3&#13;
Page 2 of 6&#13;
the complexity of administration. While copayments of insured patients, and to a larger extent, user fees&#13;
from the uninsured (many firms are failing to pay insurance contributions for workers, creating a large&#13;
pool of uninsured) have contributed to the revenues of health facilities (10-15 percent of total revenues&#13;
in recent years), the present system has generated discontent due to its inequitable application and impact&#13;
on access to care.&#13;
7.     The status quo offers no advantages over the proposed project. The proposed project will study&#13;
the issue, and then implement an administratively simpler and more equitable system for revenue&#13;
collection. The level of revenue collection can be set where policy desires within a far simpler system&#13;
to administer. The by-product will be the establishment of incentives for efficiency of health care use&#13;
in conformity with project objectives. Alternative structures of the user fee--i.e., a percentage of health&#13;
care fees versus a lump sum fee--will be consider during the technical analysis. Finally this is an area&#13;
identified for reform by the MOH. As such, it will enjoy the political support of the MOH and be&#13;
implemented aggressively in spite of expected resistance from the broad group of currently exempted&#13;
patients.&#13;
8.     Definition of a fiscally-sustainable benefits package for coverage by the NHIF - The objective&#13;
here is to define what is fundable given the limited budget of the NHIF. Instead of claiming to fund&#13;
everything, this reform will define what should be covered as the basic package by the NHIF, based on&#13;
the burden of disease and cost effectiveness of treatment, while establishing a supplemental benefits&#13;
package--and appropriate supplemental premium--for other services. A basic benefits package will be&#13;
defined which will prevent additional accumulation of financial arrears and allow gradual elimination of&#13;
the existing stock of arrears.  This is a first step in ensuring that basic services which prevent&#13;
deterioration in health status are insured, while beginning to establish a relationship between payment,&#13;
incentives, and the cost of services. This is essential to achieve the goal of efficient provision of care.&#13;
The alternative--i.e. the status quo--has nothing to recommend it. Instead it will continue the situation&#13;
where resource use is unrelated to real economic costs or the provision of efficient, high-quality care.&#13;
Expenditure control will remain impossible, leading to continued buildup of financial arrears in the health&#13;
sector (arrears accumulated every year since 1990 equal MKD 1.4 billion--about 12 percent of total health&#13;
expenditures in 1995). Until this situation is changed the objectives of the project cannot be met. This&#13;
is a first but necessary step to establish a financing system that promotes efficient high quality care.&#13;
9.     Adoption of a capitation payment system for primary care - The alternatives considered were the&#13;
status quo or movement to a fee-for-service payment system. The status quo consists of predominantly&#13;
public sector primary health care services, which have no separate budgetary allocation. Primary health&#13;
centers lie at the bottom of a budgeting hierarchy--and are, therefore, shortchanged--with funding&#13;
provided largely according to staffing, rather than services provided or patients served. No benefits&#13;
package has been defined which primary care centers are expected to provide, and there is no functional&#13;
means of allowing patient choice and development of private sector alternatives to public sector care.&#13;
These problems, coupled with recent resource constraints, have resulted in low quality care, and a&#13;
tendency for patients to bypass the primary care system altogether, leading to inappropriate use of high-&#13;
cost hospital facilities. Thus, continuation of the status quo is an inefficient and ineffective use of health&#13;
resources.&#13;
10.    Another alternative is to move to a fee-for-service payment system, often favored by the medical&#13;
profession. Such systems in other countries have led to supplier-induced demand for services (i.e.&#13;
doctors supplying unnecessary services about which patients are unable to make informed judgments),&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 3&#13;
Page 3 of 6&#13;
resulting in cost escalation. Indeed, FYR Macedonia already has a legally-mandated system of payment&#13;
for providers modeled on the German points system of fees for services. Since 1991, the NHIF has&#13;
attempted to reimburse private sector providers--mostly for primary and other ambulatory services--on&#13;
this basis. Attempts have been largely abandoned due to uncontrolled cost escalation and perceived abuse&#13;
of the system. False Llaims for reimbursement, excessive supply of services and a general inability of&#13;
NHIF to verify claims has brought fee-for-service payments to a halt.&#13;
11.    The project will support devzlopment of a capitation payment mechanism for primary care. Such&#13;
a system has the following advantages over the alternatives examined: i) a defined benefits package which&#13;
all primary care providers must offer; ii) creation of a separate budget allocation for primary care within&#13;
the NHIF; iii) a predetermined financial outflow (enhancing fiscal sustainability) which transfers financial&#13;
risk to providers, creating incentives for efficient care; iv) funds following patients, allowing patients'&#13;
choice of primary care provider, thereby creating incentives for quality care; v) equal remuneration of&#13;
public and private sector providers, stimulating private sector development. A capitation mechanism,&#13;
which allows funds to follow patients, is the equivalent of giving vouchers to patients to purchase their&#13;
package of primary care benefits. It is an overall demand-side approach to stimulating the provision of&#13;
appropriate primary  health services.   The project supports this broad demand-side approach,&#13;
complemented with narrower supply-side interventions where necessary (see Component II: Basic Health&#13;
Services, below).&#13;
Integrated Medical and Financial Information System&#13;
12.    The design, testing and introduction of a medical and financial information system at the hospital&#13;
level, linked to the NHIF and including enhanced reporting, are key activities of Component 1. The&#13;
status quo offers no accounting system that links economic costs to inputs employed or outputs provided.&#13;
Measurements of appropriateness, effectiveness or efficiency of care are not possible in the hospital or&#13;
primary health care units. Most data processing at the facility level is manual, and the NHIF is not&#13;
linked by computer to hospitals. Data collection and processing is inefficient, most policy-relevant data&#13;
is lost, and little to no data analysis is undertaken. Given that district HIF offices responsible for paying&#13;
most bills are not electronically linked to the national HIF office,  information that could allow&#13;
establishment of efficiency benchmarks nationwide--and improve policy making--is not available to the&#13;
NHIF and the MOH.&#13;
13.    In short, the status quo does not allow for the achievement of stated project objectives with&#13;
respect to increasing cost-effectiveness and fiscal sustainability in the health system. With its general&#13;
benefits for financial management, the integrated medical and financial information system also lays the&#13;
essential foundation for some type of case-mix based hospital payment system that relates real economic&#13;
cost to reimbursement (such as diagnosis-related groups--DRGs). Technical study to introduce such a&#13;
system in FYR Macedonia is anticipated under the project, using data from the pilot testing of the&#13;
information system. In countries where payment systems such as DRGs have been implemented, large&#13;
savings have been achieved. In the United States, implementation in 1983 of the Prospective Payment&#13;
System (PPS) for hospital services, which is based on DRGs, produced sudden and dramatic changes in&#13;
utilization rates and Medicare hospital payments. The average annual rate of change in hospital payments&#13;
went from 18 percent in the decade before PPS was introduced (1972-83) to 7 percent during the&#13;
following decade (1983-92). The share of payments going to hospitals also dropped from 64 percent in&#13;
1983 to 54 percent in 1992, reflecting a shift to outpatient settings and greater use of preventive services.&#13;
The average length of stay in short-stay hospitals also dropped by over 15 percent in the first two years&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 3&#13;
Page 4 of 6&#13;
after PPS introduction, significantly accelerating the downward trend begun earlier. The total days of&#13;
care per 1,000 PPS enrollees dropped dramatically--over 15 percent--by the end of the first full year of&#13;
the PPS program in 1984. FYR Macedonia has a far less efficient health system than the United States,&#13;
so that movement to payment mechanisms which transfer financial risk to providers and create incentives&#13;
for efficient behavior could be expected to have equal or greater impacts on fiscal outlays and cost-&#13;
effectiveness of care.&#13;
Enhance the Technical Skills of the NHIF and Hospital Administrators&#13;
14.    The status quo was deemed unacceptable. In order to implement the other elements of this&#13;
component, such as management information systems and policy reforms, skilled technical professionals&#13;
and hospital administrators are required. If these professionals do not have the skills to understand or&#13;
take advantage of the possibilities created in the other parts of the component, the objectives of the project&#13;
will not be met. Therefore, the status quo was rejected. There are many other combinations of training&#13;
which could also succeed, but the proposed program is reasonable and cost effective. The project is&#13;
flexible enough so that training components can be altered as needs evolve.&#13;
Component II: Basic Health Services&#13;
This component has three activities: 1) reforms in the organization of health services;&#13;
2) investments in rural primary health care centers; and 3) material support for disease prevention and&#13;
health promotion programs. All three of these activities directly contribute to improving the health of&#13;
the population by enhancing the quality of basic health services&#13;
Reforms in Organization of Health Services&#13;
15.    Supply-side investments under this component are linked to reforms to reinstate an appropriate&#13;
referral system, simplify the staffing structure for primary health care, redeploy staff to rural primary&#13;
care centers, reduce excess manpower and limit the future supply of medical professionals. Additional&#13;
policy reforms certainly could be proposed. But given limited resources, the political feasibility, and&#13;
likely impact to achieve program objectives, these policy reforms were mutually selected for attention by&#13;
the Government. These reforms address the inadequacy and inefficiency of the status quo, which is&#13;
characterized by: 1) underutilization of staff in public sector facilities; 2) duplication and fragmentation&#13;
in the provision of primary care services; 3) unemployment of graduating medical professionals; 4) lack&#13;
of basic equipment and staff for primawy care in rural areas, resulting in "self referral" to hospitals and&#13;
overreliance on high-cost nospital care.&#13;
Investment in Rural Primary Health Care Centers&#13;
16.   Investments under this component complement the overall demand-side approach taken to&#13;
stimulating appropriate primary care through development of a capitation payment mechanism (see&#13;
above). Stimulation of demand for primary care--and providing patient choice--are geared toward&#13;
increasing the quality of public seclor care and generaiing competition from private sector providers.&#13;
However, global experience demonstrates that in isolated rural areas, market incentives are insufficient&#13;
for private sector development, and will not lead to socially-desirable levels of health care for rural&#13;
populations, which tend to be poorer and more elderly than the general population. Therefore, most&#13;
governments--including in countries with highly privatized health care markets, such as the United States--&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 3&#13;
Page 5 of 6&#13;
offer special incentives and/or direct public sector provision of primary care in poor, rural areas. For&#13;
this reason, a purely demand-side approach to primary care in FYR Macedonia was rejected as an&#13;
alternative to the status quo. The project includes complementary supply-side investments to ensure&#13;
provision of quality primary health care, targeted to a limited number of rural areas where public sector&#13;
intervention will remain well-justified. These investments include basic equipment for 250 rural primary&#13;
health centers (e.g., stethoscopes, infant scales, blood pressure gauges) as well as support for a permanent&#13;
program of in-service training for primary care personnel, to update prevention and treatment algorithms.&#13;
Material Support for Disease Prevention and Health Promotion Programs&#13;
17.    The alternatives to supporting disease prevention/health promotion programs which were&#13;
considered were the status quo and treatment--rather than prevention--of the associated diseases. The&#13;
status quo is characterized by less than 2 percent of health expenditures being devoted to disease&#13;
prevention programs, an amount which has declined by 35 percent in real terms since 1991. Under fiscal&#13;
pressure, FYR Macedonia's impressive history of nearly total childhood immunization coverage, has&#13;
given way to gaps in immunization coverage resulting in epidemics of infectious diseases. In 1992, for&#13;
example, measles immunization coverage fell to only 60 percent, followed by a 600 percent increase in&#13;
measles incidence in 1993-94. One-quarter of infant deaths are due to premature delivery and low birth&#13;
weight, while another quarter are due to easily preventable and treatable infectious diseases. The status&#13;
quo is clearly not contributing to project objectives to improve health status.&#13;
18.    The project team was unable to identify alternatives to supporting well-documented, cost-effective&#13;
interventions such as childhood immunization and prenatal care, as the best means to achieve&#13;
improvements in health status. The de facto alternative--treatment of the associated diseases--is clearly&#13;
less cost effective, involving, in most instances expensive drug therapy and/or hospital stays. The&#13;
programs selected, which target immunization, maternal and child health, tuberculosis prevention. AIDS&#13;
prevention, and safe blood supply are basic public health programs. It was recognized that intervention&#13;
in prevention of smoking would have been among the most cost-effective investments, but this was&#13;
deemed too controversial for an initial IDA project. Investment in female educational attainment is&#13;
another alternative which could impact on some of these areas--but is being addressed by Government&#13;
and other donors, as well as under another proposed IDA Credit (FY98).&#13;
Component III: Pharmaceutical Policy and Supply&#13;
19.    Authorization of private sector pharmaceutical activity in 1991 led to the rapid growth of private&#13;
pharmaceutical suppliers and distributors, in a largely unregulated environment. This was coupled with&#13;
continued public sector procurement of drugs for public sector health facilities and pharmacies.&#13;
Alternative project designs considered were maintaining the status quo and moving to a completely&#13;
privatized pharmaceutical market. The status quo is characterized by inefficiency in the private sector&#13;
due to well-documented market failures (monopoly/oligopoly situations, asymmetry of information,&#13;
imperfect information, etc.) associated with the pharmaceutical market, particularly a small market such&#13;
as in FYR Macedonia.  Inefficiency is also rampant in the public sector, where procurement is&#13;
fragmented and uncompetitive, and reimbursement policies encourage inappropriate prescribing and&#13;
dispensing practices. As a result, drug choice is limited (low-cost generic equivalents are unavailable)&#13;
and prices are exorbitant. For a small sample of tracer drugs (all of which were essential drugs), local&#13;
prices in the private market were 5 to 20 times higher than world market prices. Many essential drugs&#13;
are completely unavailable in rural areas. The status quo does nothing to achieve the project objective&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 3&#13;
Page 6 of 6&#13;
of making essential drugs broadly available to consumers at the lowest possible cost.&#13;
20.    The alternative of a totally private pharmaceutical market is one which no other country has&#13;
pursued. This is because an unfettered private pharmaceutical market--prone to the market failures&#13;
indicated above--would exacerbate rather than improve current inefficiencies, raising the cost for&#13;
consumers. The option of relying solely on regulation of the private sector was deemed inadequate for&#13;
the near future due to weak regulatory and enforcement capacity of the public sector. Although a well-&#13;
regulated private market could become competitive over time, it is clear that to achieve such a system&#13;
with real competition and extensive supply, would take many years. At this point in time, a weakly-&#13;
regulated private market system would lead to unnecessarily high prices, maldistribution of supply,&#13;
discrimination against the poor, inefficiency and suboptimal medical outcomes due to lack of appropriate&#13;
drug therapy. For this reason, the option of private sector regulation plus direct public sector intervention&#13;
was selected--in order to reduce barriers to market entry and create a more competitive private market&#13;
(through changes to registration, pricing and dispensing policies), as well as develop an efficient public&#13;
sector to compete directly with the private sector through supply of public sector health facilities and&#13;
pharmacies. Changes to procurement and reimbursement policies will increase efficiency in the public&#13;
sector. Indeed, a recent change to competitive bidding for local procurement has already resulted in an&#13;
average 35 percent reduction in the cost of the drugs procured by this method.&#13;
m:\machealt\sar\annex3.sar&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 4&#13;
STATISTICAL DATA&#13;
List of Tables&#13;
Page&#13;
Table 1:      FYR Macedonia: Demographic and Health Status,&#13;
1991-1994  .      ............................................. 1&#13;
Table 2:      Demographic and Health Indicators, Selected&#13;
Countries,   1991  ...........................................  2&#13;
Table 3:      FYR Macedonia: Major Causes of Infant Death, 1994.                             3&#13;
Table 4:      FYR Macedonia: Crude Birth Rates and Infant Mortality by Mother's Ethnic&#13;
Affiliation and Educational Attainment, 1991 and 1994.                        4&#13;
Table 5:      Age-Standardized Mortality Rates, Selected Causes and Countries, 1991.         5&#13;
Table 6:      FYR Macedonia: Health Revenues and Expenditures, 1991-1995&#13;
(thousands MK Denar) ............... 6&#13;
Table 7:      FYR Macedonia: Health Revenues and Expenditures, 1991-1995&#13;
(percentage of total' ............. 7&#13;
Table 8:      FYR Macedonia: Health Revenues and Expenditures, 1991-1995&#13;
(percentage of GDP) ............. 8&#13;
Table 9:      FYR Macedonia: Health Revenues and Expenditures, 1991-1995&#13;
(constant 1990 MK Denars)  ................... 9&#13;
Table 10:     FYR  Macedonia: Health Revenues and Expenditures, 1991-1995&#13;
(real index) .10&#13;
Table 11:     Organizational Structure of the Ministry of Health .11&#13;
Table 12:     FYR Macedonia: Health Facilities, Inpatient Capacity and&#13;
Personnel, 1994 .12&#13;
Table 13:     Utilization Rates and Manpower Ratios .13&#13;
Table 14:     Acute Hospital Facilities and Manpower, 1993 .14&#13;
Table 15:     FYR Macedonia: Use of Inpatient Capacity, 1991-94 .15&#13;
Table 16:     Performance Measures for Acute Care Facilities, 1993 .16&#13;
Table 17:     Performance Measures for Special Purpose Hospitals ................... 17&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 4&#13;
Page I of 17&#13;
FYR MACEDONIA: DEMOGRAPHIC AND HEALTH STATUS, 1961-94&#13;
1961    1971   1981    1991    1992    1993    1994&#13;
Mid-year population (millions) 1/  1.411   1.653   1.916   2.039   2.056   2.066   2.075&#13;
Crude birth rate              29.9    22.9   20.6    17.1    17.2    15.7    16.1&#13;
Crude death rate               9.3     7.5      7      7.3     7.8      7.6     7.6&#13;
General fertility rate         126     90      80      68       64&#13;
Total fertility rate           3.9     2.9    2.5      2.3     2.1&#13;
Gross reproduction rate 2/                            0.98&#13;
Net reproduction rate 2/                              0.93&#13;
Population under age 15 (%)                            24&#13;
% Ann. population growth&#13;
(1980-91)                                        _    1.1&#13;
Life expectancy at birth&#13;
male                         60.8    65.6   68.1    70.1&#13;
female                       61.8   67.6   71 8    74.4&#13;
Perinatal mortality rate                              19.3    21.5    20       20.4&#13;
Stillborn rate                12.1    11.8    9.4      7.6     9.1     9.3      9.9&#13;
Infant mortality rate         112.1   82.2   51.1    28.3    30.6   24.1    22.5&#13;
neonatal mortality rate                              15.8    16.2    14.2    13.5&#13;
post-neonatal mortality rate       .                 12.5    14.4    9.9       9&#13;
Under-five mortality rate     134.1   94.5   56.1    31.6    34.4    26.9    25.8&#13;
Maternal mortality rate     _                         11.5      9      6.2    11.9&#13;
i/ 1992-94 figures are projections from 1991 Census data, to be updated based on 1994&#13;
Census results. Projections were not done by age-group, barring the calculation of indicators&#13;
requiring such data (e.g., total fertility rate) beyond 1991.&#13;
2/ Data are for 1990.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 4&#13;
Page 2 of 17&#13;
Demoranhic and Health Indicators. Selected Countnes. 1991&#13;
|~~~Awq               A_es &#13;
Per uapia inmco  (US=)                 1150 |       1.1S3         1.390        1.260        1.030     1.120&#13;
Cruds birih ran                          17           13             11          24           32        49&#13;
Cruds death rat                           7:           9             9            6           .S16&#13;
Cruds nts of naomi inr                   10            4             2           iS           24        33&#13;
Pop. itwvh 19S0-91 (% pm)                1.1         0.6           -0.2          2.0          2.6      3.4&#13;
PopulaLioa age 0-14 (%)                 24.0         19.4          20.0         35.0         41.0     45.5&#13;
Ufa expecny (mAU)                        70           73            67           66           61        49&#13;
Lifs ._'_ y (femaL)                      74           sO            75           72           65        54&#13;
Toul feALility nut                       2.3          1.7           2.1          2.7          4.3       6.6&#13;
InMf  monalizy ra                        21           _              17          23           S7      115.0&#13;
Mawrnai morality nuuo                    11            7            29               . Einmd at 10O.200 -&#13;
*Excluding Albania and the former republics of Yugoslavia.&#13;
Source: FYR Macedonia: Health Services in Transition, Sept. 1993. Human Resources&#13;
Sector Operations Division, Central and Southern Europe Departments.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 4&#13;
Page 3 of 17&#13;
FYR MACEDONIA: MAJOR CAUSES OF INFANT DEATH. 1994&#13;
(number of deaths)&#13;
Neonatal      Post-neonatal&#13;
Major causes of death         Total infant     mortality        mortality&#13;
(0-27 days)    (28-364 days)&#13;
Perinatal conditions                      411             380              31&#13;
congenital malformations                 71              43               28&#13;
complications of mother's pregnancy&#13;
labor or delivery                      10              10&#13;
delivery trauma                          19              19&#13;
premature delivery and low birthweight   177             175               2&#13;
respiratory conditions                   73              73&#13;
infections in the perinatal period       15              14                1&#13;
other perinatal conditions               46              46&#13;
Enteritis and other diarrheal diseases    82               8               74&#13;
Septicemia                                12               2               10&#13;
Other infectious and parasitic diseases    7               2                5&#13;
Meningitis                                 7               1                6&#13;
Encephalitis                               4                                4&#13;
Pneumonia and bronchial pneumonia         57               5               52&#13;
Violent deaths                             2                                2&#13;
Other diseases                            139             48               91&#13;
Undefined cause of death                  31               5               26&#13;
TOTAL                      752             451              301&#13;
(as percentage of total)&#13;
Perinatal conditions                      55              84               10&#13;
congenital malformations                  9              10                9&#13;
complications of mother's pregnancy&#13;
labor or delivery                       1              2                0&#13;
delivery trauma                           3              4                 0&#13;
premature delivery and low birthweight   24              39                1&#13;
respiratory conditions                   10              16               0&#13;
infections in the perinatal period        2               3                0&#13;
other perinatal conditions                6              10                0&#13;
Enteritis and other diarrheal diseases    11               2               25&#13;
Septicemia                                 2               0                3&#13;
Other infectious and parasitic diseases    1               0                2&#13;
Meningitis                                 1               0                2&#13;
Encephalitis                               1               0                1&#13;
Pneumonia and bronchial pneumonia          8               1               17&#13;
Violent deaths                             0               0                1&#13;
Other diseases                            18              11               30&#13;
Undefined cause of death                   4               1                9&#13;
TOTAL                      100             100              100&#13;
(as percentage of total infant mortality)  100           60               40&#13;
Source: National Statistical Office&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 4&#13;
Page 4 of 17&#13;
FYR MACEDONIA: CRUDE BIRTH RATES AND INFANT MORTALITY BY MOTHER'S ETHNIC&#13;
AFFILIATION AND EDUCATIONAL ATTAINMENT, 1991 AND 1994&#13;
Mother's educational attainment&#13;
Infant   Below&#13;
Crude  mortalitypiay   Primary Secondary Advanced Unknown&#13;
birth rate   rate  prmy&#13;
1991&#13;
Mother's ethnic affiliation&#13;
Macedonian                   13.6     17.8      43.2    21.3        13.7       6.5      262.8&#13;
Albanian                     26.7     42.8      76.9    28.9        15.8         0      244.2&#13;
Turk                         23.5     27.1      42.7      15        16.5         0      103.5&#13;
Rhoma                        28.5       39      36.4    31.9        16.9         0      119.6&#13;
Other                        12.7     29.8      47.2    24.1         26          0       84.1&#13;
AVERAGE                       17.1     28.3      59.6    25.5        14.5       6.5      198.8&#13;
1994&#13;
Mother's ethnic affiliation&#13;
Macedonian                   12.1     15.5      35.3    23.4        11.6      6.58       66.7&#13;
Albanian                     25.1     28.2      50.1    23.4         7.7         0       47.1&#13;
Turk                         19.a     21.7       30      15.5       10.1         0       55.6&#13;
Rhoma                        29.1     21.8      26.8    20.8        20.8         0          0&#13;
Other                        20.1     50.6    135.5    51.9         16.7      26.8         50&#13;
AVERAGE                       16.1     22.5      45.8    24.2        11.5       6.8       47.4&#13;
Source: National Statistical Office&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 4&#13;
Page 5 of 17&#13;
Age-SuLndardized Mortality Rates, Selected CaUs,   and Counties, 1991&#13;
(deaths per 100,000 inhabitants)&#13;
Act"  ~     ~ Trn | 8                                                 h_ | SfL_ ive ld  |    _E-&#13;
| ~~~~Brac    Lue    ^liGn i&#13;
inbucdm  01~~~~~~~~~~~~~~~~~~Dm ~     v'&#13;
______                                                              _    __ _&#13;
male&#13;
Auu                        131.7              64.7        4.a                      1.9               1.54J &#13;
94.0              712         La          14.3          5.9              12.11.9&#13;
Iky3114                                       Ms5        a.a                       2L.4              34.1             1.3&#13;
BULOwk                     101.2              52.5                   27.1          16.9                 1              .5I&#13;
FYiM                       110.2              36.        LA          27.3          14.2               9.9             6.2&#13;
H_y7                       174.0             109.6                   34.6          14.0              79.3             7.5&#13;
Female&#13;
AuWmro                      90.6              12.0      37.4          1.2          25.5              13.7             04&#13;
Growe                       51.3              13.8      24.           10.3         12.1               5.3             0.J&#13;
I1                         49.6               13.9      35.2         19.2         39.1               13.1             0.5&#13;
Bu1W*                       4.2.3            12.0       24.1         19.3         25.0               7.9              0.9&#13;
fYRM                        71.2              745          JL.                    287                3.1              3.1&#13;
Humpay                     110.9             27.7       39.7         214          2.2                2                2&#13;
Source:  FYR Macedonia:  Health  Services  in Transition,  Sept.  1993.  Human  Resources&#13;
-Sector Operations Division, Central and Southern Europe bepartments.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 4&#13;
Page 6 of 17&#13;
FYR MACEDONIA: HEALTH REVENUES AND EXPENDITURES, 1991-95&#13;
Thousands of MK Denar&#13;
1990     1991     1992      1993     1994     1995&#13;
Health Revenues              39080    81315   845222  4436749  9710745 10415654&#13;
Health Insurance Fund                55961   683153  3683497  8064107  8412321&#13;
Payroll contributions               52915   634836  3465520  7736395  7907267&#13;
wage-earners                       40924   491419  2652317  5348150  5206328&#13;
self-employed                       1165      8990    70802   210831   244592&#13;
agricultural workers                1240      6961    40883   121279   115250&#13;
pension fund                        8855   122231   677748  1840563  2100421&#13;
unemployment fund                    263      3880    13575   182247   194915&#13;
disability/social cases              468      1355    10195    33325    45761&#13;
Profit tax                           1118      5453   156660   274203   220288&#13;
Other                                1928    42864    61317    53509   284766&#13;
Central Budget                         347      2001    15960   197569   296748&#13;
User fees                            11884   141770   644090  1124715  1323681&#13;
Other                                13123    18298    93202   324354   382904&#13;
Health Expenditures          46511   103397   986526  4835428 10420690 11391071&#13;
Recurrent Expenditures              102217   976414  4794806 10289833 11193489&#13;
Personnel                           48496   422345  2164327  5006289  5680552&#13;
Drugs                               10805    88340   328016  1190686  1497982&#13;
Other consumables                   21517   188644  1043263  1045872  1540979&#13;
Utilities                                                       107404   120065&#13;
Maintenance                                                     116460   140890&#13;
Transportation                                                  59400    66934&#13;
Public health activities              865      9796    87348    99495   121405&#13;
Reimb. private providers                                       570882   402037&#13;
Cash transfers (sick pay)                0    68538   184201  1662123   977258&#13;
Other expenditures                  20534   198751   987651   431222   645387&#13;
Capital Expenditures                  1180    10112    40622   130857   197582&#13;
Increase in arrears          -7431   -22082  -141304  -398679  -709945  -975417&#13;
finance.xis&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 4&#13;
Page 9 of 17&#13;
FYR MACEDONIA: HEALTH REVENUES AND EXPENDITURES, 1991-95&#13;
Constant 1990 MK Denars&#13;
1990     1991      1992     1993      1994     1995&#13;
Health Revenues                39080    47832    33541    29837    30186    28007&#13;
Health Insurance Fund             0    32918    27109    24771    25067    22620&#13;
Payroll contributions            0    31126    25192    23305    24048    21262&#13;
wage-earners                    0    24073    19501    17837    16625    13999&#13;
self-employed                   0      685       357      476      655       658&#13;
agricultural workers            0      729       276      275       377      310&#13;
pension fund                    0     5209     4850      4558     5721      5648&#13;
unemployment fund               0      155       154       91       567      524&#13;
disability/social cases         0      275        54       69       104      123&#13;
Profit tax                       0      658      216      1054      852       592&#13;
Other                            0     1134      1701      412       166      766&#13;
Central Budget                    0      204        79      107       614      798&#13;
User fees                         0     6991      5626     4331      3496     3559&#13;
Other                             0     7719       726      627      1008     1030&#13;
Health Expenditures           46511    60822    39148    32518    32393    30629&#13;
Recurrent Expenditures            0    60128    38747    32245    31986    30098&#13;
Personnel                        0    28527    16760    14555    15562    15274&#13;
Drugs                            0     6356     3506      2206     3701      4028&#13;
Other consumables                0    12657     7486      7016      3251     4144&#13;
Utilities                        0        0         0        0       334      323&#13;
Maintenance                      0        0         0        0       362      379&#13;
Transportation                   0        0         0        0       185      180&#13;
Public health activities         0      509      389       587      309       326&#13;
Reimb. private providers         0        0         0        0      1775     1081&#13;
Cash transfers (sick pay)        0        0     2720      1239      5167     2628&#13;
Other expenditures               0    12079     7887      6642      1340     1735&#13;
Capital Expenditures              0      694       401      273       407      531&#13;
GDP (millions of MKD)            585      532       464      405       384      367&#13;
Government Expenditure             0      270       230      213       208      183&#13;
GDP Deflator                     1.0       1.7     25.2    148.7    321.7       372&#13;
finance xis&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 4&#13;
Page 10 of 17&#13;
FYR MACEDONIA: HEALTH REVENUES AND EXPENDITURES, 1991-95&#13;
Real Index: 1991=100&#13;
1990     1991      1992     1993     1994      1995&#13;
Health Revenues (1990=100)       100      122        86       76        77       72&#13;
Health Revenues (1991=100)                100        70       62        63       59&#13;
Health Insurance Fund                    100        82       75        76       69&#13;
Payroll contributions                   100        81       75        77       68&#13;
wage-earners                           100        81       74        69       58&#13;
self-employed                          100        52       69        96       96&#13;
agricultural workers                   100        38       38        52       42&#13;
pension fund                           100        93       88       110      108&#13;
unemployment fund                      100       100       59      366       339&#13;
disability/social cases                100        20       25        38       45&#13;
Profit tax                              100        33      160       130       90&#13;
Other                                   100       150       36        15       68&#13;
Central Budget                           100        39       53       301      391&#13;
User fees                                100        s0       62        50       51&#13;
Other                                    100         9        8        13       13&#13;
Health Expend. (1990=100)        100      131        84       70        70       66&#13;
Health Expend. (1991=100)                 100        64       53        53       50&#13;
Recurrent Expenditures                   100        64       54        53       50&#13;
Personnel                               100        59       51        55       54&#13;
Drugs                                   100        55       35        58       63&#13;
Other consumables                       100        59       55        26       33&#13;
Utilities                               n.a.      n.a.     n.a.      n.a.     n.a.&#13;
Maintenance                             n.a.      n.a.     n.a.      n.a.     n.a.&#13;
Transportation                          n.a.      n.a.     n.a.      n.a.     n.a.&#13;
Public health activities                100        76      115        61       64&#13;
Reimb. private providers                n. a.     n. a.    n.a.      n.a.     n. a.&#13;
Cash transfers (sick pay)               n.a.      n.a.     n.a.      n.a.     n.a.&#13;
Other expenditures                      100        65       55        11       14&#13;
Capital Expenditures                     100        58       39        59       77&#13;
GDP (1990=100)                   100       91        79       69        66       63&#13;
GDP (1991=100)                            100        87       76        72       69&#13;
Government Expend.&#13;
(1991=100)                                100        85       79        77       68&#13;
finance.xis&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 4&#13;
Page 11 of 17&#13;
ORGANISATIONAL STRUCT'JRE OF THE MINISTRY OF HEALTH&#13;
Minister&#13;
Deputy Minister&#13;
SECTOR OF HIGHLY&#13;
SECTOR OF PRIMARY               SPECIALISED HEALTH                  UNIT OF HEALTH&#13;
AND PREVENTIVE                     CARE AND                        LEGISLATION&#13;
HEALTH CARE                    INTERNATIONAL                      AND INSURANCE&#13;
CO-OPERATION&#13;
UNDER-SECRETARY                 UNDER-SECRETARY                      ASSISTANT&#13;
ADIER                                   ISER&#13;
UNIT OF HOSPITAL                                        UNIT OF&#13;
AND SPECIALIST       UNIT OF              UNIT OF      PRIVATE&#13;
CONSULTATIVE         PHARMACY             MEDICAL       HEALTH&#13;
,   HEALTH                                  SUPPLY        SERVICE&#13;
ASSISTANT            ASSISTANT            ADVISER       ASSISTANT&#13;
REPUBLIC SANITARY                          HEALTH&#13;
AND HEALTH                              INSURANCE&#13;
INSPECTION                               FUND&#13;
CHIEF REPUBLIC                       [    DIRECTOR OF&#13;
SANITARY AND      l                       THE HEALTH&#13;
HEALrH                                  INSURANCE&#13;
Source:   WHO/EURO  Healthn Care  Reform  in  the  Former&#13;
Yugoslav  Republic  of Macedonia  (draft,  Jan.  1996)&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 4&#13;
Page 12 of 17&#13;
FYR MACEDONIA: HEALTH FACILITIES. INPATIENT CAPACITY AND PERSONNEL. 1994&#13;
Health Personnel&#13;
Technl-&#13;
clans    Para-&#13;
No. of    No. of   Physi-             Pharna-  Nursing/  Elem.   medl&#13;
Facilities    Beds    clans   Dentists    cists   Adv.Trng.  Tmg.   Other  Total&#13;
National Level (tertiary)                4502      981       122        39       2298      213     1913   5566&#13;
University Hospitals/institutes  33     2461      696                 32        1413      114     1201   3456&#13;
Specialized Dental Clinics     7         40        2        120                  127       2       66      317&#13;
Specialized Rehab. Hospitals   2         910      48         1                   151       19      135    354&#13;
Specialized Institutes         2         562       66        1         1        254        59      279    660&#13;
Skopje City Hospital           1         529      141                  1        325        15      194    676&#13;
National Instit. of Public Health  1              28                   5         28        4       38      103&#13;
District Level (secondary)               6162      1466       5         9        3099      434      554    5567&#13;
Consultative Services          27                 555                           810                       1365&#13;
General Hospitals              16       4346      695        3                  1643      327       1    2669&#13;
Specialized Hospitals          6        1261      72         1                  297       82       257    709&#13;
Rehabilitation Centers         6         555      44         1         4         137       14      174    374&#13;
District Instits. for Public Healt    10          100                  5        212        11      122    450&#13;
Municipal Level (pnmary)                  136     2058       960       309       5147      124     3857   12455&#13;
Health Posts                   7                  35        23         2         71        1       21      153&#13;
Health Centers                 18                 821      334        44        1784      33       962    3978&#13;
Mediral Centers                16                 1156     603        143       2990       75     2752   7719&#13;
Outpatient Surgeries           10        136       7                             41        12              60&#13;
Public Health Units            19                  39                            50        3        16     108&#13;
Public pharmacies              32                                     120       211                106    437&#13;
TOTAL PUBLIC SECTOR                      10800    4505      1087       357       10544     771     6324   23588&#13;
Private Sector Facilities&#13;
General Practitioners         130&#13;
Medical Specialists            87&#13;
Dentists                      264&#13;
Dental Specialists             7&#13;
Pharmacies                    258&#13;
Source: National Institute for Public Health&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 4&#13;
Page 13 of 17&#13;
Utilization Rates and ManDower Ratios&#13;
CATAGORIFS              FMI           EWE            CEE       DEVELOPING COUNTRM&#13;
Cowuniea     Cowutiesl&#13;
Weighted      Weighted    COLOMBLA    MOROCCO&#13;
Average       Aver      __      _&#13;
Physicians(.C0O Pop.           2.21          2.50          2.39          0.17          0.21&#13;
NunradPhysici&amp;=                 2.30          2.21          2.46           0.6          4.50&#13;
Hoipital Ba 1d/.000 Pop.        5.40          8.32          8.04            L5         120&#13;
*Excludes Albania and the former republics of Yugoslavia.&#13;
Source:   FYR Macedonia:  Health  Servi-ces  in Transition,  Sept.  1993.&#13;
Human Resources Sector Operations Division, Central and Southern Europe&#13;
Departments.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 4&#13;
Page 14 of 17&#13;
Medical Supply&#13;
Table 1: Acute Hospital Facilities and Manpower, 1993&#13;
Medical Centers in the Republic of Macedonia&#13;
]             I.&#13;
,Occ. Beds Manpower/Occ. Bed&#13;
I        M.D./Bed Other/Bed Total/Bed&#13;
Skopje                     |     352      0.35     0.74      1.09&#13;
Tetovo                           203      0.29     0.71      1.00&#13;
Kumanovo                   |     261      0.35     0.35      0.54&#13;
Bitola                           399      0.31     0.56      0.87&#13;
Gostivar                          98      0.32     1.08      1.40&#13;
Prilep                           227      0.26     0.52      0.79&#13;
Strumica                         184      0.15     0.33     0.48&#13;
Ohrid                            125      0.33     0.90      1.22&#13;
T. Veles                         211      0.271    0.62      0.89&#13;
Struga                            92      0.35     0.82      1.16&#13;
Kicevo                            42      0.21     0.52      0.74&#13;
Stip    L                        475      0.11     0.32      0.43&#13;
Kocani                     j     136      0.13     0.46      0.59&#13;
Kavadarci                  j      93      0.23     0.48      0.71&#13;
Gevgelija                  j      81      0.27     0.51      0.78&#13;
Debar                             32      0.28     1.28      1.56&#13;
Kriva Palanka                     47      0.11     0.36      0.47&#13;
Academic Hospital Co mplex     _&#13;
Skopje                          2095      0.21     0.47     0.68&#13;
Table 2: Special Purpose Hospital Facilities and Manpower, 1993 I&#13;
lOcc.Beds Manpower Occ. Bed |&#13;
M.D./Bed Other/Bed Total/Bed&#13;
0.08     0.17     0.25&#13;
Skopje   TB                      101      0.07     0.14     0.21&#13;
Lesok    TB                       57      0.06     0.11     0.34&#13;
Jasenovo TB                      108      0.11     0.42      0.53&#13;
Ohrid    OrtholTrauma            300      0.14     0.40      0.55&#13;
Ohrid    Children  1              66      0.03     0.10      0.13&#13;
Gevgelija Neuropsychiatric       264      0 32     0.10l&#13;
D. Hisar  Neuropsychiatnc       1117      0.03     0.08     0.10&#13;
Skopje   Neuropsychiatric       1540      0.08     0.27     0.35&#13;
Skopje   Rehabilitation          165      0.22     0.56      0.78&#13;
Skopje   ENT                       9      0.191    0.79     0.99&#13;
Struga   Dialysis                 72      0.161    0.28     0.42&#13;
Ohrid    Cardiovascular           50      0.23     0.59      0.81&#13;
Katlanovo Thermal Resort          44      0.371    0 37      1.57&#13;
Other Stationaries   T            35      0.371    0.37      1.57&#13;
Source: Kanach, F.  Sustainability of Health System&#13;
Infrastructure in FYR Macedonia. Oct. 1994.&#13;
&#13;
&#13;
&amp;#12;&#13;
ANNEX 4&#13;
Page 15 of 17&#13;
FYR MACEDONIA: USE OF INPATIENT CAPACITY. 1991-94&#13;
1991    1992      1993     1994&#13;
Number of beds                 11086    10956    10824    10800&#13;
General Hospitals              4979    4867      4904     4875&#13;
Clinics and Institutes         2292    2301      2299     2301&#13;
Specialized Hospitals          3632    3623      3469     3488&#13;
Other Inpatient Facilities      183      165      152       136&#13;
Admissions                    191909  198087   189086   192631&#13;
General Hospitals            128722   132663   125931   129401&#13;
Clinics and Institutes        48905   50156    48470    48233&#13;
Specialized Hospitals         10354    11212    11293    11738&#13;
Other Inpatient Facilities     3928    4056      3392     3259&#13;
Discharges                    191411   198472   189305   191783&#13;
General Hospitals            128393  132515   126090   128796&#13;
Clinics and Institutes        49074   50545    48361    47939&#13;
Specialized Hospitals         10023    11350    11461    11791&#13;
Other Inpatient Facilities     3921     4062     3393     3257&#13;
Days of Care                 2759906 3197911  3326766  2699077&#13;
General Hospitals           1075304 1128764  1117532  1112010&#13;
Clinics and Institutes       661676  692521   689884   643440&#13;
Specialized Hospitals        999879 1361259  1506685   932455&#13;
Other Inpatient Facilities    23047    15367    12665    11172&#13;
Admissions Rate (% of pop.)       9.4      9.7      9.2      9.3&#13;
General Hospitals                6.3      6.5      6.1      6.2&#13;
Clinics and Institutes           2.4      2.4      2.4      2.3&#13;
Specialized Hospitals            0.5      0.5      0.5      0.6&#13;
Other Inpatient Facilities       0.2      0.2      0.2      0.2&#13;
Occupancy Rate (% beds)          68.2    80.0      84.2     68.5&#13;
General Hospitals               59.2    63.5      62.4     62.5&#13;
Clinics and Institutes          79.1     82.5     82.2     76.6&#13;
Specialized Hospitals           75.4   102.9    119.0      73.2&#13;
Other Inpatient Facilities      34.5    25.5      22.8     22.5&#13;
Average Length of Stay (days)    14.4    16.1      17.6     14.1&#13;
General Hospitals                8.4      8.5      8.9      8.6&#13;
Clinics and Institutes          13.5    13.7      14.3     13.4&#13;
Specialized Hospitals           99.8   119.9    131.5      79.1&#13;
Other Inpatient Facilities       5.9      3.8      3.7      3.4&#13;
Estimated Population 1/      2033964 2047591  2061310  2075196&#13;
1/ Derived from the 1991 Census by the National Statistical Office.&#13;
&#13;
&#13;
&amp;#12;&#13;
Performance Measures&#13;
Exhibit 1: Performance Measures for Acute Care Facilities, 1993&#13;
Rank     City      #Beds    ALOS    Occup.   Tmover&#13;
1IDebar           73      4.1      43.7      38.4&#13;
2 Kicevo         105       4.5     40.1      32.7  12                                                so&#13;
3 Gostivar       237       5.9     41.5      25.8                                                    so&#13;
4 Struga         109       6.7     84.6      45.9  10&#13;
5 Tetovo         397       6.7     51.2      27.9                                                    70&#13;
6 D.Med.Fac    2283        7.0     83.6      21.4             //&#13;
7 K.Palanka       80       7.7     58.4      27.5&#13;
8 Kocani         249       7.9     54.5      25.1                                                     0  M  /ALOS0&#13;
9 Kavadarci      113       8.0     82.0      37.4   6                                                4&#13;
10 Ohild          259       8.3     48.3      21.1                         .                               4--1 +u&#13;
11 Prilep         386       8.5     58.9      25.2   4 -3&#13;
12 T. Veles       291       8.7     72.6      30.4&#13;
13 Skopje Gn      529       8.9     67.0      27.3                                                    20&#13;
14 Gevgelija      199       9.2     40.5      16.0                                                    10&#13;
15 Kumanov        380       9.7     68.6      25.6&#13;
16 Bitola         640      11.0     62.4      20.5   0                                                0&#13;
17 Strumica       297      11.6     62.1      19.6      1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18&#13;
18 Stip           560      11.9     84.9      26.0   ,_ _ _ _ _ _ _-                    _ _ _ _ _ _ _&#13;
Source: Kanach, F.  Sustainability of Health System Infrastructure in FYR Macedonia, Oct. 1994.&#13;
&gt;z&#13;
oElz&#13;
OmI&#13;
&#13;
&#13;
&amp;#12;&#13;
Performance Measures&#13;
Exhibit 2: Performance Measures for Special Purpose Hospitals&#13;
8- 250&#13;
.                     ~~             ~~~~~~~700KI&#13;
Rank      Hospital           #Beds    ALOS    Occup.          f                                       /- 20&#13;
1 Other Stationares        152        3.7      22.8&#13;
2 Thermal-Katlanovo        280       21.2      15.6  50                                      /   l|               ALOS&#13;
3 Cardiovasc-Ohrid          60       21.5      82.9  40011                                                        OS I&#13;
4 Rehabilitation-Skopje    210       31.3      78.6  30                             A                   1/  W     Or-cup&#13;
5 Children-Ohrid           200       33.0      48.2&#13;
6 TB-Skopjel               112       51.4      90.7  200 -                                              50&#13;
7 OrthorTrauma-Ohrid       450       57.4      66.6  100      /&#13;
8 Nephrology-Struga        103        60       70.1       o o&#13;
9 TB-Jasenovo              100       69.6    108.0    0       2                                         0&#13;
10 ENT-Skopje               100       70.1       9.0        1234567891011121314&#13;
11 TB-LesokT                 70       91.1      82.1                  _                               :&#13;
12 Neuropsych-Skopje        700      313.7    220.0&#13;
13 Neuropsych-D.Hisar       564      537.2    198.0                                                   .&#13;
14 Neuropsych-Gevgelja      270      791.2      98.0&#13;
Source: Kanach, F.  Sustainability of Health System Infrastructure in FYR Macedonia. Oct. 1994.&#13;
-z&#13;
O X&#13;
&#13;
&#13;
&amp;#12;&#13;
IBRD 25501&#13;
FED. REP. OF  YUGOSLAVIA                      i  &#13;
FED. REP. OF YUGOSLAVIA    ~                      FORMER YUGOSLAV REPUBLIC OF&#13;
N '  _                                b&lt;o Q'oX|                                t~_           r  /  .   _  )                                            ,   _              M  A  C  E D  O  N  I A&#13;
/                                              Ky\  s R s dIP.I.A.  G   B U L G A R I A&#13;
uAmRo.noHo                                N                                                                      Major cities&#13;
i~~~~~~~~~.                         Vrto\    's            A                              C.,,A           AS *    ri.n&#13;
)  *o.,.                                                                                                   Selected cities&#13;
2  R0d?0~       \&gt;, SKOE              ~\                                                                                                 *         N ate onal tol Capital&#13;
(b0 \                                                                                         ) s 2 G N &gt; _ t $ { / n cn ~ mpp  Primary roads&#13;
_; t    v  i                                             G                                             R E Secondary roads&#13;
r k"' ,                                                                                                              ________   ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~Electrified railroads&#13;
Other railroads&#13;
I'                                                                                                                 _&#13;
4L4esJAirparts&#13;
23~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Spat elevations in meters&#13;
Rivers&#13;
Ty-   ~ ~ ~ ~ ~ ~ ~~    ---                 International boundaries&#13;
Pri                                                                           0~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 5  OILES&#13;
SI, 6-4-, -6 d-,o    - od -,y  ,nlo-oo-&#13;
o                                                                 A-~~~~~~~~~~~~~~~~~~~~~~~~~~ 4.VoA e  0. pooy  %Ry  frd oodooso'.o&#13;
q,                                                                                     -~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~owoodoh bo.o,.o.A&#13;
L,                                                                                                           k~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~SLO-KA R.E_P .  RR&#13;
A ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~AUSTRIA   ..                                                                                 NE'      Y.&#13;
7JCROATIA   "           ROMANIA&#13;
FEDREP&#13;
OR&#13;
YUGiOSLAVIA &#13;
RIJSLGAR A&#13;
TALY&#13;
ALBANIA  ~~~~~~~~~~~~~~~~~~~OOTo  J                                                                                                     ALRMAA -.3~~~~~~~~~~~~~~~~~~~~~~~~~~~~AA~I&#13;
LRE&#13;
JANUARY 1994&#13;
&#13;
&#13;
&amp;#12;&#13;
&#13;
&#13;
&amp;#12;&#13;
&#13;
&#13;
&amp;#12;&#13;
IMAGING&#13;
Report No:      15399 MK&#13;
Type: SAR&#13;
&#13;
&#13;
&amp;#12;&#13;
</ml:original-txt><ml:search-metadata><doc id="696486">
        <url>
            http://documents.worldbank.org/curated/en/1996/05/696486/macedonia-health-sector-transition-project
        </url>
        <availablein>English</availablein>
        <url_friendly_title>http://documents.worldbank.org/curated/en/1996/05/696486/macedonia-health-sector-transition-project</url_friendly_title>
        <new_url>1996/05/696486/macedonia-health-sector-transition-project</new_url>
        <disclosure_date>2010-07-01T00:00:00Z</disclosure_date>
        <disclosure_type>NA</disclosure_type>
        <ext_pub_date>2010-07-01T00:00:00Z</ext_pub_date>
        <disclstat>Disclosed</disclstat>
        <txturl>http://www-wds.worldbank.org/external/default/WDSContentServer/WDSP/IB/1996/05/24/000009265_3961214123024/Rendered/INDEX/multi0page.txt</txturl>
        <pdfurl>http://www-wds.worldbank.org/external/default/WDSContentServer/WDSP/IB/1996/05/24/000009265_3961214123024/Rendered/PDF/multi0page.pdf</pdfurl>
        <credit_no>2889;P983</credit_no>
        <docdt>1996-05-24T00:00:00Z</docdt>
        <datestored>2001-04-21T00:00:00Z</datestored>
        <totvolnb>1</totvolnb>
        <versiontyp>Final</versiontyp>
        <versiontyp_key>1309935</versiontyp_key>
        <volnb>1</volnb>
        <repnme>
            Macedonia - Health Sector Transition Project
        </repnme>
        <abstracts>
            The dual objectives of the Health Sector
            Transition Project are to: 1) improve the health of the
            population by enhancing the quality of basic health
            services; and 2) support an initial phase of policy reforms
            to increase cost-effectiveness, fiscal sustainability and
            patient choice within the health system. These broad
            objectives will be achieved through activities and reforms
            under the following three project components: 1) health
            finance and management; 2) basic health services; and 3)
            pharmaceutical policy and supply. The specific objectives of
            these three components are as follows, respectively: 1) to
            build capacity to analyze and apply information for
            policy-making and health system management; 2) to strengthen
            primary health care and support high-priority disease
            prevention and health promotion programs; and 3) to reduce
            the cost of essential drugs by creating a more competitive
            pharmaceutical market.
        </abstracts>
        <docna>
            Macedonia - Health Sector Transition Project
        </docna>
        <display_title>Macedonia - Health Sector
            Transition Project</display_title>
        <listing_relative_url>/projects/documents/1996/05/696486/macedonia-health-sector-transition-project</listing_relative_url>
        <projn>MK-Health Sector Transition Project -- P036089</projn>
        <docty>Staff Appraisal Report</docty>
        <subtopic>Health Monitoring &amp; Evaluation,Adolescent Health,Housing &amp; Human Habitats,Health Systems Development &amp; Reform,Health Economics &amp; Finance</subtopic>
        <teratopic>Health, Nutrition and Population</teratopic>
        <count>Macedonia, former Yugoslav Republic of</count>
        <geo_region_mdks>
            <geo_region_mdk>World!$!80475</geo_region_mdk>
            <geo_region_mdk>Eastern Europe!$!107233</geo_region_mdk>
            <geo_region_mdk>Europe!$!80461</geo_region_mdk>
        </geo_region_mdks>
        <entityids>
            <entityid>000009265_3961214123024</entityid>
        </entityids>
        <subsc>Non-compulsory health finance,Health,Central government administration</subsc>
        <admreg>Europe and Central Asia,Europe and Central Asia</admreg>
        <colti>World Development Sources, WDS 1996</colti>
        <lang>English</lang>
        <historic_topic>Health, Nutrition and Population</historic_topic>
        <sectr>(Historic)Health, Nutrition &amp; Population</sectr>
        <majdocty>Project Documents</majdocty>
        <keywd>
            Basic services; Disease prevention; Health;
            Health administration; Health finance; Health services;
            Pharmaceutical policy; Pharmaceuticals; Primary health care
            acute respiratory infection,adult
            mortality,alcohol,alcohol consumption,basic health
            services,basic primary care,beds,birth rate,births,blood
            pressure,breast cancer,burden of disease,care
            treatment,child health,Childbirth,chronic disease,chronic
            diseases,clinical services,Communities,Complications of
            Pregnancy,death
            rate,deaths,dentistry,Diabetes,districts,doctors,epidemics,essential
            drugs,Expenditures,Health Care,health education,health
            expenditures,health facilities,Health Finance,health
            financing,Health Indicators,health institutions,Health
            Insurance,health interventions,health needs,health
            promotion,Health Sector,Health Services,Health Status,health
            system,health system management,health systems,health
            workers,high fertility,high-risk,High-risk
            populations,Hospital admission,Hospital beds,hospital
            care,hospital
            services,hospitalization,Hospitals,immunization,immunization
            coverage,income,infant mortality,infant mortality
            rate,infant mortality rates,infectious
            diseases,inhabitants,intervention,labor force,life
            expectancy,lifestyles,lifting,living standards,lung
            cancer,malnutrition,managers,marketing,maternal
            mortality,measles,media,medical centers,Medical
            equipment,medical supplies,Mortality,National
            Health,Neonatal mortality,nongovernmental
            organizations,nurses,nursing,nutrition
            education,occupancy,occupancy rates,Parasitic
            Diseases,patient admissions,patient
            choice,patients,Perinatal
            mortality,pharmacies,pharmacists,physicians,Polio,pregnancies,Pregnancy,pregnant
            women,premature death,prenatal care,Preventive
            Health,Preventive Health Care,primary care,Primary Health
            Care,private pharmacies,private providers,private
            sector,prosthetic devices,Public Health,public
            sector,quality control,rents,risk factors,rural
            areas,safety,smoking,social marketing,social
            services,sterilization,surgery,Unemployment,waste,waste disposal,workers
        </keywd>
        <owner>Human Development Sector Unit (ECSHD)</owner>
        <geo_regions>
            <geo_region>World</geo_region>
            <geo_region>Eastern Europe</geo_region>
            <geo_region>Europe</geo_region>
        </geo_regions>
        <trustfund>TF025225-PHRD-HEALTH SECTOR TRANSITION PROJECT,TF036262-MACEDONIA, FYR - HEALTH SECTOR
            TRANSITION PROJECT</trustfund>
        <repnb>15399</repnb>
    </doc></ml:search-metadata><ml:annotations><ml:concepts><ml:concept>Finance and Development</ml:concept><ml:concept>Finance and Financial Sector Development</ml:concept><ml:concept>Economic Management</ml:concept><ml:concept>Macroeconomic Management</ml:concept><ml:concept>Macroeconomic Policy</ml:concept><ml:concept>Macroeconomics Policy</ml:concept><ml:concept>Macroeconomics and Economic Growth</ml:concept><ml:concept>Macroeconomics and Growth</ml:concept><ml:concept>General Public Administration Sector</ml:concept><ml:concept>Governance and Public Sector Management</ml:concept><ml:concept>Government</ml:concept><ml:concept>Institutions</ml:concept><ml:concept>Public Administration</ml:concept><ml:concept>Public Sector Development</ml:concept><ml:concept>Public Sector Management and Reform</ml:concept><ml:concept>Public Sector and Governance</ml:concept><ml:concept>Social Protections and Labor</ml:concept><ml:concept>Financial Sector Development</ml:concept><ml:concept>Private Sector Development</ml:concept><ml:concept>Agriculture and Food Security</ml:concept><ml:concept>Macroeconomic and Structural Policies</ml:concept><ml:concept>Economic Growth</ml:concept><ml:concept>Health, Nutrition and Population</ml:concept><ml:concept>Public Sector Management</ml:concept><ml:concept>Social Protection and Labor</ml:concept><ml:concept>Health Monitoring and Evaluation</ml:concept><ml:concept>Fiscal Sustainability and Public Financial Management</ml:concept><ml:concept>Public Finance Sustainability</ml:concept><ml:concept>Delivery of Health Care</ml:concept><ml:concept>Health Care Delivery</ml:concept><ml:concept>Health Service Management and Delivery</ml:concept><ml:concept>Health Systems</ml:concept><ml:concept>Hospital Care</ml:concept><ml:concept>Inpatient  and Outpatient Care</ml:concept><ml:concept>Secondary Health Care</ml:concept><ml:concept>Specialized Care</ml:concept><ml:concept>Medical Supplies, Drugs</ml:concept><ml:concept>Pharmaceutical Industry</ml:concept><ml:concept>Generic Name List</ml:concept><ml:concept>Generics</ml:concept><ml:concept>List of Generic Drugs</ml:concept><ml:concept>Off patent drugs</ml:concept><ml:concept>Medical Devices</ml:concept><ml:concept>BoD</ml:concept><ml:concept>Economic Cost of Disease</ml:concept><ml:concept>Social Impact of Disease</ml:concept><ml:concept>Chronic Diseases</ml:concept><ml:concept>NCDs</ml:concept><ml:concept>Vaccines</ml:concept><ml:concept>Insurance &amp; Risk Mitigation</ml:concept><ml:concept>Fiscal &amp; Monetary Policy</ml:concept><ml:concept>Fiscal Consolidation</ml:concept><ml:concept>Fiscal Decentralization</ml:concept><ml:concept>Fiscal Governance</ml:concept><ml:concept>Fiscal Governance and Structural Fiscal Reform</ml:concept><ml:concept>Fiscal Reform</ml:concept><ml:concept>Fiscal Rules</ml:concept><ml:concept>Fiscal Sustainability</ml:concept><ml:concept>Macro-Fiscal Policy</ml:concept><ml:concept>Demographics</ml:concept><ml:concept>Analysis &amp; Monitoring</ml:concept><ml:concept>Delivery Units</ml:concept><ml:concept>Grievance Redress</ml:concept><ml:concept>Indicators</ml:concept><ml:concept>M&amp;E</ml:concept><ml:concept>Performance Measurement</ml:concept><ml:concept>Performance Reviews</ml:concept><ml:concept>Rapid Results Approaches</ml:concept><ml:concept>Checks on Executive Power</ml:concept><ml:concept>Citizen Oversight</ml:concept><ml:concept>Citizen User Satisfaction Survey</ml:concept><ml:concept>Independent Commissions</ml:concept><ml:concept>Ombudsmen</ml:concept><ml:concept>Oversight</ml:concept><ml:concept>Parliament</ml:concept><ml:concept>Procurement Complaints Review Institutions</ml:concept><ml:concept>Supreme Audit Institutions</ml:concept><ml:concept>Health Monitoring &amp; Evaluation</ml:concept><ml:concept>Income</ml:concept><ml:concept>Banking</ml:concept><ml:concept>Health Insurance</ml:concept><ml:concept>Health Services Delivery</ml:concept><ml:concept>Primary Care</ml:concept><ml:concept>Secondary Care</ml:concept><ml:concept>Pharmaceuticals</ml:concept><ml:concept>Pharmaceutical Policy</ml:concept><ml:concept>Generic Drugs</ml:concept><ml:concept>Medical Equipment</ml:concept><ml:concept>Diseases</ml:concept><ml:concept>Burden of Disease</ml:concept><ml:concept>Tuberculosis</ml:concept><ml:concept>Non-Communicable Disease and Injury</ml:concept><ml:concept>Immunizations</ml:concept><ml:concept>Prevention</ml:concept><ml:concept>Insurance</ml:concept><ml:concept>Fiscal Policy</ml:concept><ml:concept>Public Health</ml:concept><ml:concept>Population</ml:concept><ml:concept>Monitoring and Evaluation</ml:concept><ml:concept>Public Accountability Mechanisms</ml:concept><ml:concept>Negotiation</ml:concept></ml:concepts><ml:geo-regions><ml:geo-region>Asia</ml:geo-region><ml:geo-region>Europe</ml:geo-region><ml:geo-region>Central Asia</ml:geo-region><ml:geo-region>The former Yugoslav Republic of Macedonia</ml:geo-region></ml:geo-regions></ml:annotations></ml:doc-envelope>